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ABSTRACT
Cancer is a disease of uncontrolled cell growth and proliferation that is predicted to
directly affect one-third of Canadians. Standard chemotherapy, which targets DNA or its
replicative machinery, effectively eradicates cancer cells but also causes non-specific
toxicity to non-cancerous cells. Pancratistatin is a natural alkaloid isolated from
Hymenocallis littoralis found to selectively induce apoptosis (programmed cell death) in
numerous human cancer cell lines with an insignificant effect on non-cancerous cells.
The major objectives of this study were to: 1) assess the selectivity and efficacy of
pancratistatin and synthetic derivatives on patient-obtained and commercially available
leukemia models; 2) test the effect of pancratistatin on human colon and prostate cancer
cells in vitro and in vivo; and 3) to determine the mechanism of action of pancratistatin.
Results suggested that 1 µM pancratistatin induces apoptosis in leukemia ex vivo with an
insignificant effect on non-cancerous peripheral blood mononuclear cells. Apoptosis was
monitored by nuclear staining and phosphatidylserine exposure by microscopy and flow
cytometry.

Structure-activity

relationship

screening

of

synthetic

derivatives

of

pancratistatin on leukemia (Jurkat) cells revealed that certain analogs retain activity of
the native compound, albeit at higher concentrations. The effects of pancratistatin on
colon (HCT116, HT-29) and prostate (LNCaP, DU145) cancer cell lines, expressing
either the wild-type or functionally inactive p53 tumor suppressor protein, were studied
using cell-based assays and animal models. Pancratistatin treatment caused increased
production of reactive oxygen species, collapse of mitochondrial membrane potential,
and release of the pro-apoptotic proteins cytochrome c, apoptosis-inducing factor and
endonuclease G to the cytosol. Furthermore, pancratistatin induced cell death
independent of p53, caspase activation or Bax expression. Importantly, components of
the mitochondrial respiratory chain were deemed crucial for pancratistatin activity, as
mtDNA-deficient 'Rho-0' cells were resistant to pancratistatin. A significant finding of this
study was that pancratistatin reduced growth of human colon and prostate tumor
xenografts in immune-compromised mice, was well-tolerated and determined to be nontoxic to vital organs compared to control. In conclusion, pancratistatin is a natural anticancer compound that selectively targets cancer cell mitochondria to induce apoptosis
and significantly reduces growth of human tumor xenografts.
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CHAPTER 1

General Introduction

1

CANCER

Background
Cancer is a major health issue in Canada that is predicted to develop in nearly
one third of the population (Canadian Cancer Society, 2010). Cancer arises from normal
tissues of the body and can stem from many different cell types. The majority of tumors
are carcinomas, which develop from epithelial tissues such as the lungs, skin, intestines
and mammary glands. Sarcomas, which arise from non-epithelial cells like fibroblasts
and osteoblasts, and cancers of hematopoietic tissue, occur with less frequency
(Weinberg, 2007). Development of cancer is attributed to various factors including
exposure to environmental carcinogens, unhealthy lifestyle, and genetic predisposition.
These factors contribute to tumorigenesis by damaging genetic material, which is
normally repaired or triggers senescence or elimination of the cell depending on extent of
damage. Accumulation of multiple mutations is required for the progression of cancer
from in situ dysplasia to malignant tumor (Weinberg, 2007). According to Hanahan and
Weinberg (2000), the various genetic alterations acquired by cancer cells ultimately
manifest as six essential properties considered the “hallmarks of cancer”: growth signal
autonomy and resistance to anti-growth signals; ability to invade and metastasize;
unlimited replication potential; sustained angiogenesis; and escape of apoptosis
(Hanahan and Weinberg, 2000). This thesis will focus on carcinomas originating from
secretory cells (prostate and colorectal adenocarcinoma) and leukemia.

Leukemia
Leukemia, specifically acute myeloid leukemia (AML), is the most common
childhood cancer and a leading cause of cancer-related death in people under forty
(Jemal et al, 2010). Leukemia is a cancer that arises from hematopoietic tissues and is
typically categorized as acute or chronic, according to progression rate and blast
phenotype, and either myelogenous or lymphocytic depending on the cell lineage
involved (Weinberg, 2007). Acute leukemia progresses quickly and contains high
numbers of blast (immature undifferentiated) cells; chronic leukemia progresses
relatively more slowly and generally has a lower blast count (Harris et al, 1999). Myeloid
progenitors normally differentiate into granulocytes and monocytes, and lymphocytic
progenitors become T-cells and B-cells of the immune system (Lehninger et al, 2000).
2

Leukemia leads to accumulation of immature white blood cells that do not function
properly or hinder the ability of red blood cells to function. The causes of leukemia are
unknown for the majority of patients; however, exposure to high doses of radiation or
carcinogens, such as benzene, as well as genetic abnormalities and family history have
been attributed to higher risk of developing leukemia (Chokkalingam and Buffler, 2008).
A genetic abnormality responsible for the onset of chronic myelogenous leukemia (CML)
is the translocation of chromosomes 9 and 22, which forms the Philadelphia
chromosome (Ph) resulting in the Bcr-Abl fusion gene that translates a constitutively
active tyrosine kinase (Druker, 2008). This unique feature enabled development of
imatinib, a targeted tyrosine kinase inhibitor that is very effective against Ph+ cases of
CML, but exerts selective pressure that generates resistance (Chabner and Roberts,
2005). At present, the only curative therapy for leukemia is allogeneic stem cell
transplantation, but is associated with a high risk of fatal complications (Druker, 2008).

Colorectal Adenocarcinoma
Colorectal cancer (CRC) is the second-leading cause of cancer-related death in
Canada, behind lung cancer (Canadian Cancer Society, 2010). This is a dire statistic
considering that recommended routine colonoscopy screenings can detect and remove
polyps, and surgical resection of stage I CRC is associated with >90% long-term survival
(Worthley and Leggett, 2010). Sporadic CRC develops from multiple and sequential
genetic mutations, a process known as the multi-hit theory of carcinogenesis (Fearon
and Vogelstein, 1990). Particularly for CRC, the sequential multiple mutations are welldocumented. The first „hit‟ induces loss-of-function of the APC (Adenomatous polyposis
coli) tumor suppressor gene, typically followed by an activating mutation of the RAS
oncogene, which precedes inactivating mutations of the TP53 tumor suppressor gene
(Fearon and Vogelstein, 1990; Knudson, 2001). Further mutations are a result of the
chromosomal instability that ensues after the loss of TP53, leading to the development of
malignant carcinoma (Knudson, 2001). Chromosomal instability generates highly
heterogeneous cancers that are fatal if diagnosed in advanced stages due to the rapid
rate of proliferation and extent of invasion and metastasis (Worthley and Leggett, 2010).
The standard line of adjuvant (post-operative) chemotherapy for earlier stage CRC is
combination of fluorouracil (5-FU), leucovorin (LV) and oxaliplatin, referred to collectively
as FOLFOX, and is generally successful albeit with serious toxic side-effects (Goodwin
3

and Asmis, 2009). Patients with metastatic CRC (mCRC) may initially respond to
therapy, but commonly relapse and succumb to the disease within two years (Goodwin
and Asmis, 2009).

Prostate Cancer
Prostate carcinoma is the leading cancer in men over 50, and the second-leading
cause of cancer-related death of North American men (Jemal et al, 2010). Prostate
cancer generally presents as hormone-dependent (androgen-receptor positive) and in
most cases, remission is achieved by endocrine therapy. Fatality associated with this
disease is a result of relapse with advanced hormone refractory (androgen-receptor
independent) metastatic cancer (Radhakrishnan et al, 2010). Androgen hormones are
important players in the differentiation, development and normal functioning of the
prostate gland, and are believed to contribute to abnormal growth in prostate
carcinogenesis (Nieto et al, 2007).
The initiating event(s) in the development of prostate cancer remain unknown
and are up for debate. Similar to many other types of cancer, the risk factors include
exposure to environmental carcinogens and poor diet; and prostate cancer is considered
an age-related disease, as the median age of onset is over 55 years (Nieto et al, 2007).
Recently, it was reported that increased reactive oxygen species (ROS) produced as a
by-product of normal cell metabolism not only contributes to the process of aging, but
may have an essential role in the development of cancer, including prostate cancer
(Khandrika et al, 2009). New insights into the molecular changes involved in metastatic
prostate cancer have enabled use of targeted therapies as adjuncts to the standard care
of chemotherapy (Fizazi et al, 2010). Today, advanced metastatic prostate cancer is
treated with docetaxel-based chemotherapy, and clinical trials to test the effectiveness of
combinations with monoclonal antibodies or tyrosine-kinase inhibitors are ongoing
(Fizazi et al, 2010).

4

CANCER METABOLISM
An alternate method to specifically target cancer cells is to exploit the extensive
metabolic reprogramming commonly observed in many types of cancer. In addition to the
aforementioned six essential changes in cancer cell physiology, cancer cell mitochondria
are known to be structurally and functionally different than their normal cell counterparts
(Figure 1) (Fulda et al, 2010a). Cancer cell mitochondria have extensive metabolic
reprogramming allowing them to rely on glycolysis for production of adenosine 5‟triphosphate

(ATP),

despite

high

oxygen

tension

(DeBerardinis,

2008).

This

phenomenon is known as aerobic glycolysis or the Warburg effect, as it was first
described by Otto Warburg in the 1920‟s (Warburg, 1956; Nijsten and van Dam, 2009).
Cancer cells essentially bypass oxidative phosphorylation, the main energy production
process in normal cells, and manage to thrive on upregulation of glucose import and
metabolism (Kaelin and Thompson, 2010). Moreover, cancer cells have increased levels
of gluconeogenesis, reduced pyruvate oxidation and increased lactic acid production
(Modica-Napolitano and Singh, 2002). These metabolic differences between normal and
cancer cells may be the primary cause of cancer, as proposed by Warburg, but the more
likely explanation is that altered metabolism is an adaptation to support malignancy
(Nijsten and van Dam, 2009; Fulda et al, 2010a). Aerobic glycolysis allows a cancer cell
to generate ATP in varying oxygen conditions, which is advantageous for survival and
proliferation (DeBerardinis, 2008).
To this end, there are three key changes to mitochondrial metabolic processes
that result from elevated oncogenic signalling or loss-of-function mutations of tumor
suppressors (Fulda et al, 2010a). One of these changes is the binding of hexokinase
(HK) to the voltage-dependent anionic channel (VDAC) on the outer mitochondrial
membrane in cancer cells (Mathupala et al, 2010). Hexokinase converts glucose to
glucose-6-phosphate, a rate-limiting step of glycolysis that requires ATP. By binding to
VDAC, HK is in close proximity to the export of residual ATP produced in the
mitochondria (Mathupala et al, 2010; Fulda et al, 2010a). VDAC is a component of the
mitochondrial permeability transition pore (MPTP), a dynamic structure comprised of
VDAC on the outer mitochondrial membrane, adenine nucleotide translocase (ANT) and
cyclophilin D (cypD) on the inner mitochondrial membrane that is reversibly permeable to
solutes < 1.5 kDa (Halestrap et al, 2002).
5

Figure 1. The key metabolic alterations in cancer cell mitochondria that may
contribute to the vulnerability of cancer cells, compared to normal cell counterparts.
Cancer cell mitochondria are structurally and functionally different in three ways: 1)
hexokinase is bound to VDAC on the outer mitochondrial membrane to facilitate
glycolysis; 2) the end product of glycolysis, pyruvate, is preferentially converted to lactic
acid leading to acidification of the tumor microenvironment; and 3) the decreased rate of
mitochondrial ATP production leads to hyperpolarization of the mitochondria, compared
to normal mitochondria.

6

A second key change in cancer cell metabolism is increased lactic acid
production and efflux (Hockenbery, 2010). In normal conditions the end product of
glycolysis (pyruvate) is converted to acetyl coenzyme A (acetyl CoA), which enters the
citric acid cycle to generate substrates (NADH, FADH 2) required for oxidative
phosphorylation. In cancer cells, pyruvate is preferentially converted to lactic acid by
lactate dehydrogenase, which diverts energy production away from the mitochondria and
contributes to acidification of the tumor microenvironment (Nijsten and van Dam, 2009).
An acidic microenvironment is proposed to enhance invasive and metastatic potential of
tumor cells by degrading components of the extracellular matrix (Robey et al, 2009).
The third key change is the observed hyperpolarization of cancer cell
mitochondria compared to normal counterparts, due to reduced dissipation of the
mitochondrial membrane potential as a result of increased glycolytic ATP production
(Modica-Napolitano and Singh, 2002; Fulda et al, 2010a; Hockenbery, 2010). In normal
cells an electrochemical gradient is established across the inner mitochondrial
membrane as protons (H+) are pumped into the intermembrane space (IMS) by
complexes I, III and IV during cellular respiration. The potential energy of built up protons
is used to drive synthesis of ATP from ADP and inorganic phosphate (P i) by ATP
synthase (Lehninger et al, 2000). In contrast, malignant tumor cells produce up to 75% of
their ATP requirements by glycolysis, and thus the electrochemical gradient generated
by mitochondrial respiratory chain (MRC) complexes is largely unused for ATP
generation, even in aerobic conditions, leading to hyperpolarization (Mathupala et al,
2010).
These key metabolic changes, as well as improper lipid remodelling of
mitochondrial (and other organelle) membranes due to the rapid proliferation rate of
cancer cells, indicate that cancer cell mitochondria may be more susceptible to
disruption (Alirol and Martinou, 2006). These generally conserved features of cancer cell
mitochondria present an attractive target for cancer therapy, specifically those designed
to stimulate mitochondrial-mediated apoptosis.
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APOPTOSIS
Apoptosis is a physiological process of programmed cell death important for
normal tissue development and homeostasis, and elimination of virally infected or
degenerate cells (Kerr et al, 1972). Apoptosis is a tightly regulated energy-requiring
process that is stimulated by various cellular stresses, such as chemotherapy and
oxidative stress (Fulda et al, 2010b). Characteristic features of apoptosis include nuclear
fragmentation, chromatin condensation, plasma membrane blebbing, cell shrinkage and
formation of apoptotic bodies (Reed, 2000). Apoptotic bodies are small-membranesurrounded fragments that are easily engulfed by phagocytes so as not to elicit an
immune response (Reed, 2000).
Dysregulated apoptosis has been implicated in numerous diseases including the
two leading causes of death in Canada: cardiovascular disease (CVD) and cancer (Fulda
et al, 2010b). Interestingly, CVD is associated with excessive apoptosis and cancer
development is associated with evasion of apoptosis (Fulda, 2009). The two main
signalling pathways of apoptosis are the extrinsic and intrinsic pathways (Figure 2). The
extrinsic pathway is dependent on death-receptor stimulation, and the intrinsic pathway
is activated in response to DNA damage through the mitochondria (Kroemer et al, 2007).
Activation of either pathway leads to activation of caspases; cysteine-dependent
aspartic-directed proteases that act as the final executioners of apoptosis by cleaving
nuclear and cytoplasmic substrates.
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Figure 2. Extrinsic and intrinsic pathways of apoptosis. The extrinsic pathway is
dependent on death receptor stimulation by the appropriate ligand, causing death
receptor trimerization and recruitment of death effector domains and pro-caspase-8 that
together make up the death-inducing signalling complex (DISC). Activation of caspase-8
leads to activation of caspase-3, and/or tBid (BH3-only protein). The intrinsic pathway is
orchestrated by p53-activation of pro-apoptotic Bcl-2 family proteins in response to DNA
damage. This leads to mitochondrial outer membrane permeabilization (MOMP) (not
shown). Permeabilization of the mitochondria is irreversible and causes release of proapoptotic factors leading to caspase-dependent (Cyt c, SMAC/DIABLO, Omi/HtrA2) or
caspase-independent (AIF, Endo G) apoptosis.
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Extrinsic Pathway of Apoptosis
The extrinsic pathway of apoptosis is triggered by stimulation of death receptors
on the plasma membrane by their respective ligands. The TNF (tumor-necrosis factor)
superfamily of death receptors, such as Fas and TRAIL receptors, oligomerize upon
binding with their ligands, FasL and TRAIL (TNF-related apoptosis-inducing ligand).
Receptors then bind to adapter proteins, such as Fas-associated death domain (FADD)
through an exposed death domain (DD). In complex with the receptor, the death effector
domain (DED) on FADD binds with the DED on pro-caspase-8 (Reed, 2000).
Assimilation of these proteins constitutes the death inducing signalling compex (DISC),
which cleaves and activates caspase-8 (Green and Evan, 2002). Caspase-8 and -10 are
initiator caspases that become activated upstream of effector caspase-3, -6, and -7
(Kroemer et al, 2007). Caspase-8 provides a link between the extrinsic and intrinsic
pathways of apoptosis, through an alternate mechanism whereby caspase-8 cleaves and
activates the pro-apoptotic Bcl-2 family protein Bid (to truncated Bid, or tBid). Proapoptotic tBid then interacts with anti-apoptotic Bcl-2 family proteins on the mitochondrial
outer membrane to promote mitochondrial-mediated apoptosis (Billen et al, 2008).

Intrinsic Pathway of Apoptosis
The intrinsic pathway of apoptosis can be induced by multiple signals such as
DNA damage, hypoxia and growth factor deprivation, which activate tumor suppressor
p53, a transcription factor that increases expression of pro-apoptotic members of the Bcl2 family of proteins (Chipuk and Green, 2006; Giménez-Bonafé et al, 2009). The Bcl-2
protein family is comprised of both anti- and pro-apoptotic members; and pro-apoptotic
proteins are further classified as multi-domain or BH3-only proteins (Gogvadze et al,
2009). Anti-apoptotic members include the archetypal Bcl-2, as well as Bcl-XL, Bcl-w and
Mcl-1, all of which contain all four Bcl-2 homology domains (BH1-4) and reside mainly in
the mitochondrial outer membrane (OM) (Kroemer et al, 2007; Letai, 2008). Proapoptotic multi-domain Bcl-2 family proteins Bax and Bak contain three BH domains
(BH1-3) and are the key proteins responsible for mitochondrial outer membrane
permeabilization (MOMP) (Letai, 2008; Brenner and Mak, 2009). In normal physiological
conditions, Bax is cytosolic and Bak resides in the OM; upon activation by pro-apoptotic
stimuli Bax translocates to the OM and Bak changes conformation (Fulda et al, 2010a).
Lastly, the BH3-only pro-apoptotic proteins are subdivided depending on their role as
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either direct activators of Bax and Bak (Bim and tBid), or as derepressors of antiapoptotic proteins (Bad, Bik, Puma, Noxa) (Bouchier-Hayes et al, 2005; Brenner and
Mak, 2009; Letai, 2008). Recently, cytoplasmic p53 has been suggested to act as a
BH3-only protein in the activation of Bax, though it is not clear whether as a direct
activator or derepressor (Green and Kroemer, 2009). Once activated, Bax and Bak form
hetero- and/or homo-oligomers that create channels permitting the rapid and complete
release of toxic proteins, such as cytochrome c and AIF (apoptosis inducing factor)
previously contained in the IMS (Armstrong, 2006; Kroemer et al, 2007). MOMP is widely
considered to be „the point of no return‟ after which cells cannot be rescued (Armstrong,
2006; Gogvadze et al, 2009). In addition to the release of pro-apoptotic factors following
MOMP, there is subsequent loss of mitochondrial membrane potential (MMP) due to
uncoupling of the MRC (Fulda et al, 2010a).
An alternate method that causes dissipation of MMP is opening of the
mitochondrial permeability transition pore (MPTP) to a high-conductance state
(Gogvadze et al, 2009). MPTP opening can be stimulated by accumulation of reactive
oxygen species (ROS) and/or calcium overload (Gogvadze et al, 2009). An unregulated
influx of solutes flows through opened MPTP, which causes swelling of the matrix and
rupture of the OM (MOMP) leading to cell death (Kinnally and Antonsson, 2007).

Cell Death Effectors Released from Mitochondria
The toxic proteins released from the mitochondria following its permeabilization
fall into three main categories: direct caspase activators; indirect caspase activators; and
caspase-independent pro-apoptotic factors. Cytochrome c forms a complex with
apoptosis-protease activating factor (apaf-1) and pro-caspase-9 called the apoptosome,
whose primary function is to cleave and activate caspase-9. Caspase-9, like caspase-8,
is an initiator caspase that cleaves and activates downstream effector caspases 3, 6 and
7 (Pradelli et al, 2010). The indirect caspase activators, Smac/DIABLO and Omi/HtrA2,
bind and inhibit the inhibitor of apoptosis proteins (IAPs), which are endogenous caspase
inhibitory proteins (Brenner and Mak, 2009; Kroemer et al, 2007). Activation of effector
caspases is often portrayed as the last step in the signalling pathway of apoptosis;
however, it should be noted that the substrates of effector caspases include poly (ADPribose) polymerase (PARP), cytoskeletal and nuclear matrix proteins (Reed, 2000).
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Along with the caspase-dependent cytotoxic factors, pro-apoptotic caspaseindependent proteins, AIF and Endonuclease G (EndoG) are also released from the
mitochondria following MOMP (Pradelli et al, 2010). These proteins bypass caspase
activation to induce a distinct form of programmed cell death, called caspaseindependent programmed cell death (CICD) (Constantinou et al, 2009). EndoG is a
mitochondrial endonuclease that translocates to the nucleus following release from the
mitochondria and induces DNA fragmentation and CICD (Pradelli et al, 2010). The
flavoprotein AIF is anchored to the IM in the IMS and is required for maintenance of the
MRC in physiological conditions (Millan and Huerta, 2009; Pradelli et al, 2010). In
response to MOMP, AIF gets cleaved and activated by calpain or cathepsin proteases
and is released to the cytosol where it induces large-scale DNA fragmentation and CICD
(Millan and Huerta, 2009). Recent studies indicate that AIF is down-regulated in
metastatic colon cancer, which may contribute to chemotherapy resistance (Millan and
Huerta, 2009).
Evasion of apoptosis is considered a hallmark of cancer cells, and is also
attributed to acquired resistance of metastatic tumor cells to chemotherapeutic agents
(Fulda, 2009). All tumor cells, however heterogeneous or advanced, are imbalanced
towards proliferation and reduced cell death through overexpression of anti-apoptotic
proteins and/or down-regulation or loss-of-function of pro-apoptotic proteins (Green and
Evan, 2002). There have been major advances in the treatment of metastatic tumors
with the development and application of small molecules that target Bcl-2 family proteins
to induce MOMP and inevitably cell death (as reviewed in Fulda et al, 2010a; GiménezBonafé et al, 2009; Hockenbery, 2010). The pro-survival process of autophagy has also
been implicated as a possible mechanism of resistance to cell death in tumor cells
(Dalby et al, 2010).
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AUTOPHAGY
Autophagy is a physiological process that enables digestion of proteins,
macromolecules and organelles (Kroemer et al, 2007). It is a catabolic process tightly
regulated by autophagy-related proteins (ATG) that become activated downstream of
inactivation of mammalian target of rapamycin (mTOR) kinase (Dalby et al, 2010; Essick
and Sam, 2010). Activation of autophagy results in formation of phagophores that
elongate and fuse together to engulf proteins within a mature autophagosome. The
autophagosome then fuses with intracellular lysosomes (now an autophagolysosome),
which leads to digestion of the engulfed macromolecules by lysosomal hydrolases
(Essick and Sam, 2010).
Autophagy is a temporary survival mechanism triggered by nutrient deprivation,
hypoxia and/or metabolic stress; it effectively clears away damaged or long-lived
proteins and recycles the intermediate metabolites to meet essential energy
requirements (Fulda et al, 2010b). Alternatively, sustained autophagy in response to
conditions of continuous stress causes autophagic cell death, either via self-cannibalism
or induction of apoptosis (Dalby et al, 2010). This supposed duality of autophagy has
recently generated tremendous controversy in regards to the role of autophagy in
tumorigenesis and chemo-resistance, and the complex interplay between autophagy and
apoptosis (Dalby et al, 2010). It is suggested that Beclin-1, an essential autophagy gene,
acts as a tumor suppressor because its mutation leads to defective (reduced) autophagy
associated with malignant transformation (Fimia and Piacentini, 2010; Dalby et al, 2010).
Conversely, tumor cells have been reported to use autophagy as a means of survival in
the harsh conditions of the tumor microenvironment and in the face of chemotherapyinduced insults (Dalby et al, 2010). Recent research supports these contradictory roles of
autophagy in cancer. Some studies suggest induction of autophagy as a novel
therapeutic strategy for the treatment of prostate and pancreatic cancers (DiPaola et al,
2008; Ullén et al, 2010; Dalby et al, 2010). Others report the effectiveness of autophagy
inhibition against chemo-resistant breast and colon cancers (Qadir et al, 2008; Sasaki et
al, 2010).
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Crosstalk between Autophagy and Apoptosis
There is significant crosstalk between autophagy and apoptosis signalling
pathways, and the mechanisms by which one modulates and/or activates the other are
not fully understood (Figure 3) (Dalby et al, 2010). Autophagy and apoptosis have
common regulators, can exert similar effects and have shared activation stimuli (e.g.,
Bcl-2 family members, cell death, hypoxic/metabolic stress) (Fimia and Piacentini, 2010).
The anti-apoptotic protein Bcl-2, as well as related proteins Bcl-XL, Bcl-w and Mcl-1,
reportedly interact with the novel BH3-only protein Beclin-1, which is critical for
autophagosome formation (Fulda et al, 2010b). This interaction inhibits autophagy and
autophagic cell death. Moreover, inhibition of Beclin-1 and the cysteine protease Atg4,
involved in the elongation step of autophagy, reportedly occurs by caspases and
contributes to inhibition of autophagy; and calpain-cleavage of Atg5, also involved in
elongation, induces apoptosis (Fimia and Piacentini, 2010; Levine, 2007). Tumor
suppressor p53 induces autophagy and/or apoptosis through its cytosolic and nuclear
effects in response to DNA damage and other stressors (Olovnikov et al, 2009; Fimia
and Piacentini, 2010). Oxidative stress, i.e., increased production of reactive oxygen
species (ROS), can also induce apoptosis and autophagy (Essick and Sam, 2010).
Although the interplay between these two pathways is undeniable, the question remains
as to whether autophagy works to promote or prevent cancer.
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Figure 3. Mechanisms of crosstalk between autophagy and apoptosis. Bcl-2 is
over-expressed in many cancers and mediates inhibition of both autophagy and
apoptosis, indicating that inhibition of autophagy promotes tumorigenesis. Tumor
suppressor p53 activates both pathways in response to cellular stress, suggesting that
autophagy induction prevents tumorigenesis. The supposed roles of autophagy in cancer
development and resistance to treatment are currently under intense scrutiny.
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REACTIVE OXYGEN SPECIES
Reactive oxygen species (ROS) are generated during normal oxidative
phosphorylation as a result of improper or incomplete electron transfer by complexes I,
and III of the MRC (Gogvadze et al, 2009). ROS is a collective term that refers to highly
reactive molecules such as superoxide anion (O2•−), hydrogen peroxide (H2O2) and
hydroxyl radical (OH•) (Fulda et al, 2010b). The deleterious effects of these pro-oxidants
are managed by an anti-oxidant defence system comprised of catalase and super-oxide
dismutase enzymes and glutathione that quench and neutralize ROS (Fulda et al,
2010b). While low to moderate amounts of ROS may have beneficial effects on
regulation of cell proliferation and gene expression, increased ROS production results in
oxidative stress-induced damage to proteins, lipids and DNA, which has implications in
diseases including diabetes, Parkinson‟s disease and cancer (Valko et al, 2007; Fulda et
al, 2010b).

ROS and Apoptosis
Mitochondria are the central players in the intrinsic pathway of apoptosis and are
also the major producers of ROS. Mitochondrial permeabilization and cell death can be
stimulated by increased ROS production (Ralph et al, 2010). ROS reportedly modifies
two thiol groups on the ANT, an IM component of the MPTP, which stimulates pore
opening and solute influx (Gogvadze et al, 2009). Furthermore, mitochondrial release of
cytochrome c (Cyt c) is facilitated by ROS. Cyt c is bound to the IM in the IMS by
electrostatic and hydrophobic interactions with the mitochondrial phospholipid,
cardiolipin. Oxidation of cardiolipin causes release of Cyt c to the IMS, allowing it to
dissociate through channels formed by Bax/Bak in the OM (MOMP) (Gogvadze et al,
2009). Another target of ROS is mitochondrial DNA (mtDNA), which encodes for 13
essential subunits of MRC complexes I, III, IV and V critical for proper oxidative
phosphorylation (Chen et al, 2009). mtDNA is especially vulnerable to ROS-induced
damage due to its close proximity to the source of ROS (MRC complexes) and its lack of
protective histones (Valko et al, 2007). Moreover, oxidative damage to mtDNA may
cause genetic instability and disruption of proper MRC function, leading to elevated ROS
production, stimulating a vicious cycle with detrimental effects on the cell (Gogvadze et
al, 2009).
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ROS and Autophagy
Oxidative stress-induced damage to proteins and organelles can induce prosurvival autophagy or autophagic cell death, depending on the extent of the damage
(Kroemer et al, 2007). Sub-apoptotic stress that causes MMP in only a small fraction of
mitochondria induces „mitophagy‟, a process of pro-survival autophagy that specifically
removes dysfunctional mitochondria (Kroemer et al, 2007). However, extensive oxidative
stress, causing damage to MRC components and production of even more ROS, is
associated with autophagic cell death and apoptosis (Essick and Sam, 2010). ROS
induces autophagy by modulating key signalling proteins, such as Beclin-1. Under
normal conditions Beclin-1 is negatively regulated by anti-apoptotic Bcl-2 family proteins,
but pathological levels of ROS can activate the ubiquitin-proteosome system, leading to
activation of Beclin-1 by degradation of Bcl-2 resulting in autophagic cell death (Essick
and Sam, 2010).

ROS and Cancer
Oxidative stress is involved in the aging process, and generally one‟s risk of
developing cancer increases with age. Oxidative damage to either nuclear or
mitochondrial DNA is implicated in the early steps of carcinogenesis (Valko et al, 2007).
Depending on the site, oxidative damage to DNA can result in induction or repression of
transcription, altered signal transduction and/or replication errors, all of which contribute
to genetic instability (Valko et al, 2007). Recent studies suggest that tumor cells are
under constant stress from their microenvironment, and have increased levels of
intracellular ROS (Khandrika et al, 2009; Fulda et al, 2010b). Prostate cancer in
particular is reported to have elevated levels of intracellular ROS and overexpression of
NAD(P)H oxidase (Nox), which facilitates NAD(P)H-dependent generation of superoxide
anion (O2•−) and is thought to contribute to tumor growth (Khandrika et al, 2009; Graham
et al, 2010). Further, the p53 tumor suppressor, which is mutated in approximately 50%
of human cancers, is a major activator of anti-oxidant defence mechanisms
(DeBerardinis, 2008; Olovnikov et al, 2009). With respect to its apoptosis-inducing
capacity, molecules that promote ROS production may be novel therapeutics, proposed
to selectively target cancer cells by elevating ROS levels beyond a tolerable threshold to
induce MOMP and cell death (Fulda et al, 2010a; Chen et al, 2010).
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p53 TUMOR SUPPRESSOR
The quintessential tumor suppressor p53 is a transcription factor that regulates
mechanisms of DNA damage response, cell cycle arrest, apoptosis, autophagy and
metabolism through its nuclear and cytoplasmic functions (Lane, 1992; Green and
Kroemer, 2009). Approximately half of all human cancers have inactivating mutations of
p53, while the rest have adapted ways to override the tumor suppressor function of p53
(Weinberg, 2007). Under normal conditions, p53 is regulated by the ubiquitinproteasome system, triggered by p53-mediated transcription of Mdm2. In response to
damaging effects of radiation, chemotherapy and/or hypoxia, p53 is phosphorylated by
kinases such as ATM, Chk1 and Chk2, which work to stabilize the protein (Weinberg,
2007; Fulda et al, 2010b).
The mechanisms of p53-mediated apoptosis are well studied. Activated p53
accumulates in the nucleus to facilitate expression of pro-apoptotic proteins like Bax,
puma and noxa (Chipuk and Green, 2006). Interestingly, cytosolic p53 also acts to
induce apoptosis in a manner similar to BH3-only proteins; p53 has been shown to bind
Bcl-2 and Bcl-XL, as well as Bax and Bak, to induce MOMP (Mihara et al, 2003;
Gogvadze et al, 2008). Puma (Figure 4) is suggested to modulate the cytoplasmic pool
of p53 by binding with anti-apoptotic Bcl-2 proteins, thus releasing p53 to activate
Bax/Bak (Green and Kroemer, 2009).
The mechanisms of autophagy regulation by p53 are contradictory. The most
direct role discovered thus far is the expression of DRAM (damage-regulated autophagy
modulator) (Figure 4) by p53 (Crighton et al, 2006). DRAM is a lysosomal protein that
induces autophagy, is required for p53-induced cell death and is reportedly downregulated in cancer (Crighton et al, 2006). Indirect regulation of autophagy by p53 may
involve AMPK (AMP-activated kinase) activation and mTOR inhibition (Olovnikov et al,
2009). In response to DNA damage p53 activates AMPK, which serves to maintain the
balance of energy (AMP:ATP), leading to inhibition of mTOR and thus induction of
autophagy (Buzzai et al, 2007; Olovnikov et al, 2009). In contrast, reports indicate that
cytoplasmic p53 is a strong inhibitor of autophagy, and cells with loss-of-function
mutations of p53 show hyperactive autophagy (Tasdemir et al, 2008).
Novel functions of p53 in the regulation of glucose metabolism have been
discovered that account for the Warburg effect in cancer cells. The recently discovered
p53 target gene TIGAR (TP53-induced glycolysis and apoptosis regulator) (Figure 4)
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Figure 4. The master regulator p53. In normal physiological conditions, p53 is
regulated by Mdm2. In response to stress/damage, p53 coordinates multiple pathways
with the overall goal of tumor suppression. The p53 target TIGAR (TP53-induced
glycolysis and apoptosis regulator) can block glycolysis at the fructose-6-phosphate step
and diverts catabolism of glucose towards the pentose phosphate pathway. The p53
target DRAM (damage-regulated autophagy modulator) can induce pro-survival
autophagy or autophagic cell death. SCO2 (synthesis of cytochrome c oxidase-2) is
activated by basal levels of p53 to promote oxidative phosphorylation. The p53 target
puma (p53-upregulated modulator of apoptosis), a BH3-only protein, induces apoptosis
by triggering Bax- and Bak-mediated mitochondrial outer membrane permeabilization
(MOMP; not shown).
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encodes a protein that is homologous to the bisphosphatase domain of 6-phosphofructo2-kinase (Bensaad et al, 2006). TIGAR lowers fructose-2,6-bisphosphate levels in cells,
effectively inhibiting glycolysis and redirecting glucose catabolism to the pentose
phosphate pathway to generate nucleotides needed for DNA repair (Bensaad et al,
2006; Green and Chipuk, 2006). Another novel target of p53 is SCO2 (synthesis of
cytochrome c oxidase-2) (Figure 4), a protein required for proper assembly of MRC
complex IV, which is reportedly upregulated by basal levels of p53 (Matoba et al, 2006).
Taken together, mutations in p53 contribute to genetic instability, accumulation of
damaged

proteins

and

organelles,

decreased

apoptosis,

down-regulation

of

mitochondrial respiration and increased glycolysis. The recently discovered metabolismrelated regulatory roles of p53 provide a clear explanation of factors that support aerobic
respiration in cancer cells, originally observed by Otto Warburg in the 1920s.
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CURRENT CANCER THERAPY
The current standard of care for cancer is adjuvant chemotherapy that elicits a
cell death response, typically by causing damage to the DNA or interfering with its
replicative machinery (Chabner and Roberts, 2005). Cancer therapeutic agents are
generally categorized as (standard) chemotherapy, targeted therapy or natural products.
Chemotherapy
Standard chemotherapy is used for treatment of advanced stage cancer and is
generally administered following surgical resection of the primary tumor mass (adjuvant
chemotherapy). Aside from improvements to stability and toxicity, chemotherapy has not
dramatically changed since the mid-1970s (Chabner and Roberts, 2005). For instance,
the front-line of therapy for advanced colorectal carcinoma, one of the most fatal
cancers, is 5-fluorouracil (5-FU), a pyrimidine analogue that inhibits DNA synthesis and
has been used to treat cancer for over half a century (Goodwin and Asmis, 2009). Other
drugs that have been used for decades against cancer include anti-metabolites like
methotrexate, DNA alkylating agents such as cyclophosphamide or cisplatin, antimitotics like paclitaxel, and topoisomerase inhibitors like etoposide and camptothecins
(Chabner and Roberts, 2005). While their long-track record implies superior utility in the
fight against cancer, it belies the serious toxic effects associated with drugs that have
such universally-vital targets and is always combined with agents that offer protection of
normal cells (Blagosklonny, 2005; Chabner and Roberts, 2005).

Targeted Therapy
Development of targeted therapy resulted from increased understanding of the
complex molecular and genetic changes associated with cancer. The first breakthrough
targeted therapy was imatinib for the treatment of (Ph+) CML nearly a decade ago, which
paved the way for new targeted molecules against other types of cancer (Chabner and
Roberts, 2005). Soon after, monoclonal antibodies developed against oncogenic
receptor tyrosine kinases (HER-2, Herceptin; EGF-R, Cetuximab) and growth factors
(VEGF, Gefitinib) were approved for clinical use (Blagosklonny, 2005; Goodwin and
Asmis, 2009). Hormone-dependent cancers can be effectively prevented and treated
with endocrine therapy, such as tamoxifen for breast cancer. Tamoxifen is an estrogenreceptor antagonist that has been used in the fight against breast cancer for nearly 30
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years (Wang et al, 2009). Recent studies indicate that tamoxifen also inhibits
components of the MRC, leading to increased ROS production and apoptotic cell death
(Parvez et al, 2008; Chatterjee et al, 2011). These targeted therapies are often used in
combination with standard chemotherapy to enhance the cancer cell-killing effect
(Goodman and Asmis, 2009; Fizazi et al, 2009). Unfortunately, tumors adapt to the
selective pressures of targeted therapy, and gain resistance to treatment and metastatic
capabilities (Don and Hogg, 2004; Letai, 2008; Fulda et al, 2010a).

Natural Products
There has been a recent revival in the development of natural products as anticancer agents, based on their historical use in folk, Ayurvedic and traditional Chinese
medicine

(Deorukhkar et al, 2007; Fulda and Kroemer, 2009). Plants and

microorganisms are incredible sources of diverse phytochemicals, classified into various
families such as alkaloids, flavinoids and isothiocyanates, with potential medicinal
properties (Deorukhkar et al, 2007). In addition to the well known natural products used
as standard chemotherapy, such as paclitaxel (obtained from the bark of the Pacific Yew
tree) or etoposide (derived from roots of the mayapple plant), new products that directly
target the mitochondria to induce cell death are of current interest (Chen et al, 2010;
Fulda and Kroemer, 2009; Fulda et al, 2010a). Exemplary models of a new class of
mitochondrial-targeting anti-cancer agents, called mitocans, include the natural products
betulinic acid, phenylethyl isothiocyanate, resveratrol and α-tocopheryl succinate, among
others (Ralph and Neuzil, 2009; Biasutto et al, 2010). Due to the direct-targeted action of
these agents on the mitochondria, they may bypass mechanisms of resistance to
standard chemotherapy by tipping cancer cells over the „point-of-no-return‟ that is
mitochondrial outer membrane permeabilization (MOMP).

Natural Mitocans
Betulinic acid (BA) is a natural phytochemical found in various plants worldwide,
including white-barked birch trees used by Native Americans as a folk remedy (Fulda
and Kroemer, 2009). BA is proposed to induce mitochondrial outer membrane
permeabilization (MOMP) and loss of mitochondrial membrane potential (MMP) in a
manner that can be inhibited by bongkrekic acid, an inhibitor of the mitochondrial
permeability transition pore (MPTP) (Fulda and Kroemer, 2009). It has been speculated
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that BA increases ROS production to stimulate loss of MMP; however the mitochondrial
target of BA remains unknown (Ralph and Neuzil, 2009). BA is currently under
evaluation as a topical agent in phase I/II cancer prevention clinical trials (Fulda and
Kroemer, 2009).
Phenylethyl isothiocyanate (PEITC) is found in cruciferous vegetables such as
watercress, broccoli and cabbage, and is considered a chemo-preventative agent (Chen
et al, 2010; Xiao et al, 2010). Recent studies show that PEITC inhibits the glutathione
(GSH) anti-oxidant system, leading to increased ROS production, MOMP and apoptosis
selectively in cancer cells (Xiao et al, 2010; Wu et al 2010). PEITC is currently being
tested in a Phase II cancer prevention clinical trial (Chen et al, 2010).
Resveratrol is a flavinoid polyphenol found in the skin of red grapes, wine and
blueberries (Deorukhkar et al, 2007; Chen et al, 2010). Polyphenols are often touted for
their anti-oxidant properties, but can also act as pro-oxidants in cancer cells with already
elevated levels of intracellular ROS (Biasutto et al, 2010). Although multiple possible
effects of resveratrol have been reported (Chen et al, 2010; Deorukhkar et al, 2007),
recent studies indicate that resveratrol inhibits synthetic and hydrolytic function of the F 1ATPase, thereby inhibiting mitochondrial ATP synthesis leading to cell death due to ROS
over-production (Fulda et al, 2010a; Ralph and Neuzil, 2009). Resveratrol is currently
undergoing phase II clinical trials against colorectal cancer (Chen et al, 2010).
Alpha-tocopheryl succinate (α-TOS) is a vitamin E analogue that has been shown
to target the ubiquinone-binding site on MRC complex II, preferentially in cancer cell
mitochondria, triggering increased ROS production (Dong et al, 2009). Interestingly,
mtDNA-deficient cells resisted the effect of α -TOS, defining the mitochondria as a
crucial component for its anti-cancer activity (Fulda et al, 2010a). Furthermore, studies
indicate that α-TOS is deprotonated at neutral pH, but becomes significantly more
protonated in the acidic tumor microenvironment, resulting in enhanced uptake and
activity in cancer cells (Biasutto et al, 2010). Alpha-TOS is currently in pre-clinical
development (Chen et al, 2010). Together, these studies showcase the potential of
natural products as anti-cancer agents that induce apoptosis specifically in cancer cells
by directly acting on the mitochondria.
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PANCRATISTATIN
Pancratistatin is an Amaryllidaceae alkaloid isolated from the bulbs of the
Hawaiian spider lily (Hymenocallis littoralis) (Pettit et al, 1993). Extracts from the
Amaryllidaceae family of plants have been used in folk medicine for the management of
cancer and other ailments dating back centuries (Pettit et al, 1993; Kornienko and
Evidente, 2008). Recent research efforts have focused on pancratistatin, narciclasine
and related constituents (Figure 5), which are considered the most important metabolites
responsible for the therapeutic benefits of these plants (Kornienko and Evidente, 2008).
Studies from our laboratory indicate that pancratistatin induces loss of MMP and
increased ROS production, leading to apoptosis in several different types of cancer
including colon, prostate and breast carcinomas, leukemia, melanoma and glioblastoma,
with minimal toxicity to non-cancerous counterpart cells (Griffin et al, 2010; Griffin et al,
2011a; Griffin et al, 2011b; Siedlakowski et al, 2008; Chatterjee et al, 2011). It has been
shown that pancratistatin does not target the DNA or have anti-mitotic properties (like
other natural products, e.g., anthracyclines, taxanes, vinca alkaloids); however, the
target of pancratistatin remains elusive (Kekre et al, 2005; Griffin et al, 2011a). The high
medicinal potential of this alkaloid, and the time-consuming and expensive multi-step
process of extraction from the natural source, have fuelled major efforts to produce
pancratistatin using a biosynthetic approach (McNulty et al, 2008; Pettit et al, 1993;
Rinner et al, 2004a).

Other Amaryllidaceae Alkaloids
Lycorine was the first alkaloid isolated from bulbs of the Amaryllidaceae family of
plants; its anti-tumor properties were being studied nearly 40 years before the more
oxygenated constituents (Figure 5) were identified (Hudlicky et al, 2002). Lycorine
reportedly has anti-tumor, anti-viral, anti-malarial and anti-inflammatory effects, and may
also inhibit ascorbic acid biosynthesis (Liu et al, 2009). Recent studies indicate that
lycorine activates caspase-3, 8 and 9, and also modulates the expression of antiapoptotic Bcl-2 family member, Mcl-1, leading to apoptosis in leukemia cells (Liu et al,
2004; Liu et al, 2009).
Narciclasine, lycoricidine (also referred to as 7-deoxynarciclasine in literature)
and 7-deoxypancratistatin are all natural Amaryllidaceae alkaloids of the same type as
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Figure 5. Representative members of the Amaryllidaceae family of alkaloids, the
minimum pharmacophore and a recently synthesized derivative with comparable activity.
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pancratistatin (McNulty et al, 2008). To date, the majority of reports on lycoricidine and 7deoxypancratistatin detail various approaches for their synthesis, with little focus on
biological activity. These compounds lack the free phenolic hydroxyl group (at C-7) that
the more oxygenated forms (pancratistatin and narciclasine) possess, which accounts for
their higher (10-fold or more) biological activity, i.e., anti-tumor and anti-viral (Rinner et
al, 2004b). Narciclasine, isolated from the bulbs of different varieties of daffodil
(Narcissus), is known to modulate plant growth; florists know that arranging fresh-cut
daffodils in a vase with other flowers will have a negative effect on their appearance and
will significantly shorten their vase-life (Kornienko and Evidente, 2008). Recent studies
suggest that, at nanomolar concentrations, narciclasine suppresses growth and
proliferation of glioblastoma multiforme cancer cells by inhibiting protein synthesis
pathways (LeFranc et al, 2009; Van Goietsenoven et al, 2010). Earlier studies reported
that, at pharmacologic doses (micromolar range), narciclasine induces apoptosis in
breast and prostate cancer cells, characterized by cytochrome c release from the
mitochondria and caspase activation (Dumont et al, 2007).

Synthetic Derivatives
Targeted design and synthesis of Amaryllidaceae constituents has been driven
by their historical medicinal properties, the complex extraction process and limited yield
of these compounds from their natural sources (McNulty et al, 2008; Pettit et al, 1993;
Rinner et al, 2004a). Numerous synthetic derivatives of native pancratistatin have been
subject to SAR (structure-activity relationship)-based screening efforts, which helped to
identify the minimally active anti-cancer pharmacophore of pancratistatin (Griffin et al,
2007; McNulty et al, 2008). Recently, SAR-based screening of 7-deoxypancratistatin
derivatives has revealed, for the first time, a C-1 acetoxymethyl derivative with promising
anti-cancer activity comparable to that of native pancratistatin (Collins et al, 2010).
Despite the historical medical usage of Amaryllidaceae alkaloids and the
extensive research efforts on pancratistatin and its congeners, these compounds have
not yet advanced to clinical trials for the treatment of human cancers (Hudlicky et al,
2002; Kornienko and Evidente, 2008; Collins et al, 2010). Identification of the site and
mechanism of action of pancratistatin will provide crucial information required for
advancement to clinical application.
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HYPOTHESIS and OBJECTIVES
This research aims to determine the efficacy and selectivity of pancratistatin and
to elucidate its mechanism of action using in vitro, ex vivo and in vivo models of
leukemia, colon and/or prostate cancer. Our working hypothesis is that pancratistatin
targets the mitochondria of cancer cells to induce apoptosis with minimal effect on noncancerous cells or tissues, and thus would improve cancer patient outcomes if used in
the clinical treatment of human cancer.

This hypothesis will be tested through the following objectives:


Evaluate the efficacy and selectivity of pancratistatin on cultured and patientobtained leukemia models



Determine the mechanism of action and anti-tumor efficacy of pancratistatin in
colon and prostate cancer using in vitro and in vivo models



Assess the biological activity of synthetic derivatives of pancratistatin compared
to the native natural structure

Results obtained through this study will identify the molecular effects of treatment
with pancratistatin and synthetic derivatives on cancer cells, and provide rationale for
pharmaceutical development of pancratistatin, or active synthetic analogues, and
progression to clinical trials.
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CHAPTER 2

Pancratistatin causes early activation of caspase-3 and the flipping of
phosphatidyl serine followed by rapid apoptosis specifically in human
lymphoma cells
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BACKGROUND
Despite an extensive research effort to conquer cancer, this disease remains
largely irremediable. The research effort towards cancer has become centralized around
the mechanism of apoptosis since its discovery (Kerr et al, 1972). Apoptosis is a
physiological process involving a cell suicide program that is essential in normal
development and tissue homeostasis (Corcoran et al, 1994; Green et al, 1998). This
process is characterized by cell shrinkage and nuclear condensation (Jaattela, 2002).
The biochemical pathways involved in apoptosis offer a variety of targets for inducing the
cell suicide program that eliminates cancer cells. Several research groups have been
successful in inducing apoptosis by targeting specific components of the cell (Hu and
Kavanagh, 2003). Most of the currently used anti-cancer treatments, including
chemotherapeutics and radiotherapies, are capable of triggering apoptotic cell death in
cancer cells by causing DNA damage. Unfortunately, these treatments come with the
consequence of causing toxicity to normal cells due to the fact that cancer cells tend to
differ from normal cells in their DNA replication mechanism and rate of proliferation. For
example, etoposide (Vp-16), a topoisomerase II inhibitor, is known to be a genotoxic
anti-cancer drug (Boose and Stopper, 2000) that may exhibit this toxicity against normal
cells. This damage to normal cells is most relevant in the recurrence of cancer in patients
because mutations caused by these therapies may predispose normal cells to become
cancerous. There are very few anti-cancer drugs that are capable of targeting receptors
or other components of the cell without producing any genotoxic effects.
Current therapies thought to be non-genotoxic include paclitaxel and tamoxifen
(Abal et al, 2003; Bursch et al, 1996). Since the discovery of the potent anti-cancer
activity of the natural product paclitaxel, scientific efforts have been made to find other
natural products capable of specifically targeting cancerous cells. Although it was
believed that paclitaxel induces non-genotoxic apoptosis by stabilizing tubulin, it has only
recently been shown to be genotoxic (Cunha et al, 2001). Recently, natural products
such as N-thiolated β-lactam and a labdane diterpene have been found to specifically
target cancer cells in inducing apoptosis. However, the concentrations of these
compounds required to induce apoptosis are high and their toxicity against normal blood
cells is not known (Kazi et al, 2004; Souza-Fagundes et al, 2003). Pancratistatin is a
natural compound first isolated in 1992 from the spider lily (Pettit et al, 1993). It has been
shown to have anti-neoplastic and cytostatic activity (Luduena et al, 1992; Pettit et al,
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1993), but its biochemical mechanism of action is still unknown. The critical evaluation of
the specificity and efficacy of pancratistatin in targeting cancer cells and its toxicity
against normal noncancerous cells are yet to be established.
In the present work, we evaluated the efficacy of pancratistatin in inducing
apoptosis in Human lymphoma (Jurkat) cells and its effect on normal non-cancerous
mononculeated blood cells. Since blood is one of the body‟s first lines of defense and all
blood cells get exposed to any drug administered, it was important for us to determine
the toxicity of pancratistatin against normal nucleated blood cells (lymphocytes).We
report an interesting and exciting finding that pancratistatin is capable of effectively
inducing apoptosis specifically in cancerous cells within a short period of time at a very
low concentration. Interestingly, in all experiments, no toxic effect of pancratistatin
treatment was found in normal blood cells. More importantly, no DNA damage was
detected following pancratistatin treatment of these cells. On the other hand, Vp-16 was
clearly genotoxic to cancerous as well as normal blood cells. We further studied the
mechanism of action of pancratistatin by investigating the effects of pancratistatin on
caspase-3 activation, ROS production and DNA damage by sensitive procedures. The
results of these experiments were further compared with those of experiments with the
currently used chemotherapeutic agent, Vp-16. An interesting observation made with
regard to the mechanism of action of pancratistatin in cancer cells was the rapid
activation of caspase-3 and flipping of phosphatidylserine to the outer leaflet of the
plasma membrane in the pathway of apoptosis. These results collectively suggest that
pancratistatin could be a very effective and nontoxic alternative for anti-cancer therapy.
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METHODS
Cell cultures
A human lymphoma cell line (Jurkat cells) was purchased from ATCC (Manassas
VA). These cells were grown and maintained in an incubator set at 37°C with an
atmosphere containing 5% CO2 and of 95% humidity. These cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) and 40 µg/ml
gentamicin (Life Technologies, Mississauga ON). Human nucleated blood cells were
purified from whole blood obtained from healthy male and female volunteers as
approved by the University of Windsor ethical committee, REB# 04-060. Whole blood (7
ml) was collected into a BD Vacutainer CPT Tube (Cell Preparation Tube) obtained from
Becton Dickinson (Franklin Lakes NJ). The whole blood was centrifuged in a table-top
low-speed centrifuge at 500 x g for 30 min at 25°C. The red blood cells went through the
polyester gel and the top layer containing mononuclear cells, platelets and plasma was
collected. These cells were kept in the same incubator as the Jurkat cells (37°C, 5% CO 2
and 95% humidity).
Cell treatment
For the induction of apoptosis by treatment with pancratistatin, Jurkat cells were
grown to 70% confluence and then treated for varying periods of time. Pancratistatin was
isolated from Hymenocallis following the literature scheme (99% pure) (Pettit et al,
1993). Jurkat cells were directly treated with pancratistatin at a concentration of 1 µM or
as indicated. Normal nucleated blood cells were treated in a similar manner after being
purified from whole blood. In a parallel set of separate experiments involving Vp-16
treatments, Vp-16 (Sigma Chemical Company, Mississauga, Ontario) was also directly
added to the culture medium, but to a final concentration of 10 µM (which is the
concentration currently used clinically).

Cellular staining and viability assay
To examine the viability of Jurkat cells after treatment, a cell suspension was
added to 20 µl of 0.4% Trypan Blue dye (Life Technologies). Using a hemocytometer
(Fisher Scientific), both dead (Trypan blue-positive) and live cells were counted four
times. The results were then calculated and tabulated as percentage of dead cells using
Microsoft Excel 6.0 software. To examine apoptotic morphology changes, the Jurkat
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cells and lymphocytes were grown and treated, and then stained with cell-permeable
Hoechst 33342 (Molecular Probes, Eugene OR) at a final concentration of 10 µM and
incubated for 5 min at 37°C. The cells were then examined under a fluorescent
microscope (Leica DM IRB, Germany) and both phase-contrast and fluorescent pictures
were taken. Five fields with at least 100 cells/field were used to count apoptotic versus
live cells (where brightly stained cells with condensed nuclei were considered apoptotic).
These results were then calculated and tabulated as percentage of apoptotic cells using
Microsoft Excel 6.0 software. The pictures at higher magnification were compiled using
Adobe Photoshop 7.0 software.
Comet assay
The comet assay was performed using a slight modification of a previously
published method (Naderi et al, 2003). Briefly, the slides were pre-coated with 0.10%
agarose and left to dry for at least 30 min. The desired cell suspension was added to 50
µl of 0.75% warm low-melting point agarose and immediately spread over the pre-coated
slide. The slides were placed at 4°C for 5 min to solidify, and then immersed in cold lysis
buffer (2.5 mM NaCl, 100 mM Na2EDTA, 10 mM Tris at pH 10, 1% Triton X-100, 10%
DMSO) for 1 h at 4°C. Following incubation, slides were washed in alkaline
electrophoresis buffer (0.3 M NaOH and 1 mM Na 2EDTA at pH >13). The DNA was
electrophoresed at 300 mA for 30 min, washed in neutralizing buffer (0.4 M Tris, pH 7.5)
and stained with 10 µM Hoechst 33342. The cells were examined under a fluorescent
microscope (Leica DM IRB) and fluorescence pictures were taken. All pictures were
processed using Adobe Photoshop 7.0 software.
Annexin-V binding assay
After treating Jurkat cells and lymphocytes, the Annexin-V binding assay was
conducted using a purchased kit and the manufacturer‟s protocol (Cat. No. A13201,
Molecular Probes). After treatment, cells were washed in phosphate-buffered saline
(PBS) and resuspended in Annexin-V binding buffer (10 mM HEPES/NaOH pH 7.5, 140
mM NaCl, 2.5 mM CaCl2), containing 1:50 Annexin-V AlexaFluor 488 conjugate for 15
min at 25°C. Cells were then examined under a fluorescent microscope (Leica DM IRB),
and fluorescence pictures were taken. All pictures were processed using Adobe
Photoshop 7.0 software.
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Caspase-3 activity
The caspase-3 assay was performed using a previously published method
(Naderi et al, 2003). To determine the caspase-3 activity, the total protein from Jurkat or
lymphocyte cell lysates was incubated with a fluorogenic substrate (DEVD-AFC), a
tetrapeptide sequence corresponding to the substrate cleavage site. The caspase assay
was carried out according to the manufacturer‟s protocol (Enzyme System Products,
USA). The fluorescence was measured at an excitation wavelength of 400 nm and
emission wavelength of 505 nm using a Spectra Max Gemini XS (Molecular Devices,
Sunnyvale CA). Caspase-3 activity was calculated per microgram of protein, and protein
concentration was determined with BioRad protein assay reagent (BioRad, Mississauga
ON) using bovine serum albumin as a standard. Microsoft Excel 6.0 software was used
for data representation and statistical analysis.
Mitochondrial membrane potential
Control and treated Jurkat cells were stained with 0.5 µM Mitotracker CM-XH2Ros dye (Molecular Probes) to determine mitochondrial membrane potential. After 30
min at 37°C, Jurkat cells were centrifuged and resuspended in PBS. The cells were
examined under a fluorescent microscope (Leica DM IRB). Fluorescence pictures were
taken; all pictures were processed using Adobe Photoshop 7.0 software.

Measurement of total ROS generation
After cells were treated, production of total reactive oxygen species (ROS) in
Jurkat cells and lymphocytes was measured using the membrane permeable dye 2‟,7‟dichlorofluorescein diacetate (H2DCFDA) (Molecular Probes) and a slight modification of
a previously published procedure (Siraki et al, 2002). The cells were incubated with
H2DCFDA at 37°C for 30 min, and fluorescence was measured at an excitation
wavelength of 500 nm and emission wavelength of 524 nm using a Spectra Max Gemini
XS multiwell plate fluorescence reader (Molecular Devices). Fluorescence readings were
expressed in terms of the total cell count per well, determined using Trypan blue
staining. Microsoft Excel 6.0 software was used for data representation and statistical
analysis.
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H2AX staining
Jurkat cells and lymphocytes were grown and treated, and the pellet was
resuspended in 4% paraformaldehyde and incubated. The cell suspension was added to
slides pre-coated with 0.01% poly-L-lysine (Sigma) and allowed to dry. The slides were
washed with PBS three times for 5 min each time and incubated in 70% ethanol for 5
min. The slides were washed again and then incubated in 10% FBS in PBS for 1 h
followed by an additional washing with PBS. After incubation for 1 h with the primary
antibody, 1:300 anti-phosphohistone H2AX (Upstate Biotechnology, Lake Placid NY), the
slides were washed again with PBS. The cells were then incubated in secondary
antibody, 1:200 anti-mouse IgG-conjugated to FITC (Sigma) for 1 h and washed with
PBS. The slides were stained with Hoechst 33342 and washed again with PBS. A glass
coverslip was mounted over the dried slides using Cytoseal mounting medium (VWR,
Mississauga ON). The slides were examined under a confocal microscope (BioRad
MRC600) using oil immersion and pictures were taken. All pictures were processed
using Adobe Photoshop 7.0 software.
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RESULTS
Induction of apoptosis by pancratistatin in Jurkat cells
In order to evaluate the efficacy of pancratistatin in inducing cell death in cancer
cells, we carried out experiments to determine the concentration- and time-dependent
effects of pancratistatin on Jurkat cells. Jurkat cells were treated with different
concentrations of pancratistatin for 6 h and stained with Hoechst dye, and apoptotic cells
were counted as described in „„Materials and methods‟‟. At a concentration as low as 500
nM, pancratistatin was efficient in causing approximately a third of the cells to undergo
apoptosis (Figure 1A). At 1 µM, however, more than 70% of the Jurkat cells were
apoptotic, meaning that apoptosis was effectively being induced. Hence, in all following
experiments, this effective concentration of 1 µM was used.
Further examination of the time kinetics of cell death triggered by 1 µM
pancratistatin indicated that apoptosis was detected as early as within 1 h of treatment
(Figure 1B). More than 90% of the Jurkat cells displayed apoptotic morphology after 24 h
of treatment whereas normal blood cells remained unaffected (Figure 1B). Results of
Trypan blue staining to determine the number of permeable (dead) cells (Figure 1C)
indicated that apoptotic cells were eventually becoming necrotic. This is evident by a
higher percentage of apoptotic cells than dead cells within a short time of treatment, as
seen by comparing data from figure 1B and 1C.
Apoptotic characteristics including cellular and nuclear morphology and
biochemical features were studied in Jurkat cells with various times of pancratistatin
treatment. Hoechst staining clearly indicated typical nuclear morphological changes
induced by apoptosis, such as increased brightness of the nuclei and nuclear
condensation (Figure 1D). DNA fragmentation is another key feature of apoptosis that
was examined by using the comet assay as previously described (Naderi et al, 2003).
The presence of a comet after 24 h indicated that massive apoptotic DNA fragmentation
had occurred in most of the Jurkat cells (Figure 1E).
A specific biochemical characteristic of apoptosis is the flipping of phosphatidyl serine
from the inner leaflet of the plasma membrane to the outer leaflet. This change can be
observed as an increase in fluorescence due to the binding of the Annexin-V AlexaFluor
conjugate to phosphatidyl serine. As shown in figure 1F, Annexin-V binding was obvious
after 1 h of pancratistatin treatment in Jurkat cells, indicating early activation of the
pathway of apoptosis.
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Figure 1.
Induction of apoptosis in Jurkat cells treated with different
concentrations of pancratistatin. (A) Jurkat cells were treated with various
concentrations of pancratistatin as indicated. After 6 h of treatment, cells were stained
with Hoechst dye and the percentage of apoptotic cells (the apoptotic index) determined.
A minimum of five different fields at 100x magnification were counted and an average
was taken for each experiment. The standard error was calculated using the data from
three separate sets of experiments. (B) Induction of apoptosis over time in Jurkat (open
columns) and normal blood cells (shaded columns) treated with pancratistatin. Jurkat or
normal blood cells were treated with 1 µM pancratistatin for the indicated times. The
apoptotic index was calculated as described above using a minimum of five different
fields per experiment at 100x magnification. The standard error was calculated using the
data from three separate sets of experiments. (C) Trypan blue staining for dead and live
Jurkat cells treated with pancratistatin. Jurkat cells were treated with pancratistatin for
the indicated times. The cells were then stained with Trypan blue dye so that the number
of dead cells could be determined. The results are presented as the percentage of
permeable (dead) cells. A minimum of eight different fields at 100x magnification were
counted and an average was taken for each experiment. The standard error was
calculated using the data from three separate sets of experiments. (D) Nuclear and
cellular morphology of Jurkat cells treated with pancratistatin. The cells were treated with
pancratistatin at 1 µM for the indicated times. Cells were then stained with Hoechst to
examine nuclear morphology. Apoptosis is evident in cells with bright, condensed and
rounded nuclei. (E) DNA degradation in Jurkat cells treated with pancratistatin as
indicated by the comet assay. Jurkat cells were treated with either solvent (control,
0.001% DMSO) or 1 µM pancratistatin for 24 h. DNA degradation is indicated by the
comet-like images due to migration of damaged DNA during electrophoresis. (F)
Induction of the flipping of phosphatidyl serine in the plasma membrane of Jurkat cells by
1 µM pancratistatin treatment. Fluorescence indicates the flipping of phosphatidyl serine
to the outer leaflet of the plasma membrane. Pictures were taken at 400x magnification.
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These results collectively illustrate that pancratistatin is a very potent inducer of
apoptosis in Jurkat cells. Normal nucleated blood cells including lymphocytes are not
affected by pancratistatin.
Normal lymphocytes purified from a healthy person are the best candidates to
determine the effect of pancratistatin on non-cancerous cells in comparison to the effect
on cancerous Jurkat cells. These cells respond differently than Jurkat cells when
subjected to pancratistatin treatment under similar conditions. We investigated the
sensitivity of nucleated blood cells including lymphocytes to pancratistatin by quantifying
the degree of apoptosis as with Jurkat cells. Unlike the Jurkat cells, the apoptotic index
of the pancratistatin-treated lymphocytes did not increase over a significant amount of
time (up to 24 h, Figure 1B). Furthermore, the nuclear shrinkage and brightness detected
in Jurkat cells were not visible in the normal lymphocytes (Figure 2A). This suggests that
apoptosis was not being induced in normal non-cancerous blood cells. Moreover, there
was no increase in fluorescence following the Annexin-V binding assay (Figure 2B),
implying that this apoptotic event was not present following treatment of lymphocytes
with pancratistatin. The pathway of apoptosis is therefore not activated by pancratistatin
in normal lymphocytes as it is in Jurkat cells.
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Figure 2.
Pancratistatin selectively induces apoptosis in cancer cells. (A)
Nuclear morphology of Jurkat (cancerous) and normal blood cells (non-cancerous
peripheral blood mononuclear cells) treated with pancratistatin. Cells were treated with
solvent (control, 0.001% DMSO) or 1 µM pancratistatin for 24 h. Apoptosis is evident in
cells with bright, condensed and rounded nuclei. (B) Specific induction of the flipping of
phosphatidyl serine in the plasma membrane of Jurkat cells by pancratistatin treatment.
After 3 h of treatment with 1 µM pancratistatin, the Annexin-V binding assay was
performed. Fluorescence indicates the flipping of phosphatidyl serine to the outer leaflet
of the plasma membrane only in Jurkat cells, not in normal blood cells. Pictures were
taken at 400x magnification.
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Pancratistatin provokes early activation of caspase-3 in Jurkat cells, but not in
normal lymphocytes
Caspase-3 is a required component of the apoptotic machinery which is activated
specifically in the pathway of apoptosis. To determine whether pancratistatin treatment
caused caspase-3 activation, the activity of caspase-3 was assayed in cell extracts
prepared at different times after pancratistatin treatment. There was an early increase in
caspase-3 activity upon treatment of Jurkat cells (Figure 3) indicating that caspase-3
might be involved in the early phase of apoptosis induced by pancratistatin in Jurkat
cells. This increase in activity was not evident in lymphocytes; again illustrating that
pancratistatin does not induce apoptosis in lymphocytes (data not shown).
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Figure 3.
Early activation of caspase-3 in Jurkat cells treated with
pancratistatin. The caspase-3 assay was performed as described in Materials and
methods. The average of nine readings was used to determine the reading for each well.
A minimum of three wells were run per experiment and the average was taken for each
experiment. The results were calculated per microgram of protein and the standard error
was calculated using the data from three separate sets of experiments.
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Role of mitochondria in pancratistatin-induced apoptosis in Jurkat cells
The collapse of the mitochondrial membrane potential is a common event in the
apoptotic pathway that leads to mitochondrial dysfunction and production of ROS.
Mitotracker Red staining was carried out as described in Materials and methods to
assess the mitochondrial membrane potential. Figure 4A clearly illustrates that the
mitochondrial membrane potential in Jurkat cells was not lost prior to activation of
caspase-3 by pancratistatin treatment. Furthermore, total cellular ROS was measured
using the redox-sensitive fluorescent dye DCFDA, and the readings further confirmed
that the production of ROS occurred after activation of caspase-3 (Figure 4B). There was
minimal ROS production relative to Jurkat cells in normal blood cells (data not shown).
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Figure 4.
The effect of pancratistatin treatment on the mitochondrial
membrane potential of Jurkat cells. (A) Jurkat cells were treated with solvent (control,
0.001% DMSO) or 1 µM pancratistatin for 30 min and stained with Mitotracker Red;
fluorescence indicates that the mitochondrial membrane potential is intact. Pictures were
taken at 400x magnification. (B) Generation of ROS in Jurkat cells treated with
pancratistatin determined using DCFDA. The average of nine readings was used to
determine the reading for each well. A minimum of three wells were run per experiment
and the average was taken for each experiment. The results were calculated per 10 000
cells and standard error was calculated using the data from three separate sets of
experiments.
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Pancratistatin is a non-genotoxic inducer of apoptosis as compared to Vp-16
Pancratistatin treatment of Jurkat cells caused caspase-3 activation and ROS
production within 3 h, but no comet had been produced at this time. This indicates that
DNA degradation is not an early event in the pathway of apoptosis induced by
pancratistatin in Jurkat cells. On the other hand, Vp-16 had clearly produced comets at
this time (Figure 5A). This absence of DNA degradation by pancratistatin at an early
phase, and its presence in a later phase indicates that DNA degradation is a result of the
apoptotic mechanism. With Vp-16, the DNA damage was detected very early, which
indicates that apoptosis was caused by DNA damage. These results signify that
pancratistatin is a non-genotoxic inducer of apoptosis in Jurkat cells in contrast to Vp-16
which is a known genotoxic anti-cancer drug. In order to rule out the possibility of DNA
double-strand breaks (DSB) caused by pancratistatin, we performed antiphosphohistone
H2AX immunostaining. This assay is one of the most sensitive methods of detecting
DNA fragmentation in mammalian cells (Rothkamm and Löbrich, 2003). Phosphorylation
of the histone H2AX, symbolized as γ-H2AX, is one of the earliest events of DNA repair
in response to DSB. Hence a positive staining indicates the presence of DSB (Martin,
2001; Bassing et al, 2002; Huang et al, 2004). As shown in figure 5B, pancratistatin did
not stain for H2AX at the early time point of 3 h. This illustrates that indeed pancratistatin
does not induce DSB in Jurkat cells; however we cannot rule out the possibility of singlestrand breaks. A positive staining in Vp-16-treated cells confirms that this drug truly is a
genotoxic anti-cancer drug.

50

Figure 5.
Detection of DNA degradation at an early phase of treatment in
Jurkat cells. (A) Jurkat cells were treated with solvent (control, 0.001% DMSO), 1 µM
pancratistatin (PST-1) or 10 µM Vp-16 for 3 h. The comet assay was then performed as
described. DNA degradation is indicated by the comet-like images due to migration of
damaged DNA during electrophoresis. Pictures were taken at 400x magnification.
(B) Detection of DNA DSB by H2AX staining. Cells were treated with solvent (control,
0.001% DMSO), 1 µM pancratistatin (PST-1) or 10 µM Vp-16 for various times as
indicated. Bright fluorescence indicates the presence of DNA DSB. Pictures were taken
at 600x magnification, using oil immersion.
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Vp-16 induces genotoxicity in normal cells
Although it has clearly been proven that Vp-16 (a topoisomerase-II inhibitor) is
genotoxic to cancerous cells (Boose and Stopper, 2000), we decided to test its effect on
the DNA of normal blood cells. Vp-16 treatment caused DNA damage as seen by comet
formation, demonstrating its genotoxic effect on lymphocytes (Figure 6A). The absence
of comets in normal blood cells (lymphocytes) treated with pancratistatin indicated that it
may not cause DNA damage (Figure 6A). These results indicate that Vp-16 is genotoxic
to Jurkat cells as well as normal lymphocytes whereas pancratistatin did not show any
sign of genotoxicity to normal nucleated blood cells even after 24 h. This was further
confirmed by the fact that no H2AX staining was observed following pancratistatin
treatment, but was clearly evident following Vp-16 treatment (Figure 6B). Therefore,
unlike Vp-16, pancratistatin specifically induces apoptosis in Jurkat cells, but does not
seem to affect lymphocytes.
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Figure 6.
Effect of pancratistatin and Vp-16 treatment on the DNA integrity of
normal blood cells. (A) Normal blood cells were treated with solvent (control, 0.001%
DMSO), 1 µM pancratistatin (PST) or 10 µM Vp-16 for 24 h. The comet assay was then
performed as described. DNA degradation is indicated by the comet-like images due to
migration of damaged DNA during electrophoresis. Pictures were taken at 400x
magnification. (B) Detection of DNA double-strand breaks (DSB) in normal blood cells
treated with Vp-16. Cells were treated with solvent (control, 0.001% DMSO), 1 µM
pancratistatin (PST) or 10 µM Vp-16 for 3 h. Fluorescence indicates the presence of
DNA DSB. Pictures were taken at 600X magnification using oil immersion.
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DISCUSSION
We report here for the first time that pancratistatin is selective in inducing
apoptosis strictly in cancerous cells (specifically Jurkat cells). Second, since the
chemical structure of pancratistatin does not resemble any existing genotoxic chemicals,
DNA is unlikely to be a direct target of this drug. Due to the desperation for a treatment,
genotoxic drugs are currently being used to target this disease. Unfortunately, we have
found that some of these drugs, such as Vp-16 and paclitaxel are toxic to normal blood
cells.
Although pancratistatin has been studied for many years, most of the research
done on this drug has been in the field of organic chemistry (Khan et al, 1999; McNulty et
al, 2001; Kim et al, 2002). For this reason, little information is available regarding its
biochemical activity. However, it has been found that the pharmacophore of this drug is
capable of specifically killing cancerous cells by inducing apoptosis.
The rapid and efficient induction of classical apoptosis by a very low
concentration of pancratistatin in human lymphoma cells illustrates that this chemical is
very specifically targeting a biochemical component of the apoptotic pathway. More
importantly, however, is the fact that pancratistatin left the normal blood cells unaffected
both biochemically and morphologically after 24 h. We have also tested the effect of
pancratistatin on other normal non-cancerous cells, including dividing human fibroblasts,
and human embryonic endothelial cells, and have found that it is not affecting the
population doubling or viability of these cells (McLachlan et al., unpublished results). On
the other hand, Vp-16, a commonly used chemotherapeutic agent, causes DNA damage
in normal nucleated cells. This suggests that pancratistatin is a more specific inducer of
apoptosis in cancer cells than currently used drugs such as Vp-16. We have also
observed that paclitaxel causes apoptosis in normal nucleated cells (data not shown).
Although the efficacy of pancratistatin was highest in Jurkat cells, we have shown that it
is also effective in inducing apoptosis in various cancer cell lines, including human breast
cancer (MCF-7), rat hepatoma (5123) and neuroblastoma (SH-SY5Y) cells.
What is therefore the biochemical target of pancratistatin? DNA is a less likely
target of pancratistatin action since is not structurally similar to any known genotoxic
drugs. Our results from the comet assay further confirmed that indeed there is no early
DNA degradation, but that DNA fragmentation is a late event in the apoptotic cascade
resulting from pancratistatin treatment. In contrast, Vp-16 caused massive DNA damage
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at an early phase (3 h). Furthermore, we applied H2AX staining, a sensitive technique to
monitor DNA DSB. This indicated that pancratistatin did not induce DSB, whereas Vp-16
caused DSB soon after treatment. These experiments imply that pancratistatin could be
a non-genotoxic compound that induces apoptosis by targeting non-genomic targets.
It is commonly accepted that a mitochondrial target can trigger apoptosis. This
would suggest that pancratistatin might be targeting the mitochondrial membrane.
However, this possibility was ruled out because our preliminary results indicated that
within a short time of treatment, there was neither depolarization of the mitochondrial
membrane nor production of ROS.
Interestingly, during the first hour, the apoptotic events triggered by pancratistatin
were found to be the flipping of phosphatidyl serine on the plasma membrane and the
activation of caspase-3. Surprisingly, this activation of caspase-3 came before that of
caspase-8 which was found to be activated only after 3 h of treatment (refer to Appendix
B, Figure 1). This evidence leads to two possibilities: pancratistatin directly activates
caspase-3 or pancratistatin is targeting an enzyme on the plasma membrane. Incubation
of a cell extract from untreated Jurkat cells with pancratistatin did not result in the
activation of caspase-3 thus indicating that pancratistatin was not directly interacting with
caspase-3 (data not shown).
The other possible mechanism includes interaction with the plasma membrane
and cytosolic proteins as a target for pancratistatin. Receptor-mediated Fas inducedapoptosis in Jurkat cells is one of the best-studied biochemical pathways (Ashkenazi and
Dixit, 1998). It is generally believed that caspase-8 is recruited to the death-inducing
signalling complex (DISC) following oligomerization of the Fas receptor. It is this initiator
caspase of DISC that cleaves and activates caspase-3 as well as the Bid protein
(Chinnaiyan et al, 1995). Intriguingly, it has been recently shown that caspase-3 is
recruited to the DISC and processed to its active form before activation of caspase-8 or
mitochondrial depolarization (Aouad et al, 2004). Recently evidence has also been found
suggesting that caspase-3 may be present in the plasma membrane of the cell (Aouad et
al, 2004). It is possible that pancratistatin may be directly targeting the Fas receptors on
the plasma membrane of blood lymphoma cells which further activates caspase-3
followed by the activation of caspase-8. This is our hypothesis currently under
investigation. Our preliminary results have indicated that indeed there is a significant
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increase in caspase-3 activity following pancratistatin treatment in the plasma membrane
fraction of Jurkat cells (data not shown).
With this mechanism of action, why are normal cells not being affected by
pancratistatin? This could be due to the expression of the Fas receptors which is found
to be greater in blood lymphoma cells than normal blood cells. Furthermore, in fastdividing cancer cells, the plasma membrane tends to run short of lipids, perhaps
changing the fluidity of the membrane.
CONCLUSIONS
We are aggressively pursuing this hypothesized mechanism of action of
pancratistatin in cancerous cells. Current investigation is underway to determine exactly
what the biochemical targets of pancratistatin are on blood lymphoma cells. Given the
significance

of

our

in

vitro

results, pancratistatin

could

be a

much better

chemotherapeutic agent than those presently available.
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CHAPTER 3

Pancratistatin induces apoptosis in clinical leukemia samples with
minimal effect on non-cancerous peripheral blood mononuclear cells
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BACKGROUND
Chemotherapy for acute myeloid leukemia, despite earnest attempts, has not
significantly changed in the last 30 years. Treatment continues to be based on the
cytotoxic chemotherapies of anthracyclines and cytarabine. The natural compound,
pancratistatin, extracted from the Hymenocallis littoralis, has broad-range efficacy
against several cancer cell lines at 1 μM, with minimal effect on non-cancerous cell lines
of the same origin (McLachlan et al, 2005; Siedlakowski et al, 2007). Pancratistatin
treatment causes phosphatidyl-serine flipping, caspase-3 activation, generation of
reactive oxygen species (ROS), and loss of mitochondrial membrane potential, which
leads to apoptosis in cultured T-cell (Jurkat) leukemia cells (Kekre et al, 2005). Although
pancratistatin is a non-genotoxic drug, its target has not yet been elucidated (Kekre et al,
2005; Dumont et al, 2007). The efficacy of pancratistatin in inducing apoptosis selectively
in cultured (commercial) cancer cell lines is well established, though its effect on
leukemia cells obtained from patients has not been tested.
In this study, clinical leukemia and non-cancerous peripheral blood mononuclear
cells (ncPBMCs) were treated with pancratistatin to determine its selectivity and efficacy
to induce apoptosis ex vivo. Activity of pancratistatin was compared to that of the widely
used chemotherapeutic, paclitaxel, against cancer cells. Peripheral blood samples from
patients with a diagnosis of acute myeloid leukemia (AML; n=11), acute lymphoid
leukemia

(ALL;

n=1),

chronic

myelogenous

leukemia

(CML;

n=1),

chronic

myelomonocytic leukemia (CMML; n=1) and Mantle cell lymphoma (n=1) were obtained.
The majority of samples were taken at diagnosis, that is, in chemo-näive patients. Of the
15 patients, 5 did not go into remission with induction chemotherapy. The median
duration of remission was 3 months. Our pre-clinical results demonstrate that
pancratistatin is effective against all types of leukemia tested and does not induce
apoptosis in non-cancerous mononuclear cells.
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METHODS
Cell culture
Human T-cell (Jurkat) leukemia cells were purchased from ATCC and maintained
in RPMI 1640 medium supplemented with 10% fetal bovine serum and 10 μM
gentamycin in an incubator set at 37°C and 5% CO 2 in air. Peripheral blood was
obtained from leukemia patients at the Windsor Regional Cancer Centre (WRCC,
Windsor Regional Hospital REB #04-043 and 04-044) upon written, informed consent
and from healthy non-smoking volunteers aged 25-50 y (University of Windsor REB #04147). Whole blood samples were collected in BD VacutainerTM Cell Preparation Tubes,
and mononuclear cells were separated by density gradient centrifugation. The isolated
cells were maintained in RPMI 1640 media supplemented and maintained in the same
way as the Jurkat cultures. Cells were treated within 3 h of collection with 1 μM
pancratistatin or 500 nM paclitaxel for up to 48 h.
Apoptosis assays
Apoptotic cells were detected by microscopy with cell-permeable Hoechst 33342
dye (Molecular Probes, Eugene OR) or by flow cytometry with Annexin-V AlexaFluor-488
(Sigma-Aldrich, Missisauga, ON) using established protocols (Siedlakowski et al, 2007).
Briefly, cells were treated with 1 μM pancratistatin for either 24 or 48 h, or with 500 nM
paclitaxel for 24 h. For flow cytometry, cells were washed twice in room temperature
PBS, resuspended in Annexin-V binding buffer and incubated with AlexaFluor-488 (1:50)
for 15 min. They were washed in calcium-binding buffer and a minimum of 20,000 were
analyzed on a Beckman Coulter Cytomics FC500 flow cytometer. To achieve the highest
cell number per sample, propidium iodide was not used in this study. For microscopy, 5
min incubation with 10 μM Hoechst 33342 dye was added to the Annexin-V binding step.
Brightly stained, condensed nuclei were visible with Hoechst dye, characteristic of
apoptotic cells, as is phosphatidylserine externalization detected by Annexin-V binding.
Images were captured on an inverted fluorescence microscope (Leica DM IRB,
Germany). The percentage of apoptotic cells was calculated from a minimum of 5 fields
with >100 cells/field. Statistical analysis by unpaired t-test, where † represents p<0.05;
significantly different between means of untreated and pancratistatin treated leukemia
samples.
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RESULTS
Pancratistatin induces apoptosis in cultured leukemia cells
From previous experiments on the effects of pancratistatin on cultured Jurkat
cells (T-cell leukemia), the majority of cells were apoptotic after 24 h (Kekre et al, 2005).
Pancratistatin rapidly induced apoptosis in >80% of Jurkat cells in the present study,
whereas paclitaxel induced cell death in ~25% of cells, as determined by flow cytometry
using Annexin-V AlexaFluor 488 (Figure 1A).
Pancratistatin induces apoptosis in clinical leukemia samples
Table 1 gives details of each patient‟s age, leukemia type and percent blasts at
diagnosis, alongside their response to pancratistatin treatment ex vivo. Nine of the 15
samples showed an increase in apoptosis of 40% greater than untreated PBMCs of the
same patient after exposure to pancratistatin, as determined by Hoechst staining (Table
1). This result was confirmed by detection of Annexin-V AlexaFluor 488 binding by flow
cytometry (Figure 1B). Figure 2 shows the efficacy of pancratistatin on both cultured
leukemia (Jurkat) cells and patient-obtained leukemia PBMCs as observed by Hoechst
staining and Annexin-V binding.
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Figure 1.
Detection of apoptosis in cells treated for 24 h with paclitaxel or
pancratistatin. Flow cytometry with Annexin-V AlexaFluor 488 was used to detect
apoptosis in Jurkat cells (A) and patient-obtained leukemic PBMCs (B) that were
untreated, treated with 500 nM paclitaxel or treated with 1 µM pancratistatin for 24 h. The
leukemic PBMCs were obtained from a chemo-näive female patient (65 y) diagnosed
with AML – M1. Flipping of phosphatidylserine from the inner to the outer leaflet of the
plasma membrane, which binds to Annexin-V in the presence of calcium, is a
characteristic feature of apoptosis. A minimum of 20 000 events were measured for each
sample on a Beckman Coulter Cytomics FC500 flow cytometer. Relative event number is
displayed on the Y-axis, and relative fluorescence intensity is displayed on the X-axis.
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Patient #

Age

13
9
11
2
8
1
10
5
3
14

47
45
68
81
74
60
57
23
53
71

15

65

6
4
7
12

66
73
62
80

Clinical
Diagnosis

AML
AML
AML – M2
AML – M2
AML – M2
AML – M3
AML – M3
AML – M5a
AMoL – M5a
AML – M0,
relapsed
AML – MDS,
relapsed
ALL – L3
CML
CMML – M4
Mantel cell
lymphoma

% Blasts

Clinical
Response

Exposure

% Apoptosis

44%
84%
n/a
20%
60%
85%
43%
70%
96%
52%

censored
censored
CR
NR
NR
censored
PR
NR
CR
relapsed

48h
48h
48h
24h
48h
24h
48h
24h
24h
48h

37.3 ± 7.7
63.9 ± 4.2
46.8 ± 12.2
33.5 ± 7.7
48.6 ± 6.7
64.9 ± 4.2
70.8 ± 5.9
30.6 ± 1.6
46.5 ± 7.9
45.3 ± 11.3

48%

CR

48h

37.3 ± 8.5

34%
9%
32%
0%

NR
censored
NR
censored

48h
24h
48h
48h

61.8 ± 9.8
63.9 ± 2.2
17.7 ± 2.7
35.2 ± 6.6

Table 1.
Clinical features, disease state, response in the clinic and in vitro of
patient-obtained leukemia treated with pancratistatin. Apoptosis percentage values
are corrected for the percentage of apoptosis observed in untreated samples of the
same patient. All diagnoses are 1st occurrence unless otherwise stated. Patients were
diagnosed in the clinic with: Acute Myeloid Leukemia (AML), subtyped as M0 – M7 or
MDS (myelodysplastic syndrome); Acute Monocytic Leukemia (AMoL); Acute
Lymphoblastic Leukemia (ALL), subtyped as Burkitt‟s (L3); Chronic Myelogenous
Leukemia (CML); or Chronic Myelomonocytic Leukemia (CMML). Response to
chemotherapy administered in the clinic is indicated as complete response (CR), partial
response (PR), no response (NR), relapsed or censored.
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Figure 2.
Response of clinical leukemia and cultured Jurkat cells to treatment
with pancratistatin. The apoptotic effect of 24 h exposure to 1 µM pancratistatin was
observed by microscopy using cell-permeable Hoechst dye. Compared to the nuclear
morphology of untreated cells (A, B), treatment with pancratistatin resulted in apoptosis
characterized by condensed, brightly stained nuclei in Jurkat (E) and patient obtained
leukemic PBMCs (F). Annexin-V binding, another characteristic feature of apoptosis, was
minimal in untreated cells (C, D) in contrast to the binding observed after pancratistatin
treatment (G, H). Hoechst and Annexin-V images are not of the same field.

65

Pancratistatin is non-toxic to non-cancerous PBMCs
To determine if the apoptosis-inducing effect of pancratistatin is selective for
cancer cells, PBMCs isolated from blood samples from healthy volunteers (n=8) were
treated with 1 μM pancratistatin for up to 48 h. Interestingly, pancratistatin did not
enhance apoptosis in these cells as in leukemic PBMC isolates, as determined by flow
cytometry analysis using Annexin-V binding and nuclear morphology after Hoechst
staining

(Figure

3A,

3B).

The

cancer-selective

apoptosis-inducing

activity

of

pancratistatin was a trend that was observed in all samples obtained (Figure 4). These
data demonstrate that pancratistatin is selectively toxic to cancer cells ex vivo,
irrespective of leukemia type, with an insignificant effect on non-cancerous PBMC
isolates.
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Figure 3.
Non-cancerous peripheral blood mono-nucleated cells (PBMCs) are
relatively unaffected by pancratistatin. (A) Flow cytometry analysis using Annexin-V
AlexaFluor 488 was performed on PBMCs that were untreated (left panel) or treated with
1 µM pancratistatin (right panel) for 48 h. A minimum of 20 000 events were measured
for each sample on a Beckman Coulter Cytomics FC500 flow cytometer. Relative event
number is displayed on the Y-axis, and relative fluorescence intensity is displayed on the
X-axis. (B) Hoechst staining and Annexin-V binding depicts the selective activity of
pancratistatin; there is minimal difference in nuclear morphology (i, ii) and amount of
externalized phosphatidylserine (iii, iv) between untreated and treated non-cancerous
PBMCs.
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Figure 4.
Comparative effect of 48 h pancratistatin treatment. Leukemia
samples (n=10) and non-cancerous PBMCs (n=8) treated for 48 h with pancratistatin
were stained with Hoechst dye and counted manually (a minimum of 5 fields with 100
cells per field); percent apoptosis was calculated per total cell number. Statistical
analysis was performed (unpaired t-test, two-tailed p value); † represents p<0.05
between untreated and pancratistatin treated leukemia samples.
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DISCUSSION
We report the novel finding that pancratistatin has selective apoptosis-inducing
activity ex vivo at a low dose in a random sampling (n=15) of patient-obtained leukemias.
In contrast, pancratistatin has no effect on non-cancerous peripheral blood mononuclear
cells (n=8). Cellular subtypes in the PBMC samples may have differing sensitivities to
pancratistatin and separation of these populations is needed to clarify this point, but
requires much greater numbers. However, our results indicate that PBMCs collected
from healthy volunteers of various ages were unaffected by pancratistatin. It is therefore
unlikely that pancratistatin is toxic to a particular subtype of non-cancerous PBMC
samples. The efficacy and selectivity of pancratistatin against clinical leukemia is based
on two characteristic features of apoptosis, namely nuclear morphology and lipid
rearrangement within the plasma membrane. Our results suggest that pancratistatin
could be a novel way to treat leukemia and may not cause adverse effects common to
intravenous chemotherapy (Gerber, 2008). Paclitaxel has been used to treat many types
of cancer, including leukemia, for over a decade; but it causes harsh side effects often
associated with chemotherapy (Sonnichsen, 1994). In contrast, pancratistatin is more
effective against cancer cells than paclitaxel and has no significant effect on noncancerous PBMC samples.
The mechanism of action and biochemical target of pancratistatin is currently
being studied. Due to its broad-range effectiveness, we hypothesize that pancratistatin
may selectively target cancer cell mitochondria, as opposed to a specific kinase or
signalling protein. We have previously shown that pancratistatin causes mitochondrial
membrane potential collapse and permeabilization, leading to reactive oxygen species
(ROS) generation, cytochrome c leakage, caspase-3 activation, and apoptosis (Kekre et
al, 2005; Siedlakowski et al, 2007; Griffin et al, 2007). Recent reports indicate that some
leukemia cells have increased basal levels of ROS, suggesting increased susceptibility
to oxidative stress, which can lead to mitochondrial permeabilization and subsequent
apoptosis (Wang et al, 2008). It has also been reported that cancer cell mitochondria are
dysfunctional and more susceptible to attack compared to non-cancerous cell
mitochondria,

which

presents

an

opportunity

for

the

development

of

new

chemotherapeutics, especially for leukemia (Vondrácek et al, 2006). Liu and colleagues
reported that Lycorine, also an Amaryllidaceae alkaloid, induces caspase-dependent
apoptosis in leukemia cells by down-regulating the anti-apoptotic protein, Mcl-1 (Liu et al,
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2009). It is possible that pancratistatin is also targeting a protein that regulates the
balance of apoptosis/survival, which could explain the broad-range efficacy of this
compound against cancer cells in vitro. This is supported by our evaluation of
pancratistatin on patient-obtained leukemia cells ex vivo at a low dose (1 μM).

CONCLUSIONS
Our results show that pancratistatin is an effective and selective anti-cancer
agent with potential for advancement to clinical trials (Kornienko and Evidente, 2008).
Targeted therapies are the holy grail of systemic cancer therapy; the ideal drug should
kill cancer cells without harming non-cancerous cells. This is an exciting development in
the treatment of AML, for which treatment regimens used over the last 30 years have not
significantly improved survival.
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CHAPTER 4

Selective cytotoxicity of pancratistatin-related natural amaryllidaceae
alkaloids: evaluation of the activity of two new compounds
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BACKGROUND
The initial report by Pettit and colleagues in 1993 demonstrated that
Pancratistatin (PST) a natural compound isolated from the Hawaiian spider lily
(Hymenocallis littoralis) displayed potent cytotoxicity against human tumor cell lines
(Pettit et al, 1993). They also noted that in the NCI “disease oriented” in vitro anti-tumor
screen against 60 cell lines representing lung, colon, ovarian, renal, brain, melanoma
and myelocytic leukemia, the pattern of activity of PST against various tumor types was
distinct from that of other known anti-tumor drug classes. Recently, we demonstrated the
selective toxicity of PST to cancer cells and the sparing of normal cells at micromolar
doses (Kekre et al, 2005). In addition we have demonstrated that PST acts by affecting
mitochondrial function and inducing apoptosis in malignant cell lines (McLachlan et al,
2005).
A systematic synthetic approach has been used to determine the minimum
cytotoxic pharmacophore and is known to comprise the trans-fused b/c-ring system
containing the 2, 3, 4-triol unit in the C-ring (McNulty et al, 2001; Rinner et al, 2004;
McNulty et al, 2005). It has also been noted that the 2, 3-diol derivatives have significant
activity (McNulty et al, 2001), indicating that the C3-hydroxyl is a moderating influence.
The C-7 phenolic and C-1 hydroxyl functions are not essential (Pettit et al, 2004; Pettit et
al, 2006).
The aim of present work was to further evaluate the structure-activity
relationships of two other AMD alkaloids, AMD4 and AMD5 (Figure 1). Both these
compounds lack the multiple hydroxyl groups but instead have a methoxy group that
varies in orientation between AMD4 (α) and AMD5 (β). Our results indicated that like
PST, AMD5 has the capability of selectively inducing apoptosis in cancer cells while
sparing normal cells, albeit at a concentration 10-fold higher.
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Figure 1.
Chemical structure of native Pancratistatin (A) and of
Amaryllidaceae alkaloids AMD4 and AMD5 (B). The phenanthridone skeleton is a
conserved feature in alkaloids of the Amaryllidaceae family. The Amaryllidaceae
compounds have a methoxy group that varies in orientation between AMD4 (α) and
AMD5 (β).
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METHODS
Cell culture
Human T-cell leukemia (Jurkat) cells were obtained from ATCC, Manassas, VA.
These cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS) and 10 µM gentamycin (Life Technologies, Mississauga, ON) in an
incubator set at 37°C, 5% CO2 and 95% humidity. Human nucleated blood cells were
isolated from whole blood taken from a healthy non-smoking male (University of Windsor
REB #04-147). The whole blood sample was collected in a BD VacutainerTM CPT (Cell
Preparation Tube) obtained from Becton Dickinson, Franklin Lakes, NJ, and centrifuged
at 500 x g for 30 min at 25ºC. The upper layer consisting of mononuclear cells, platelets
and plasma was collected and maintained in RPMI 1640 media supplemented with 10%
FBS and 10 µM gentamycin (Life Technologies) in the same incubator as Jurkat cells.
Cell treatment
Cells were grown and treated with either AMD4 or AMD5 alkaloids at various
concentrations and time-points. AMD4 and AMD5 (99.5% pure) were derived as detailed
by Pettit and colleagues (Pettit et al, 1993).

Cellular viability assay
Cells were grown to 70% confluence and treated with AMD4 and AMD5 at a final
concentration of 10 µM. The cells were then stained with the cell permeable dye Hoechst
33342 (Molecular Probes, Eugene, OR) at 10 µM final concentration and incubated for
10 min at 25ºC. Brightly stained, condensed nuclei are characteristic features of
apoptotic cells, as visualized with a fluorescent microscope (Leica DM IRB, Germany).
Images were captured at 10X and 40X objectives; the percentage of apoptotic cells was
calculated from the total number of cells with Microsoft Excel 6.0 software and pictures
were compiled using Adobe Photoshop 7.0 software. A minimum of 5 fields of at least
100 cells per field was counted. Statistical significance was determined using
STATISTICA software.

Annexin-V binding assay
Jurkat cells were treated with 10 µM AMD4 and AMD5 for 24 hours. The
Annexin-V binding assay was conducted according to the manufacturer‟s protocol using
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a kit purchased from Molecular Probes, Eugene, OR. Briefly, cells were washed with
phosphate-buffered saline (PBS) and re-suspended in Annexin-V binding buffer (10 mM
HEPES/NaOH pH 7.5, 140 mM NaCl, 2.5 mM CaCl 2), containing Annexin-V Alexa
Fluor® 488 conjugate (1:50) for 15 min at 25ºC; pictures were taken with a fluorescent
microscope (Leica DM IRB, Germany) at 40X objective and compiled using Adobe
Photoshop 7.0 software.
TUNEL assay
After treating Jurkat cells with AMD4 and AMD5 at indicated times the TUNEL
Assay was performed as per manufacturer‟s protocol (Molecular Probes, Eugene, OR)
and a previously published method (McLachlan et al, 2005), to detect DNA damage.
Cells were fixed by suspending them in 70% (v/v) ethanol and stored at -20oC overnight.
The sample was then incubated with DNA-labelling solution (10 µL reaction buffer, 0.75
µL TdT enzyme, 8 µL BrdUTP, 31.25 µL of dH2O) for 1 h at 25ºC. Each sample was
then exposed to an antibody solution consisting of 5 µL Alexa Fluor® 488 labeled antiBrdU antibody with 95 µL rinse solution and allowed to react for 20 min; pictures were
taken at 20X objective using a fluorescent microscope (Leica DM IRB, Germany).

Caspase-3 assay
The caspase-3 assay was carried out using a previously published method
(Kekre et al, 2005). Briefly, Jurkat or normal lymphocyte cellular lysates were collected
and incubated with the fluorogenic substrate DEVD-AFC (MP Biomedicals, Aurora, OH)
in DEVD buffer (0.1 M HEPES, pH 7.4, 2 mM DTT, 0.1% CHAPS, 1% sucrose) and
allowed to incubate at 37ºC for 45 min. Fluorescence was measured at 400 nm
excitation and 505 nm emission using the Spectra Max Gemini XS (Molecular Devices,
Sunnyvale, CA). Caspase-3 activity was calculated per microgram of protein, and
expressed as a percentage of control activity. Protein concentration was determined
utilizing the BioRad protein assay reagent (BioRad, Mississauga, ON, Canada) with
bovine serum albumin as a standard. Microsoft Excel 6.0 software was used for data
representation; statistical significance was determined using STATISTICA software.
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Mito-Casp assay
The Mito-Casp assay was performed as per manufacturer‟s protocol using a kit
purchased from Cell Technology Inc., Mountain View, CA. Briefly, cells were treated with
either alkaloid at 10 µM concentration for the desired times and washed twice in PBS.
Cells were re-suspended in PBS according to protocol and incubated with both MMP dye
and caspase reagent at a 1:30 dilution for 60 min at 37°C in darkness. Following
incubation, the cell pellet was collected and re-suspended in wash buffer; fluorescence
was measured from a 96-well micro-titre plate at 549 nm excitation and 574 nm emission
using the Spectra Max Gemini XS (Molecular Devices, Sunnyvale, CA). Loss of MMP
was presented as a loss in relative fluorescence units per 10 000 cells. Microsoft Excel
6.0 software was used for data representation; statistical significance was determined
using STATISTICA software.
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RESULTS
Amaryllidaceae alkaloids induce apoptosis in Jurkat cells
Jurkat cells were incubated with different concentrations of AMD4 and AMD5 for
up to 72 h. The degree of apoptosis resulting from treatment was observed by Hoechst
staining where condensed, brightly stained nuclei indicated apoptotic cell death. The
number of apoptotic nuclei was expressed as a percentage of the total number of cells in
a dose-dependent manner; alkaloid AMD5 at a concentration of 10 µM incited apoptosis
in over 40% of Jurkat cells after 48 h and was the working concentration used for further
experiments (Figure 2, 3A). In contrast to this finding, alkaloid AMD4 had a minimal
effect on cancer cell viability under similar treatment conditions. To compliment Hoechst
staining, the Annexin-V assay was carried out at several time-points in order to monitor
phosphatidylserine flipping to the outer leaflet of the plasma membrane, a characteristic
apoptotic event. As previously reported, Annexin-V staining is specific to apoptotic cells,
and background staining is low in unaffected cells (Kekre et al, 2005). Jurkat cells
incubated with 10 µM AMD5 resulted in a high incidence of phosphatidylserine flip;
approximately 45% of Jurkat cells were observed to be labelled with Annexin-V-FITC
(Figure 3B).
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Figure 2.
Amaryllidaceae alkaloids induce apoptosis in Jurkat cells. Cells were
stained with cell-permeable Hoechst 33342 dye; the number of brightly stained and
condensed nuclei were counted over the total number of cells visible and displayed as a
percentage. A minimum of 5 fields with at least 100 cells per field were counted. (A)
Dose-response curve for Jurkat cells treated with increasing concentration of AMD4 or
AMD5 for 48 h. Columns, mean (n=5); bars, SD; *, P < 0.05, significantly different from
control by paired t-test. (B) Time-response curve for Jurkat cells treated with 10 μM of
AMD4 or AMD5. Columns, mean (n=5); bars, SD; *, P < 0.05, significantly different from
control by paired t-test.
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Figure 3.
Effect of 10 μM AMD5 after 24 or 48 h on Jurkat cells. (A) Jurkat cells
were stained with cell-permeable Hoechst 33342 dye to observe apoptotic nuclear
morphology. Apoptotic nuclei are brightly stained and condensed compared to healthy
nuclei. (B) Jurkat cells were incubated with Annexin-V 488 Alexa-Fluor conjugate to
observe phosphatidyl-serine flipping from the inner to the outer leaflet of the plasma
membrane, a characteristic event of apoptosis. Magnification: 400×
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DNA fragmentation observed in Jurkat cells treated with Amaryllidaceae alkaloids
The TUNEL (terminal transferase dUTP nick end labeling) assay was used to
measure the extent of DNA fragmentation that occurs following treatment with alkaloid
AMD5. Cells were grown and treated at 10 µM final concentration for 24 h. At this timepoint, approximately 20% of cells displayed characteristic apoptotic morphology with
Hoechst staining. As shown in Figure 4, extensive DNA fragmentation was visible by
fluorescence microscopy in cells treated with AMD5; this corresponds with the increase
in apoptotic morphology at 48 h of treatment with this alkaloid.
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Figure 4.
TUNEL assay on Jurkat cells treated with AMD5 at 10 μM for 24 h.
Treated Jurkat cells were fixed and immuno-stained with anti-BrdU antibody to observe
DNA damage. The level of staining indicates the degree of DNA damage induced by
treatment, where positively stained cells are in the final stages of apoptosis.
Magnification: 200×
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Amaryllidaceae alkaloid AMD5 causes early activation of caspase-3; disruption of
the mitochondrial membrane potential delayed
The role of caspases as molecular mediators of apoptosis was examined after
treatment up to 48 h with these alkaloids. A slight increase in caspase-3 activation was
observed after 6 h in Jurkat cells treated with AMD4; however, a more drastic increase of
3-fold over control was incited after a 3 h treatment with AMD5 (Figure 5A). This assay
detects activation of caspases-3, -6 and -7 (executioner caspases) and also measures a
change in mitochondrial membrane potential. Our results show that after 48 h the
mitochondrial membrane potential has destabilized in correspondence with an increased
number of apoptotic cells (Figure 5B). Destabilization of the mitochondrial membrane
potential indicates leakage of cytotoxic mitochondrial contents into the cytoplasm,
initiating the cell death process.
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Figure 5.
Effect of AMD5 on caspase activity and mitochondrial function. (A)
Jurkat cells were treated with 10 μM AMD4 or AMD5 for 3 and 6 h and assayed for
caspase activity levels. The level of caspase-3 activity was calculated per microgram of
protein and then displayed as a percent increase in fluorescence from caspase-3 activity
in untreated (control) cells. Columns, mean (n=3); bars, SD; *, p<0.05 significantly
different from control by paired t-test. (B) Jurkat cells were treated with 10 μM AMD5 for
48 h and monitored with the Mito-Casp Assay. A mitochondrial membrane potential
(MMP) sensitive dye was used to measure loss of MMP indicated by a loss of
fluorescence. Columns, mean (n=3); bars, SD; *, p<0.05 significantly different from
control by paired t-test.
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Normal nucleated blood cells are unaffected by treatment with Amaryllidaceae
alkaloid AMD5
Mononuclear cells from peripheral venous blood were purified from whole blood
obtained from a healthy volunteer. Cells were then treated with 10 µM AMD5 for 48 h,
and stained with Hoechst dye to observe apoptotic morphology. As shown in Figure 6,
this alkaloid had minimal effect on the viability of normal nucleated blood cells in
comparison to untreated cells. This result suggests that AMD5 may be less toxic to
healthy cells at a dosage capable of inducing apoptosis in approximately 45% of
cancerous Jurkat cells after 48 h. As the effect of AMD4 against Jurkat cells was
minimal, this alkaloid was not tested against normal nucleated blood cells for specificity.
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Figure 6.
Effect of AMD5 on non-cancerous blood cells. (A) Degree of apoptosis
in healthy peripheral mono-nucleated blood cells (PMBCs) treated with 10 μM AMD5 for
48 h. Cell permeable Hoechst 33342 dye was used to observe apoptotic nuclear
morphology. The percentage of nuclei with apoptotic morphology was calculated by the
number of brightly stained condensed nuclei over the total number of nuclei visible. A
minimum of 5 fields with at least 100 cells per field were counted. Columns, mean (n=5);
bars, SD. (B) Non-cancerous PBMCs were treated with 10 μM of AMD5 for 48 h and
stained with Hoechst dye to observe apoptotic nuclear morphology. Magnification: 200×.
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DISCUSSION
Here we observe that AMD5, a natural alkaloid from the Amaryllidaceae family, is
capable of inducing apoptosis in more than 40% of Jurkat cells at a 10 µM concentration
after 48 h treatment. In addition, this alkaloid was observed to have low toxicity to
healthy mono-nucleated blood cells after 48 h treatment. This result suggests that
crinane-type Amaryllidaceae alkaloids may possess anti-cancer activity similar to the
lycorane derivatives related to PST. PST has been shown to be a highly specific anticancer agent, able to induce apoptosis in over 90% of Jurkat cells in only 24 h at 1 µM
final concentration (Kekre et al, 2005; Griffin et al, 2007; Pandey et al, 2007). It appears
that a correctly functionalized phenanthridone core may thus be a common minimal
structural requirement for these cell specific anti-cancer agents. Although, AMD5 was
found to be well tolerated in non-cancerous cell lines in a cell culture model, its effects on
physiological parameters in animal models should be evaluated for pharmacokinetic
studies to determine the adsorption, distribution, metabolism, excretion and toxic
properties.
An early increase in caspase-3 activation upon treatment with AMD5 suggests
that the extrinsic pathway of apoptosis may be stimulated by this alkaloid. Our study also
found that mitochondrial membrane potential was disrupted after 48 h, when over 40% of
cells had apoptotic nuclear morphology. There is substantial cross-talk between the
extrinsic and intrinsic pathways of apoptosis, both of which lead to activation of caspase3 downstream of cleavage and activation of initiator caspases. In comparison with
AMD5, AMD4 had minimal effect against cancerous cells, which indicates that the
position of the methoxy side-group is crucial. AMD5, with the β-methoxy configuration,
may have a stronger interaction with a critical protein versus AMD4, whose functional
group is in the alpha configuration. This difference may account for our finding that
AMD5 is more efficient at inducing apoptosis in Jurkat cells than AMD4. It must be noted
that the addition of an oxymethyl group has been shown to alter the activity of natural
alkaloids (Gastpar et al, 1998). For example, researchers have observed increased
cytotoxic activity of 8-methoxycaffeine compared to the parent compound (Russo et al,
1991). Nonetheless, the impact of the configuration of methoxy group and its varied
effect on the activity of these AMD alkaloids is a novel and interesting observation.
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CONCLUSIONS
A

correctly

functionalized

phenanthridone

skeleton

present

in

natural

Amaryllidaceae alkaloids may be a significant common element for selectivity against
cancer cells. Importantly, the configuration of the methoxy-side groups is responsible for
higher binding affinity to the target protein/s thus making for a more efficient anti-cancer
agent.
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CHAPTER 5

Pancratistatin selectively targets cancer cell mitochondria and
reduces growth of human colon tumor xenografts
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BACKGROUND
Colorectal cancer is the third most diagnosed cancer worldwide and has a
mortality rate of nearly 1 in 2 (Weekes et al, 2009). Current adjuvant chemotherapy of
metastasized colorectal cancer includes DNA machinery-targeting drugs irinotecan,
oxaliplatin, leucovorin and/or 5-fluorouracil (Weekes et al, 2009). More than 50% of
chemotherapy agents currently in use are natural products or derived directly from
natural sources, and recently there has been increasing interest in natural products as
potential sources for novel therapeutics (Newman and Cragg, 2007; Deorukhkar et al,
2007). The findings presented in this article suggest that the natural alkaloid
pancratistatin may act directly on the mitochondria to induce apoptosis selectively in
human colorectal adenocarcinoma cells.
Pancratistatin is an Amaryllidaceae alkaloid isolated from the bulb of the H.
littoralis species of spider lily. Numerous Amaryllidaceae alkaloids have been isolated
and have diverse bioactivities; a few with potential medicinal properties (Kornienko and
Evidente, 2008). We have recently shown that Pancratistatin induces apoptosis in
several cancer cell lines and in ex vivo models of leukemia, with minimal effect on the
growth and survival of non-cancerous counterpart cells (Chatterjee et al, 2011; Griffin et
al, 2010; Kekre et al, 2005). We have previously reported that pancratistatin promotes
reactive oxygen species (ROS) generation and mitochondrial depolarization leading to
apoptosis in breast carcinoma cells independent of estrogen receptor status (McLachlan
et al, 2005; Siedlakowski et al, 2008).
Apoptosis is a cell death program that can be induced by either the extrinsic or
intrinsic pathways, although extensive cross-talk exists between them (Ravizza et al,
2004). Classical genotoxic chemotherapeutic agents cause intrinsic apoptosis by
inducing extreme stress to the DNA and its repair mechanisms, but are also toxic to noncancerous cells (Dy et al, 2008). Development of targeted therapeutics has lead to
increased selectivity, albeit these options are often effective against only a small subset
of cancers. Recently, a number of naturally derived mitochondria-directed small
molecules, referred to as mitocans, have shown promise as selective anti-cancer agents
(Ralph et al, 2010; Wang et al, 2010). Mitochondrial perturbation, either directly by small
molecules or indirectly by activation of pro-apoptotic proteins, causes release of cytotoxic
components such as cytochrome c, which leads to caspase activation, and ultimately
apoptosis (Armstrong, 2006). Mitochondria-targeted compounds may be able to induce
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apoptosis independent of p53 – a frequently mutated tumor suppressor in human
carcinomas (Fantin and Leder, 2006).
In response to cellular stress, multifunctional p53 transcription factor induces the
intrinsic pathway of apoptosis by activating specific pro-apoptotic BH3-only proteins of
the Bcl-2 family (Green and Kroemer, 2009). Activated BH3-only proteins further activate
multi-domain pro-apoptotic proteins Bax and/or Bak, which localize to the mitochondria
and form oligomers that cause mitochondrial outer membrane permeabilization, leading
to apoptosis (Wang et al, 2010). In this way, p53 plays a very important role as a potent
tumor suppressor protein. Loss-of-function mutations in p53 correlate to aggressive,
chemo-resistant tumors, especially in patients with colorectal cancer (Ravizza et al,
2004). In this study, the p53-negative HT-29 colorectal adenocarinoma cell line was
compared to the wild-type p53 HCT116 colorectal carcinoma cell line to determine the
efficacy of pancratistatin in both systems (Ravizza et al, 2004).
Here we report the novel finding that pancratistatin induces apoptosis in HT29
and HCT116 colon carcinoma cell lines in vitro and reduces growth of HT-29 xenografts
in vivo. This study suggests that cell death induced by pancratistatin may be dependent
on a component of the mitochondrial respiratory chain (MRC). For the first time we show
that pancratistatin significantly reduces growth of p53-mutant HT-29 xenografts in nude
mice and importantly, pancratistatin does not cause cell death in non-cancerous CCD18Co colon fibroblasts. Our findings suggest that pancratistatin selectively targets cancer
cell mitochondria to induce apoptosis, with minimal toxicity to non-cancerous cells.
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METHODS
Chemicals
Media, gentamycin, Hoechst 33342 dye, JC-1 dye, Annexin-V AlexaFluor 488,
and the TUNEL assay kit (Cat# A23210) were purchased from Invitrogen (GIBCO),
Burlington, ON. Cell proliferation reagent WST-1 was purchased from Roche
(Mississauga, ON). A water-soluble formulation of Coenzyme Q10 (ws-CoQ10) was
developed and provided by Dr. M. Sikorska at the National Research Council of Canada
(US patents #6,045,826,6,191,172 B1 and 6,632,443). Benzyloxycarbonyl-Val-AlaAsp(Ome)-fluoromethylketone (z-VAD-fmk) was used as a general caspase inhibitor,
purchased from EMD BioSciences, Inc (Gibbstown, NJ). Anti-β-actin and anti-SDH-A
antibodies were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Anticytochrome c, anti-AIF and anti-EndoG antibodies were purchased from AbCam
(Cambridge,

MA).

Anti-Bcl-2

family

antibodies

were

purchased

from

Sigma

(Mississauga, ON). Anti-phosphohistone (Ser139) antibody (H2AX) was purchased from
Upstate Chemicals (Billerica, MA). Bradford reagent was obtained from BioRad,
Mississauga, ON. Pancratistatin (Figure 1A) was isolated from H. littoralis as previously
described (McNulty et al, 2001) and provided by Dr. J. McNulty. All other chemicals were
purchased from Sigma-Aldrich (Oakville, ON).
Cell lines, culture conditions, and assessment of apoptosis
Normal colon fibroblasts (CCD-18Co) and human colorectal adenocarcinoma
(HT-29, HCT116) cells were purchased from American Type Culture Collection
(Manassas, VA). Cells were passaged for fewer than 6 months and no authentication of
cell lines was performed by the authors. HT-29 and HCT116 cells were grown in
McCoy‟s 5A media and CCD-18Co cells were grown in Eagle‟s MEM; both
supplemented as recommended by ATCC. Parental stock glioblastoma (U87MG) and
the counterpart mtDNA-depleted cell line (U87MG ρ0) were a generous gift from Dr. M.
Sikorska at NRC, Ottawa, ON (Sandhu et al, 2005). These cells were grown in MEM
supplemented with 10% FBS and 10 μM gentamycin. Human neuroblastoma (SH-SY5Y)
cells transfected with single-domain antibodies against Bax protein were established and
maintained as previously described (Gueorguieva et al, 2006). All cells were maintained
at 5% CO2 and 37°C. Cells were treated as indicated with 1 µM pancratistatin,
predetermined as the effective concentration (Kekre et al, 2005; Pandey et al, 2005).
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Nuclear morphology was evaluated by fluorescence microscopy after staining with
Hoechst 33342 dye. Percent condensed nuclei (indicative of apoptosis) was calculated
as [(number of cells with condensed, brightly stained nuclei / total number of cells)*100]
with a minimum 5 fields with 100 cells/field counted.
Cytotoxicity assays
Cytotoxicity was measured using the WST-1 colorimetric assay following the
manufacturer‟s protocol. Briefly, cells were seeded at 2 000 – 5 000 cells/well in 96-well
tissue culture plates, allowed to adhere overnight and treated as indicated. Cells were
then incubated with WST-1 for 4 h at 37°C. Absorbance was measured at 450 nm on a
VICTOR3 microplate reader. Absorbance is directly proportional to the number of living
cells in culture. Percent viability was calculated based on average absorbance of
untreated cells. To monitor the effect of pancratistatin on cell growth, cells were counted
using the Trypan Blue Exclusion assay.
Mitochondrial functionality assays
Mitochondrial membrane potential (MMP) was observed using cell permeable JC1 dye (1 µM) as previously described (McLachlan et al, 2005). To detect generation of
reactive oxygen species (ROS) cells were treated with pancratistatin for the indicated
time, trypsinized and incubated with H2DCFDA (1 µM) for 45 min at 37°C in an opaque
96-well plate. Fluorescence was measured at Ex. 513 nm and Em. 530 nm using a
SpectraMax GeminiXPS spectrofluorometer. Change in ROS generation was calculated
as the fold difference from control (RFU) per 10 3 cells; cells were counted using the
Trypan Blue Exclusion assay. Cytotoxicity and ROS generation was used to analyze the
effect of anti-oxidants on pancratistatin treatment. Cells were co-treated with
pancratistatin (1 µM) and either N-acetyl cysteine (5 mM) or ws- CoQ10 (50 µg/ml) for 48
or 72 h.
Mitochondrial isolation and western blotting
Cells treated with pancratistatin were washed with ice-cold PBS and the pellet
was re-suspended in cold mitochondrial isolation buffer (75 mM sucrose, 20 mM HEPES,
225 mM mannitol, 0.5 mM EDTA, pH 7.2) and then disrupted by homogenization. Nonlysed cells/nuclei were pelleted by centrifugation at 500 x g for 15 min at 4°C. The
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supernatant was further centrifuged at 4°C and 10 000 x g for 10 min, twice. The
resulting pellet was designated as the mitochondrial fraction and the supernatant as the
cytosolic fraction. Protein samples (20 μg) were separated by SDS-PAGE, transferred to
nitrocellulose and probed with the indicated primary antibody (1:1000) overnight at 4°C.
Membranes were then incubated with peroxidase-conjugated secondary antibody
(1:1000) for 1 h at 25°C and visualized using enhanced chemiluminescence reagent.
Equal loading of the protein samples was confirmed by parallel western blots for β-actin
or SDH-A. Images were digitized and band intensity was quantified using NIH Image J
software.
β-Tubulin polymerization activity assay
To determine whether pancratistatin affects the rate of β-tubulin polymerization /
depolymerization compared to known polymerizing agent paclitaxel, the HTS-Tubulin
Polymerization Assay kit (Cat. # BK004, Cytoskeleton Inc., Denver, CO) was utilized as
described by the manufacturer and elsewhere (Li et al, 2009). Microtubule assembly was
monitored by spectrophotometry as a change in absorbance at 340 nm every minute for
60 min at 37°C using a SpectraMax M5 e microplate reader.

Histone H2AX phosphorylation
To detect double-strand DNA breaks, cells were grown on cover-slips and treated
with pancratistatin for 6 hrs then processed for immunohistochemical analysis of histone
H2AX phosphorylation on Ser-139, as previously described (Kekre et al, 2005).

In vivo xenograft models
Six-week old male homozygous CD-1 nude mice (25 – 30 g) were obtained from
Charles River Laboratories, St. Constant, QC. Animals were housed in constant
laboratory conditions of a 12 h light/dark cycle at 21°C in accordance with institutional
animal protocols (University of Windsor Research Ethics Board - AUPP05). Prior to
injection, HT-29 cells were washed with PBS and centrifuged at 500 x g for 5 min; cell
pellets were suspended in aliquots of 200 µl PBS (4 x 10 6 cells per mouse). The cell
suspension was injected s.c. in the right hind flank of each mouse. Tumors were allowed
to grow to ~50 mm3 and thereafter animals were randomized into treatment groups of 6
mice each (day 14 of study). Animals were treated intra-tumor (I.T.) with vehicle (5 µl
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Me2SO in PBS) or pancratistatin (3 mg/kg) twice a week for 5 weeks (Gabrielsen et al,
1992; Shah et al, 2009). Tumors were assessed at each treatment by measuring length
and width using standard calipers; tumor volume was calculated using the formula [π/6 x
length x width2]. In parallel, tumor-free mice were treated intra-peritoneally (I.P.) twice a
week for 2 months with vehicle or pancratistatin for toxicity studies. All animals were
assessed for weight-loss twice weekly for the duration of the experiment.
Hematoxylin & Eosin staining and immunohistochemical analysis
One week after the last treatment, the tumor, liver and kidneys were collected
from all animals and fixed in 10% formalin in PBS for up to 24 h, then moved to 70%
ethanol. Sections of 8 µm thickness were sliced from paraffin-embedded tissues and
placed on Superfrost/Plus microscope slides (Fisher Scientific, Ottawa, ON) for
histopathological (H&E) and immunohistochemical (TUNEL) analysis. Slides were
deparaffinized and hydrated for terminal deoxynucleotide transferase dUTP nick end
labeling (TUNEL) assay.
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RESULTS
Pancratistatin selectively induces cell death in colon cancer cells
We determined the effect of pancratistatin (refer to Figure 1A for chemical
structure) on the viability of HT29 and HCT116 human colorectal adenocarcinoma cells,
and non-cancerous human colon fibroblast CCD-18Co cells. Nuclear morphology of HT29 and HCT116 cells after 72 h of pancratistatin exposure revealed brightly stained
condensed nuclei characteristic of cells undergoing apoptosis, in contrast to CCD-18Co
nuclear morphology, which was unchanged (Figure 1B). Viability of both colon cancer
cell lines was significantly reduced after 72 h exposure to pancratistatin in a
concentration-dependent manner, with an IC50 of ~100 nmol/L for both cell types (Figure
1C). By comparison, 100 nmol/L pancratistatin was significantly less toxic to noncancerous CCD-18Co, and the IC50 for this non-cancerous cell line was determined to be
10 μmol/L (Figure 1C). We have previously reported the selective anti-cancer activity of
pancratistatin using human cancerous and non-cancerous breast cell lines, and human
leukemic and non-cancerous peripheral blood mononuclear cells (6, 9). As shown in
Figure 1D, growth of HT-29 cells was dramatically reduced when treated with
pancratistatin, especially when pancratistatin was added again after 72 h initial exposure.
Moreover, HT29 cells remaining after 144 h pancratistatin single treatment were unable
to proliferate when given fresh drug-free media and cultured for up to 72 h (Figure 1D). A
similar effect was also observed in HCT116 cells (Supplementary Figure 1). These
results indicated that pancratistatin decreased survival of human colorectal carcinoma
cells, irrespective of p53-status, with minimal toxicity to non-cancerous colon fibroblasts.
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Figure 1.
Pancratistatin selectively affects colon carcinoma cells. (A) Chemical
structure of pancratistatin. (B) Representative nuclear morphology of HT-29, HCT116
and CCD-18Co cells stained with Hoechst dye after 72 h with 1 µM pancratistatin (PST)
or control (Me2SO). Scale bars represent 20 µm. (C) HT-29, HCT116 and CCD-18Co
cells were treated with control (Me2SO) or the indicated doses of pancratistatin for 72 h.
Cytotoxicity was measured by the WST-1 colorimetric assay. Data points, mean (n=3);
bars, SD. *, P < 0.05, significantly different between cell lines by two-tailed, paired t-test.
(D) HT-29 cells treated for the indicated times with control (Me2SO) or 1 µM
pancratistatin (PST). Cell number was determined by Trypan blue dye exclusion assay.
Cells cultured with fresh drug-free media (UT) after exposure to PST for the indicated
time were unable to proliferate. Data points, mean (n=3); bars, SD.
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Supplementary Figure 1. Cell growth of HCT116 determined by Trypan blue
exclusion assay. HCT116 cells were treated for the indicated times with control
(Me2SO) or 1 µM pancratistatin (PST) and cell number was determined by Trypan blue
dye exclusion assay. Cells cultured with fresh drug-free media (U) after exposure to PST
for the indicated time were unable to proliferate. Data points, mean (n=3).
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Pancratistatin destabilizes cancer cell mitochondria
Dissipation of the mitochondria membrane potential (MMP), increased generation
of reactive oxygen species (ROS) and release of pro-apoptotic factors like cytochrome c
are characteristic features of mitochondria-mediated apoptosis. Thus, we monitored the
occurrence of these phenomena in HT-29, HCT116 and CCD-18Co cell lines following
pancratistatin treatment. First, the effect of pancratistatin on MMP using JC-1
fluorescence microscopy was observed. HT-29 cells treated with pancratistatin had a
reduction in JC-1 aggregation compared to Me 2SO-treated (control) cells, as observed
by a decrease in fluorescence. HCT116 cells also displayed reduced aggregation of JC1 dye compared to control, indicating loss of MMP. Importantly, there was no evidence of
MMP collapse in non-cancerous CCD-18Co cells treated with the same concentration of
pancratistatin for 96 h (Figure 2A). This finding suggested that pancratistatin specifically
targets cancer-cell mitochondria to cause MMP collapse and subsequent cell death,
without affecting the potential of non-cancerous mitochondria.
Next, we tested the degree of ROS generation in HT-29 and HCT116 cells
following exposure to pancratistatin. Over-production of ROS can trigger intrinsicallymediated apoptosis and has recently been described as a powerful method to induce
cancer cell death in a selective manner (Ralph et al, 2010). Indeed in both cell lines there
was a significant increase in ROS production that correlated with increased
pancratistatin-incubation time (Figure 2B). Lastly, we tested for the release of the proapoptotic protein cytochrome c from the mitochondria to the cytosol in pancratistatin
treated HT-29 cells. In accordance with pancratistatin-mediated MMP collapse, western
blot analysis showed release of cytochrome c into the cytosolic fraction of cells treated
with pancratistatin compared to untreated control cells (Figure 2C). These results
indicated that pancratistatin caused collapse of MMP that was associated with release of
cytochrome c and increased ROS generation.
To determine the effect of anti-oxidants on pancratistatin-induced ROS
generation and cell death, HT-29 cells were co-treated with pancratistatin and Nacetylcysteine (NAC) for 48 and 72 h. As expected, co-treatment with NAC reduced ROS
generation by approximately 2-fold compared to pancratistatin alone; however, NAC
failed to protect cells from pancratistatin-induced apoptosis (Figure 2D). To extend this
finding, the effect on cell viability of co-treatment of pancratistatin with other potential
antagonists was tested on HT-29 cells. Cells were treated with and without 1 µM
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pancratistatin, and with and without antagonists of mitochondria-specific components.
The effect of NAC and another anti-oxidant, water-soluble Coenzyme Q10 (Q10), along
with inhibitors of mitochondrial respiratory chain (MRC) complex I, Rotenone, and
complex III, Antimycin A was monitored after 72 h treatment. In addition, we tested the
effect of co-treatment with mitochondrial permeability transition pore (MPTP) inhibitor
Cyclosporin A. Incubation with each of these antagonists alone did not significantly
decrease cell viability of HT-29 cells after 72 h. Pancratistatin treatment decreased cell
viability to less than 40%, and this response was unaltered by co-treatment with
Rotenone, NAC or Q10. Co-treatment with pancratistatin and cyclosporin A resulted in a
nearly 80% decrease in cell viability compared to cyclosporin A alone. Interestingly, cotreatment of pancratistatin with complex III inhibitor Antimycin A increased cell viability by
approximately 45% over pancratistatin treatment alone (Supplementary Figure 2). These
results indicate that pancratistatin may be targeting complex III of the MRC in colon
cancer cells to induce ROS production leading to cell death.
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Figure 2.
Pancratistatin selectively affects mitochondrial function of colon
cancer cells. (A) Representative fluorescence micrographs HT-29, HCT116 and CCD18Co cells stained with Hoechst and JC-1 dye after 96 h with 1 µM pancratistatin (PST)
or control (Me2SO). Scale bars represent 15 µm. Pancratistatin induced MMP collapse in
HT-29 and HCT116, but not in CCD-18Co cells. (B) Measurement of whole-cell ROS
production in HT-29 and HCT116 cells after indicated length of exposure to control
(Me2SO) or 1 µM pancratistatin. Fluorescence generated by the oxidized product of
H2DCFDA is expressed as fold-difference of control per 10 000 cells in relative
fluorescence units (RFU) and is indicative of cellular ROS levels. Columns, mean (n=3);
bars, SD; *, P < 0.05, significantly different from control by one-tailed paired t-test. (C)
HT-29 cells were treated with control (Me 2SO) or 1 µM pancratistatin for 72 h. Cytosolic
and mitochondrial fractions were separated by SDS-PAGE followed by immunoblotting
using specific antibodies against cytochrome c; antibodies against β-actin and succinate
dehydrogenase-a (SDHA) were used as loading controls. Immunoblot images were
digitized and the optical densities were quantified. (D) Measurement of whole-cell ROS
production in HT-29 cells after 48 or 72 h exposure to 5 mM N-acetylcysteine (NAC) or 1
µM pancratistatin (PST) or co-treatment with both compounds. Fluorescence generated
is expressed as fold-difference of control per 10 000 cells in relative fluorescence units
(RFU). Columns, mean (n=3); bars, SD; *, P < 0.05, significantly different from
pancratistatin treatment by one-tailed paired t-test. Quantification of condensed nuclei,
characteristic to apoptotic cells, by Hoechst dye. HT-29 cells were treated with 5 mM
NAC or 1 µM PST or co-treatment for 72 h and manually counted. A minimum 5 fields
with 100 cells/field was counted. Columns, mean (n=5); bars, SD; *, P < 0.05,
significantly different from NAC treatment by one-tailed paired t-test.
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Supplementary Figure 2. Effect of co-treatment with pancratistatin and antioxidants or MRC inhibitors on HT29 cell viability. HT-29 cells were treated with 1 µM
pancratistatin (pst, p) with and without various antagonists. The effect of treatment on
cell viability was determined by WST-1 assay after 72 h. Antagonists studied: 10 µM
Rotenone (rot), 5 µM Antimycin A (aa), 5 µM cyclosporin A (ca), 5 mM N-acetylcysteine
(nac), 50 µg/ml water-soluble Coenzyme Q10 (q10). Columns, mean (n=6); bars, SD; *,
p<0.05 significantly different between indicated treatments by one-tailed paired t-test.
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Mitochondrial DNA-deficient ρ0 cells are resistant to pancratistatin-induced
apoptosis
To firmly establish that mitochondria are involved in pancratistatin-induced cell
death, we used the Rho-0 (ρ0) variant of U87MG glioblastoma cells in parallel with wildtype “parental” U87MG cells. Rho-0 cells depend on ATP derived from anaerobic
glycolysis for survival; these cells lack the machinery required for oxidative
phosphorylation and thus cannot generate ROS (Hu et al, 2000). We then aimed to
determine whether pancratistatin can induce apoptosis in either the parental and ρ 0
U87MG cancer cells. As anticipated, we found that ρ 0 cells were resistant to 1 μM
pancratistatin compared to wild-type cells, which had nuclear and cellular morphology
characteristic of apoptosis (Figure 3A). Exposure to pancratistatin for 120 h resulted in a
significant (50%) increase in apoptosis of wild-type cells over to ρ0 cells (Figure 3B). This
finding suggested that pancratistatin may target a component of mitochondrial
respiratory chain (MRC) complexes to selectively induce apoptosis in cancer cells.
Bax inhibition does not attenuate pancratistatin-induced apoptosis
The Bcl-2 family of anti- and pro-apoptotic proteins is involved in the regulation of
the intrinsic pathway of apoptosis. Activation of pro-apoptotic Bax protein leads to
permeabilization of the mitochondrial outer membrane and subsequent cell death. To
investigate if mitochondrial destabilization caused by pancratistatin is mediated by Bax,
we utilized intracellularly expressed anti-Bax single-domain antibodies (sdAbs), also
termed intra-bodies, previously established in our lab (Gueorguieva et al, 2006). Stable
transfection with one of three anti-Bax intra-bodies (sdAb-1, -2, -4) into human
neuroblastoma (SH-SY5Y) cells effectively blocks the pro-apoptotic function of Bax
protein in vivo, and has been shown to prevent oxidative stress-induced apoptosis
(Gueorguieva et al, 2006). As shown in figure 3C, Bax inhibition was unable to protect
SH-SY5Y cells from pancratistatin-induced apoptosis. This novel finding suggested that
pancratistatin acts independent of Bax function to induce cell death in cancer cells.
Furthermore, we studied the expression and localization of endogenous Bcl-2
family proteins in HT-29 and HCT116 cell lines. Interestingly, pancratistatin treatment
caused increased mitochondrial localization of Bax protein in wild-type p53 HCT116 cells
compared to control (Figure 3D). In contrast, pancratistatin caused no change in
localization of Bax in p53-negative HT-29 cells, but instead caused increased expression
105

of the protein in the cytosol (Figure 3D). The significance of the differential response to
pancratistatin treatment between cell lines is unknown at this time, and may be due to
p53-mediated effects. In both cell lines, Bcl-2 protein was largely contained to the
mitochondrial fraction, and pancratistatin treatment resulted in an increased proportion of
cytosolic Bcl-2 significantly in HCT116 cells (Figure 3D). Taken together, these findings
suggested that although pancratistatin may alter expression and localization of Bcl-2
family proteins, the pro-apoptotic function of Bax is not required for cell death induced by
pancratistatin.

106

107

Figure 3.
Pancratistatin activity is mitochondria-dependent. (A) Representative
nuclear and cellular morphology of parental and ρ0 (Rho-0) glioblastoma U87MG cells
stained with Hoechst dye after 96 h with 1 µM pancratistatin (PST) or control (Me2SO).
Scale bars represent 15 µm. (B) Quantification of condensed brightly stained nuclei by
Hoechst dye, characteristic of apoptotic cells. Parental and ρ0 (Rho-0) glioblastoma
U87MG cells were treated with control (Me 2SO) or 1 µM pancratistatin for 72, 96, or 120
h and manually counted. A minimum 5 fields with 100 cells / field was counted. Columns,
mean (n=6); bars, SD; *, P < 0.05, significantly different from control by paired t-test. (C)
Quantification of condensed, brightly stained nuclei by Hoechst dye, characteristic of
apoptotic cells. Human neuroblastoma SH-SY5Y cells stably expressing intracellular
anti-Bax intra-bodies (sdAB-1, sdAB-2 or sdAB-4), treated with control (Me2SO) or 1 µM
pancratistatin (PST) for 24 or 48 h and manually counted. Columns, mean (n=5); bars,
SD. (D) HCT116 and HT-29 cells were treated with control (Me 2SO) or 1 µM
pancratistatin for 72 h. Cytosolic and mitochondrial fractions were separated by SDSPAGE followed by immunoblotting using specific antibodies against Bax or Bcl-2;
antibodies against succinate dehydrogenase-a (SDHA) and β-actin were used as loading
controls. Immunoblot images were digitized and the optical densities were quantified.
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Pancratistatin induces apoptosis independent of caspase activation
To further characterize the mechanism of action of pancratistatin, we treated HT29 cells in the presence of a cell permeable, irreversible pan-caspase-inhibitor (z-VADfmk) to determine whether pancratistatin-induced apoptosis is caspase-dependent. After
72 h exposure to pancratistatin in the presence or absence of z-VAD-fmk, cells were
monitored for apoptotic nuclear morphology and viability using Hoechst dye and WST-1
assay. Unexpectedly, we found that pancratistatin effectively induced apoptotic nuclear
morphology in HT-29 cells independent of caspase activity (Figure 4A). Indeed,
pancratistatin retained the ability to significantly reduce cell viability of HT-29 cells when
co-treated with a pan-caspase-inhibitor at various concentrations (Figure 4B). These
results suggested that pancratistatin induced cell death independent of caspase
activation. To further investigate this hypothesis, the effect of pancratistatin on caspaseindependent pro-apoptotic proteins was analyzed. Figure 4C depicts the release of
apoptosis-inducing factor (AIF) and endonuclease G (Endo G) to the cytosol following
treatment with pancratistatin in HT-29 cells. Similar results were observed in HCT116
cells (not shown). These findings suggested that pancratistatin-induced cell death may
occur via caspase independent mechanisms.
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Figure 4.
Pancratistatin induces cell death independent of caspase activation.
(A) Representative images of nuclear and cellular morphology of HT-29 cells treated with
a pan-caspase inhibitor and/or pancratistatin. Cells were treated with control (Me2SO),
50 µM z-VAD-fmk, 1 µM pancratistatin (PST) or combination of 50 µM z-VAD-fmk and 1
µM PST for 96 h. Scale bars represent 15 µm. (B) HT-29 cells were treated with z-VADfmk and/or pancratistatin at indicated concentrations for 72 h. Effect of a pan-caspase
inhibitor and pancratistatin or combination treatment on viability of cells was determined
by WST-1 assay. Columns, mean (n=3); bars, SD; *, P < 0.05, significantly different from
control by paired t-test. (C) HT-29 cells were treated with control (Me 2SO) or 1 µM
pancratistatin for 72 h. Cytosolic and mitochondrial fractions were separated by SDSPAGE followed by immunoblotting using specific antibodies against AIF and Endo G.
Immunoblot images were digitized and the optical densities were quantified.
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Pancratistatin does not interfere with microtubules or induce DNA damage as a
primary mechanism of action
To determine if pancratistatin induces apoptosis in a manner similar to other plant
alkaloids, namely the microtubule interfering compounds vincristine and paclitaxel, we
tested the ability of pancratistatin to alter the polymerization rate of β-tubulin. In a direct
comparison between pancratistatin and paclitaxel, we found that pancratistatin had no
effect on β-tubulin polymerization rate compared to the expected rate increase caused
by paclitaxel (Supplementary Figure 4A). This result indicated that pancratistatin does
not interfere with microtubules to illicit a cell death response.
We have previously reported that, unlike genotoxic chemotherapeutics like
etoposide, pancratistatin does not damage DNA as a primary mechanism of action, as
evidenced by comet assay and histone H2AX phosphorylation (Kekre et al, 2005). Here
we report a similar negative result that 6 h pancratistatin treatment did not cause doublestrand DNA breaks in HT-29 and HCT116 cells. At this early time point there were no
visible foci, which are representative of phosphorylation of histone H2AX in response to
DNA damage (Supplementary Figure 4B). This result supported our earlier findings that
pancratistatin is a non-genotoxic compound.
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Supplementary Figure 4. Effect of pancratistatin on tubulin polymerization and
DNA DSB formation. (A) Polymerization rate of purified bovine β-tubulin by control
(general tubulin buffer), paclitaxel (10 µM) and pancratistatin (10 µM). Polymerization
was started by incubating purified tubulin (4 mg/ml) with the indicated compound at
37°C, and absorbance readings at 340 nm were monitored for 60 min. Data points, mean
(n=3); bars, SD. (B) Immuno-histochemical analysis of Histone H2AX phosphorylation
with corresponding nuclear morphology by Hoechst staining of HT-29 and HCT116 cells
treated with pancratistatin or control (Me2SO) for 6 h. Scale bars represent 35 µm. There
are only minimal visible foci, which are representative of double strand DNA breaks.
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Pancratistatin administration reduces growth of HT-29 xenografts
To test the in vivo significance of our cellular observations, we determined the
effect of pancratistatin administration on HT-29 xenograft growth in nude mice.
Pancratistatin was administered intra-tumor (I.T.) twice a week at 3 mg/kg into animals
bearing HT-29 xenografts. After 5 weeks of treatment, the average tumor volume in
pancratistatin treated mice (18.0 ± 0.6 mm3) was ~15-fold lower than the average tumor
volume in control mice (249.5 ± 170.2 mm3). Furthermore, after the 10 treatments there
was a ~2.5-fold reduction in tumor volume in pancratistatin-treated animals compared to
the average tumor volume in all animals (45.9 ± 5.4 mm 3) on day 1 of treatment (Figure
5B, 5C). These results indicated that pancratistatin significantly reduces growth of HT-29
xenografts in nude mice without causing any observable side effects. To determine if
pancratistatin-mediated inhibition of HT-29 xenograft growth in vivo was accompanied by
increased apoptosis, tumor tissues from control and pancratistatin-treated animals were
processed for TUNEL assay. Compared to control, the pancratistatin-treated tumors had
an increased amount of TUNEL positive cells, which corresponded with brighter DAPI
staining (Figure 5D). The average body weight of control or pancratistatin-treated mice
did not vary significantly throughout the study (Figure 5A). There were no observable
signs of distress such as impaired movement, areas of redness or swelling or change in
behaviour in pancratistatin-treated animals compared to control.

Intra-peritoneal administration of pancratistatin non-toxic to vital organs
To further assess whether pancratistatin had toxic effects on non-cancerous
tissues, the liver and kidneys from animals treated with control or intra-peritoneal (I.P.)
injection of pancratistatin were processed for histological analysis. H&E staining of the
liver and kidneys revealed no gross morphological difference between treatment groups
(Figure 6A). Tumor sections from control and pancratistatin-treated (I.T.) animals were
also prepared for histological analysis by H&E staining. Figure 6B shows the difference
in cellular morphology and tumor organization between the two groups. Together, our in
vivo data indicated that pancratistatin significantly reduced tumor volume in HT-29
xenograft tumors by inducing apoptosis, without causing weight loss or obvious adverse
effects to non-cancerous tissues.
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Figure 5.
Pancratistatin reduces growth of and induces apoptosis in colon
tumor xenografts. (A) Average body weights of control (5 µl Me2SO in 200 µl PBS) and
3 mg/kg pancratistatin (PST)-treated (I.T. and I.P.) mice. The body weights of the control
and PST-treated mice did not vary significantly throughout the study. Data points, mean
(n=6); bars, SD. (B) Representative tumor size in CD-1 nude mice at day 1 of treatment
(day 14 of study) and at time of sacrifice (day 52 of study). (C) Tumor growth curve
showing efficacy of 3 mg/kg pancratistatin (PST) I.T. administration in reducing HT-29
tumor growth compared to control-treated animals. Data points, mean (n=6); bars, SD. *,
P < 0.05, tumor volume of PST-treated mice significantly different between day 14 and
day 52, and between control at day 52 of study, by paired t-test. (D) Histological analysis
by TUNEL staining of tumors from control and 3 mg/kg PST-treated (I.T.) mice, with
corresponding nuclear morphology by DAPI staining. Scale bars represent 35 µm.
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Figure 6.
Histopathological analysis by H&E staining of pancratistatin treated
tumors and non-cancerous tissues. (A) Representative images of liver and kidney
from tumor-free mice treated intra-peritoneal (I.P.) with control (5 µl Me2SO in 200 µl
PBS) or 3 mg/kg pancratistatin (PST). Scale bars represent 35 µm. (B) Representative
images of tumor sections from control and pancratistatin-treated (I.T.) animals. Scale
bars represent 25 µm.
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DISCUSSION
Induction of apoptosis by chemotherapeutic agents is often mediated through
p53-dependent mechanisms; however, the majority of human carcinomas have p53
inactivation or mutations. The aim of this study was to investigate the potential anticancer activity of the natural alkaloid pancratistatin against p53-negative (HT-29) and
wild-type p53 (HCT116) human colorectal carcinoma cell lines, and to delineate its
mechanism of action. The present study revealed that pancratistatin has significant
apoptotic activity against both cancer cell lines in culture and suppresses growth of HT29 xenograft tumors. Interestingly, pancratistatin did not elicit an apoptotic response in
non-cancerous human colon fibroblast (CCD-18Co) cells. This differential sensitivity to
pancratistatin has been observed for other cancer cell lines and normal counterparts,
both in vitro and ex vivo (Griffin et al, 2010; Griffin et al, 2011; McLachlan et al, 2005;
Siedlakowski et al, 2008). We have previously shown that pancratistatin does not induce
double-strand DNA breaks or comet formation at early time points compared to
etoposide and paclitaxel in Human lymphoma cells (Kekre et al, 2005; Risinger et al,
2009). In this report, pancratistatin did not cause double-strand breaks in the DNA of HT29 or HCT116 cells, nor did it affect microtubule assembly. Instead, pancratistatininduced cell death was found to be mitochondria-dependent. Pancratistatin caused
increased ROS production, collapse of mitochondrial membrane potential (MMP), and
cytochrome c release. Furthermore, pancratistatin was found to act independent of p53,
Bax and caspase activation, through the use of p53-negative HT-29 cells, mtDNAdepleted (ρ0) cells, and caspase- and Bax-inhibition assays. Lastly, pancratistatin
treatment caused significant growth reduction of HT-29 tumor xenografts with limited
effects on non-cancerous tissues.
Collapse of the MMP and release of cytochrome c indicates that the intrinsic
pathway of apoptosis is induced by pancratistatin. Once released, cytochrome c
complexes with pro-caspase-9 and Apaf-1 to form the apoptosome, which activates
caspase-3 resulting in apoptosis (Pradelli et al, 2010). Along with cytochrome c, other
pro-apoptotic proteins are released including AIF and Endo G, which can trigger
caspase-independent cell death (Constantinou et al, 2009; Pradelli et al, 2010). In this
report we show that pancratistatin reduced viability of HT-29 cells in the presence of a
general caspase-inhibitor, and also lead to the release of AIF and Endo G from the
mitochondria of these cells (figure 4). Our hypothesis that this alkaloid targets the
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mitochondria and triggers death upstream of caspase activation is bolstered by our result
that caspase inhibitors cannot prevent pancratistatin-induced cell death. Complimentary
to this study, we have previously reported that pancratistatin induces cell death in
caspase-3-deficient estrogen-receptor positive MCF-7 breast cancer cells, and was also
effective against estrogen-receptor negative Hs-578-T breast cancer cells (Siedlakowski
et al, 2008).
A common mechanistic theme of mitochondriotoxic small molecules is that they
act as antagonists of anti-apoptotic Bcl-2 family proteins, or are designed to mimic BH3only proteins (Fantin and Leder, 2006; Fulda et al, 2010). In either case, the result is
activation

of

Bax,

which

is

responsible

for

mitochondrial

outer

membrane

permeabilization (MOMP) (Pradelli et al, 2010). In this study, we utilized intracellularly
expressed anti-Bax single-domain antibodies (intra-bodies) previously established in our
lab to examine the effect of functional inactivation of Bax on pancratistatin activity
(Gueorguieva et al, 2006). Interestingly, stable expression of anti-Bax intra-bodies did
not attenuate pancratistatin-induced apoptosis in neuroblastoma cells, suggesting that
pancratistatin is neither a Bcl-2 family protein antagonist nor a BH3-mimetic. In wild-type
p53 colorectal carcinoma cells, pancratistatin induced mitochondrial-localization of Bax,
where its pro-apoptotic function is activated; and increased the proportion of cytosolic
Bcl-2, which inactivates the anti-apoptotic function of this protein. In contrast, Bax and
Bcl-2 sub-cellular localization was largely unaffected by pancratistatin treatment in p53negative HT-29 cells. These findings indicate that although pancratistatin alters the
locale, and thus activity, of Bcl-2 family proteins, the pro-apoptotic member Bax is not a
direct target of pancratistatin treatment and its function is indispensible for pancratistatininduced cell death. Possible involvement of the functionally similar pro-apoptotic Bak
protein however, cannot be ruled out, as it has been shown to compensate for Bax
inhibition (Fantin and Leder, 2006).
Cancer cell mitochondria are prime targets for the development of selective anticancer agents, as they have manipulatable differences from normal cell mitochondria
that can be exploited (Fulda et al, 2010; Modica-Napolitano et al, 2007). Unlike normal
cell mitochondria, which utilize oxidative phosphorylation to generate ATP, cancer cells
mainly depend on anaerobic glycolysis for energy (Warburg Theory) (Gogvadze et al,
2008). As a result, cancer cells have increased dependence on glucose and their
mitochondria are typically hyperpolarized (DeBerardinis, 2008). Targeting components of
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the mitochondrial respiratory chain (MRC) complexes, which are essentially dormant in
cancer cells, should result in selective cancer cell death (Modica-Napolitano et al, 2007).
Compounds shown to inhibit MRC complex activity, such as the natural
phytochemicals benzyl- and phenethyl-isothiocyanate, cause increased ROS production
and MOMP specifically in cancer cells (Xiao et al, 2008). In this study, we show that
pancratistatin treatment increased ROS production, collapse of MMP and release of
cytochrome c, in colorectal cancer cells. In this study and in previous reports, we have
shown that pancratistatin does not affect MMP nor lead to increased ROS production in
non-cancerous cells (McLachlan et al, 2005). In an attempt to delineate the hierarchy of
ROS production in pancratistatin-induced cell death, co-treatment with specific antioxidants or MRC complex inhibitors was performed. Our results demonstrate that the
anti-oxidant

N-acetylcyteine

effectively

quenched

pancratistatin-induced

ROS

production, but it was unable to prevent cell death. Interestingly, co-treatment with the
anti-oxidant CoQ10 did not alter the significant reduction in cell viability following
pancratistatin treatment (Supplementary Figure 2B). These findings indicated that either
pancratistatin does not directly compete with compounds, or that oxidative insult is not
the primary cause of pancratistatin-induced cell death. Moreover, we report that mtDNAdeficient ρ0 cancer cells resisted pancratistatin-induced cell death, which indicated that
pancratistatin may be targeting a component of MRC complexes, as the parental cell line
was sensitive to treatment (Sandhu et al, 2005; Xiao et al, 2008).
In response to cellular stress, Bax is activated either directly by p53 or indirectly
by p53 mediated transcriptional regulation of BH3-only proteins Puma and Noxa
(Gogvadze et al, 2008). A potent tumor suppressor, loss-of-function mutations of p53
correlates with chemo-resistant and aggressive tumors; p53 mutation is considered to be
an early step in the development of colon carcinoma (Bertholon et al, 2006). Here we
report that pancratistatin effectively induced apoptosis and caspase-independent cell
death in human colorectal adenocarcinoma (HT-29) cells that have a loss-of-function
mutation of p53. Additionally, wild-type p53 colorectal carcinoma (HCT116) cells were
proven sensitive to pancratistatin-induced apoptosis. Importantly, as proof-of-concept,
we report that intra-tumor administration of pancratistatin caused a significant reduction
in the growth of HT-29 xenograft tumors in nude mice. The concentration of
pancratistatin used in this study (3 mg/kg) is below the previously determined maximum
tolerated dose (Gabrielsen et al, 1992). There was no morbidity due to treatment, nor
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was there drastic variation in activity level or significant weight loss/gain between control
and treated animals, indicating low toxicity of pancratistatin in vivo. This observation
correlated with histopathology analysis of the liver and kidneys from control and
pancratistatin-treated animals having no gross morphological differences. The anti-tumor
activity of pancratistatin was found to be more potent than the water-soluble sodium
pancratistatin 3, 4-o-cyclic phosphate derivative, which was reported by Shnyder (2008)
to have anti-tumor activity at a dose of 100 mg/kg (Shnyder et al, 2008). Other
Amaryllidaceae alkaloids, including lycorine and narciclasine, have anti-tumor activity at
doses that complement our findings (Liu et al, 2007; Ingrassia et al, 2009).
The minimal structural pharmacophore required for potent anti-cancer activity has
been defined in the pancratistatin series of alkaloids based on a number of structureactivity correlations that have been conducted with both natural and synthetic analogues
(Pettit et al, 1993; Rinner et al, 2004; McNulty et al, 2005; Pettit et al, 2009). The
pharmacophore consists of the 2,3,4-triol structural element in ring-C. Although not
requirements, the pharmacophoric element is moderated slightly by the incorporation of
the C7 phenolic hydroxyl group and, interestingly, through the inclusion of a β–benzyloxy
substituent on the C-1 position (Pettit et al,1993; Pettit et al, 2004). Since these features
are not crucial, they highlight areas where further elaboration is possible on top of the
intact pharmacophore. Fully functionalized seco-analogues of both the lactam and
cyclitol rings are inactive, indicating that a fully intact tetracyclic core, having the correctly
positioned hydroxyl groups in ring-C, is required (McNulty et al, 2008).
CONCLUSIONS
The results presented in this article show that pancratistatin selectively induces
cell death and reduces growth of human colorectal adenocarcinoma cells in culture and
in vivo. Pancratistatin effectively induces cell death independent of Bax and caspaseactivation by targeting cancer cell mitochondria. We are currently working to further
unravel the networks, interactions and pathways that pancratistatin employs to induce
cell death in both p53 wild-type and mutated cell lines. Overall, mitochondriotoxic
compounds show great promise as specific and potent anti-cancer agents.
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CHAPTER 6

Pancratistatin induces apoptosis and autophagy in metastatic
prostate cancer cells
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BACKGROUND
Natural alkaloids of the Amaryllidaceae family of plants have been used in
traditional medicine for centuries and have wide-ranging properties such as anti-viral,
anti-bacterial and anti-neoplastic activity (Kornienko and Evidente, 2008). The
phenanthridone alkaloid pancratistatin, isolated from the bulb tissues of Hymenocallis
littoralis plants, has shown potential to be a potent anti-cancer agent with a notable
therapeutic window, albeit with an elusive target (Griffin et al, 2011a). Our previous
studies indicated that pancratistatin selectively and effectively induces apoptosis
associated with mitochondrial destabilization and increased reactive oxygen species
(ROS) production in human leukemia, melanoma and hormone-refractory breast
carcinoma cells (Kekre et al, 2005; Chatterjee et al, 2011; Seidlakowski et al, 2007). We
recently reported that pancratistatin-induced apoptosis occurs in a p53-independent
manner and that cancer cell mitochondria are essential for the anti-cancer activity of
pancratistatin (Griffin et al, 2011a).
The intrinsic pathway of apoptosis involves loss of mitochondrial membrane
potential, rupture/opening of the outer mitochondrial membrane, and release of proapoptotic proteins to the cytosol (Ralph et al, 2010). Mitochondria-mediated apoptosis
may be induced by increased reactive oxygen species (ROS) production, which is an
indicator of cellular stress (Valko et al, 2007). Mitochondria, and more specifically
mitochondrial respiratory chain (MRC) complexes I and III, are the primary sources of
cellular ROS production (Valko et al, 2007). A review of recent literature reveals the
potent anti-cancer properties of natural compounds that specifically target mitochondria
or metabolic pathways, including resveratrol, betulinic acid and the vitamin E analog αtocopheryl succinate (α-TOS) (Fulda et al, 2010; Liu et al, 2009; Neuzil et al, 2006).
Alpha-TOS induces apoptosis in cancer cells via ROS generation by blocking MRC
complex II activity (Dong et al, 2009). Additionally, Xiao and colleagues reported that
isothiocyanates (constituents of cruciferous vegetables) generate excessive ROS by
inhibiting oxidative phosphorylation, leading to mitochondrial-mediated apoptosis in
prostate cancer cells (Xiao et al, 2010).
There are limited therapy options for hormone-refractory metastatic prostate
carcinoma and patients often have poor prognosis. Recent studies have reported that a
novel therapeutic strategy for advanced androgen-independent prostate cancer may be
to target autophagy (DiPaola et al, 2008). Autophagy is a lysosomal process of self124

digestion, which is understood to be a survival mechanism employed by cells facing
adverse environmental conditions, such as nutrient deprivation or hypoxia (Fimia and
Piacentini, 2010). Ever the opportunists, tumor cells use the self-preservation facet of
autophagy to overcome chemotherapeutic insult, thereby acquiring resistant phenotypes
(Dalby et al, 2010). Thus a novel strategy for treatment is to combine standard
chemotherapy with inhibition of autophagy, which may resensitize the resistant tumor
cells (Qadir et al, 2008; Morselli et al, 2009). Conversely, several reports indicate that
sustained autophagy actually results in programmed cell death type-II, or autophagic cell
death, in cancer cells and that induction of autophagy may be a valid treatment tactic
(Gibson, 2010; White et al, 2009).
The interplay between apoptosis and autophagy involves regulation of autophagy
by classically defined anti-apoptotic proteins, such as Bcl-2 and Bcl-XL (Dalby et al,
2010). Another key regulator of apoptosis and autophagy processes is the tumor
suppressor p53 (Olovnikov et al, 2009). Interestingly, in this report the two metastatic
prostate cancer cell lines studied not only differ in their androgen sensitivity, but also in
p53 status. DU145 cells are both androgen-refractory and contain functionally mutated
p53 protein, and LNCaP cells maintain androgen sensitivity and wild-type p53
(Radhakrishnan et al, 2010). In this study, both cell lines were observed to undergo
apoptosis induced by pancratistatin, which caused increased ROS production, and
destabilization of the mitochondrial membrane potential. For the first time, we report the
effect of pancratistatin on induction of autophagy, as well as the efficacy of pancratistatin
against xenograft models of DU145 prostate tumors.
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METHODS
Chemicals
Media, gentamycin, L-glutamine, amino acids, Hoechst 33342 dye, Tetramethyl
Rhodamine Methyl Ester (TMRM) dye, and Annexin-V AlexaFluor 488 are products of
Invitrogen (GIBCO). Caspase-3, -8 and -9 fluorometric substrates were purchased from
MP Biomedicals. Cell proliferation reagent WST-1 was purchased from Roche. Anti-LC3
antibody was purchased from Abcam, and anti-β-actin antibody was purchased from
SantaCruz Biotechnology. Pancratistatin (Figure 1A) was isolated from H. littoralis as
previously described (McNulty et al, 2001) and provided by Dr. J. McNulty. All other
chemicals were purchased from Sigma-Aldrich.
Cell culture
Androgen-sensitive human prostate LNCaP cells, which express wild-type p53,
and androgen-refractory, p53 mutant DU145 cells were purchased from ATCC (Hu H et
al, 2008). LNCaP cells were grown in RPMI media and DU145 cells were grown in
DMEM; supplemented as recommended by ATCC. Human diploid fibroblast (AG09309)
cells (NHF), purchased from the Coriell Institute for Medical Research, were grown in
Earle‟s minimum essential medium supplemented with 15% (v/v) fetal bovine serum, 2
mM L-glutamine, 1.5 g/l sodium bicarbonate, essential and non-essential amino acids,
vitamins, and gentamycin. All cultures were maintained at 5% CO2 and 37 °C.
Cytotoxicity assays
Cytotoxicity was measured using the WST-1 colorimetric assay. Cells were
seeded at 2 000 cells/well in 96-well tissue culture plates. After treatment with
pancratistatin as indicated, cells were incubated with WST-1 according to manufacturer‟s
protocol for 4 h at 37 °C. Absorbance was measured at 450 nm on a VICTOR 3
microplate reader. Absorbance is directly proportional to the number of living cells in
culture. Each assay was performed in triplicate and the mean of three assays was
calculated based on average absorbance of control-treated (Me2SO) cells.
Assessment of apoptosis
Cells were treated as indicated and nuclear morphology was evaluated by
fluorescence microscopy using cell-permeable Hoechst 33342 dye and an inverted
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fluorescence microscope (Leica DM IRB, Germany). The percent of condensed nuclei
(indicative of apoptosis) was calculated as: [(number of cells with condensed, brightly
stained nuclei / total number of cells)*100] with a minimum 5 fields counted with 100 cells
/ field. To monitor phosphatidyl serine exposure, Annexin-V binding assay was
performed. Cells were treated as indicated, trypsinized and washed 2X

in room

temperature PBS, then resuspended in Annexin-V binding buffer (10 mM HEPES/NaOH
pH 7.5, 140 mM NaCl, 2.5 mM CaCl2), containing Annexin-V AlexaFluor 488 conjugate
(1:50) for 15 min at 25ºC; images were captured on an inverted fluorescence microscope
(Leica DM IRB, Germany).
Trypan blue exclusion viability assay
Cell viability was assessed by Trypan Blue Exclusion after incubation of cells at
increasing intervals with 1 µM pancratistatin. Cells were trypsinized and the cell pellet
was resuspended in PBS. Cell suspension was diluted 1:1 with Trypan Blue Exclusion
dye and cells were counted using a Fisher Hemocytometer. Data represents the mean of
three assays calculated as percent Trypan Blue positive per total cells counted.
Mitochondrial functionality assays
Mitochondrial membrane potential (MMP) was observed using cell permeable
TMRM dye (1 µM final concentration). Cells were grown on cover-slips and following
treatment TMRM was added directly to the media and incubated for 30 min at 37°C in
darkness; cell permeable Hoechst dye was added for the last 5 min of the incubation
period, to observe nuclear morphology. To detect generation of reactive oxygen species
(ROS) cells were treated with pancratistatin, trypsinized and counted using the Trypan
Blue Exclusion assay prior to incubation with H 2DCFDA (1 µM) for 45 min at 37°C in an
opaque 96-well plate. Fluorescence was measured at Ex. 513 nm and Em. 530 nm using
a SpectraMax GeminiXPS spectrofluorometer. Change in ROS generation was
calculated as the fold difference from control (RFU) and expressed per 10 000 cells.
Assessment of caspase activity
Caspase activity assays were carried out using a previously published method
(Kekre et al, 2005). Briefly, cellular lysate was collected from LNCaP and DU145 cells
and incubated with the desired fluorogenic substrate (caspase-3, DEVD-afc; caspase-8,
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IETD-afc; caspase-9, LEHD-afc) in assay buffer (0.1 M HEPES, pH 7.4, 2 mM DTT,
0.1% CHAPS, 1% sucrose) and allowed to incubate at 37ºC for 45 min. Fluorescence
was measured at 400nm excitation and 505nm emission using a SpectraMax Gemini
XPS spectrofluorometer. Caspase activity was calculated per microgram of protein, and
expressed as a percentage of control activity.
Wound-healing assay
Prostate cancer cells were seeded in 12-well plates and cultured to at least 95%
confluence. Monolayer cells were scraped with a plastic 200 µL pipette tip, rinsed with
warmed PBS and immediately cultured in fresh media with or without 1 µM
pancratistatin. Phase-contrast microscopy was used to observe the wound-area at 0, 24
and 48 h after treatment. The relative migration distance (%) is equal to (A-B)/A*100,
where A is the wound width before incubation, and B is the wound width after.
Monitoring autophagic vacuole formation
To detect the formation of autophagic vacuoles, cells were grown on cover-slips
and treated as indicated. Monodansylcadaverine (MDC) was added directly to the media
at 0.1 mM final concentration and incubated at 37ºC for 20 min in darkness; images were
captured on an inverted fluorescence microscope (Leica DM IRB, Germany).

Western blot analysis
Cells treated with pancratistatin were mechanically lysed in ice-cold hypotonic
buffer with protease inhibitors (10 mM Tris HCl (pH 7.2), 5 mM KCl, 1 mM MgCl 2, 1 mM
EGTA, 1% Triton-X-100; 10 µM Leu-pep and Pep-A, 100 µM PMSF). Protein samples
(20 μg) were separated by SDS-PAGE, transferred to nitrocellulose and probed with the
indicated primary antibody (1:1000) overnight at 4°C. Membranes were then incubated
with HRP-conjugated secondary antibody (1:1000) for 1 h at 25°C and visualized using
enhanced chemiluminescence reagent. Equal loading of the protein samples was
confirmed by parallel western blots for β-actin. Images were digitized and band intensity
was quantified using NIH Image J software.
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In vivo xenograft models
Six-week old male homozygous CD-1 nude mice (25 – 30 g) were obtained from
Charles River Laboratories, St. Constant, QC. Animals were housed in constant
laboratory conditions of a 12 h light/dark cycle at 21°C in accordance with institutional
animal protocols (University of Windsor Research Ethics Board - AUPP05). Prior to
injection, DU145 cells were washed with PBS and centrifuged at 500 x g for 5 min; cell
pellets were suspended in aliquots of 200 µl PBS (4 x 10 6 cells per mouse). The cell
suspension was injected s.c. in the right hind flank. Tumors were allowed to grow for 4
weeks and thereafter animals were randomized into two treatment groups (n=3). Animals
were treated intra-tumor (IT) with vehicle (5 µl Me2SO in PBS) or pancratistatin (3 mg/kg)
4 times over 3 weeks (Gabrielsen et al, 1992; Shah et al, 2009). Tumors were assessed
at the end of the study by 2D digital volume extrapolation, using Image J software. Body
weight of all animals was taken twice weekly during the study as a measure of overt
toxicity. Intra-peritoneal injection of 3 mg/kg pancratistatin twice weekly for up to 2
months was previously shown to be non-toxic to liver and kidneys by histopathological
analysis (Griffin et al, 2011).

Statistical analysis
Data were presented as the mean ± standard deviation and significance was
determined by using Student's t-test or ANOVA, where appropriate. Values of p<0.05 (*)
and p<0.005 (**) were considered significant.
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RESULTS
Cytotoxic effect of pancratistatin on prostate cancer cells
To determine whether pancratistatin selectively affects prostate cancer cell
viability, we tested this natural alkaloid on androgen-responsive LNCaP cells and
androgen-refractory DU145 cells, as well as non-cancerous human fibroblast NHF cells.
Cytotoxicity was assessed following exposure to increasing concentrations of
pancratistatin over 72 h (Figure 1B). An EC50 value of approximately 100 nM resulted for
both cancer cell lines. Treatment of NHF cells with pancratistatin for 72 h did not cause
viability to drop below 50% (Figure 1B). To further test this result the Trypan Blue
Exclusion assay was used, which confirmed that at 1 µM, pancratistatin selectively
decreases viability of LNCaP and DU145 prostate cancer cells, but does not significantly
increase cell death in non-cancerous NHF cells (Figure 1C). These results suggest that
pancratistatin selectively reduces viability of cancer cells regardless of androgen
sensitivity with an insignificant effect on non-cancerous cells.
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Figure 1.
Pancratistatin selectively affects viability of prostate carcinoma
cells. (A) Chemical structure of pancratistatin. (B) DU145, LNCaP and NHF cells were
treated with control (Me2SO) or the indicated doses of pancratistatin for 72 h. Cytotoxicity
was measured by the WST-1 colorimetric assay. Data points, mean (n=3); bars, SD; **,
P < 0.005, significantly different between cell lines by paired t-test. (C) DU145, LNCaP
and NHF cells treated for the indicated times with control (Me2SO) or 1 µM pancratistatin
(PST). Cell viability was determined by Trypan blue dye exclusion assay. Data points,
mean (n=3); bars, SD; **, P < 0.005, significantly different from control by one-way
ANOVA.
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Pancratistatin induces apoptosis in metastatic prostate cells
Pancratistatin has been shown to effectively induce apoptosis in breast cancer
cells, independent of estrogen receptor status in vitro, and in acute and chronic forms of
leukemia ex vivo (Siedlakowski et al, 2008; Griffin et al, 2010). To investigate whether
the observed cytotoxicity of 1 µM pancratistatin on prostate cancer cells was due to
induction of apoptosis, we performed Hoechst staining at 48 and 96 h of treatment. In
both DU145 and LNCaP cell lines, there was an increased number of cells with brightly
stained, condensed nuclei, characteristic to apoptotic cells (Figure 2A). Moreover, in both
prostate cancer cell lines, there was a marked increase in Annexin-V positive cells,
indicative of phosphatidyl serine exposure, a characteristic marker of apoptosis (refer to
Appendix B, Figure 6). In line with previous reports (Griffin et al, 2011), pancratistatin did
not affect nuclear morphology in non-cancerous cells (Figure 2A). Exposure to
pancratistatin for increased lengths of time resulted in increased apoptotic morphology in
cancer cells, with a 70% increase in apoptosis over control after 96 h in both prostate
cancer cell lines. There was an insignificant change in the number of cells with apoptotic
nuclear morphology in NHFs exposed to pancratistatin at all time points (Figure 2B).
These findings indicate that pancratistatin induces apoptosis selectively in prostate
carcinoma cells.

132

Figure 2.
Pancratistatin induces apoptosis in prostate cancer cells. (A)
Representative nuclear morphology of DU145, LNCaP and NHF cells stained with
Hoechst dye after 72 h with 1 µM pancratistatin (PST) or control (Me2SO). Scale bars
represent 15 µm. (B) Quantification of condensed brightly stained nuclei by Hoechst dye,
characteristic of apoptotic cells. DU145 (AR-) and LNCaP (AR+) cells were treated with
control (Me2SO) or 1 µM pancratistatin for 48-, 72-, or 96-h and stained with Hoechst. A
minimum 5 fields with 100 cells/field was counted. Columns, mean (n=6); bars, SD; **, P
< 0.005, significantly different from control by two-way ANOVA.
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Inhibition of the wound-healing capacity of prostate cancer cells by pancratistatin
To evaluate the anti-migratory effect of pancratistatin on metastatic prostate
cancer cells, we monitored the wound-healing capacity of DU145 prostate cancer cells.
A scratch-wound was made in a sub-confluent cell monolayer and cells were allowed to
migrate into the cell-free area for up to 48 h (Figure 3A). Pancratistatin treatment caused
a 35% reduction in the ability of prostate cancer cells to migrate into the wound-area
compared to control at 24 h, and a 50% reduction after 48 h (Figure 3B). This result
presents the novel finding that pancratistatin affects the migration capacity of metastatic
prostate cancer cells in vitro.
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Figure 3.
Pancratistatin reduces wound-healing capacity. (A) Wound healing
capacity, indicative of migration potential, was decreased in DU145 cells after treatment
with pancratistatin compared to control. Images represent data obtained from three
independent experiments. (B) Quantification of wound-healing capacity. Percent
migration distance was calculated in relation to the mean width of the wound at 0 h, as:
[100*(A-B)/A)]; where A is the mean wound width at t = 0 h, and B is the mean wound
width at the indicated treatment time. Columns, mean (n=5); bars, SD; **, P < 0.005,
significantly different from control by two-way ANOVA.
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Pancratistatin induces ROS production
Due to its selective anti-cancer activity we hypothesized that pancratistatin may
be targeting the mitochondria of cancer cells, which have distinct properties and
metabolic alterations from normal mitochondria (Fulda et al, 2010). Increasing reports
indicate that mitochondrial-mediated ROS production activates apoptotic cell death in
cancer cells more potently than in non-cancerous cells (Ralph et al, 2009; Wang et al,
2010). Here we report that pancratistatin treatment increased ROS production in
metastatic prostate cancer cells and that longer treatment with pancratistatin
corresponded with higher ROS levels, up to 72 h. As shown in figure 4A, ROS
production in p53-mutant DU145 cells was significantly higher than control, with as much
as 10-fold increase in ROS production after 72 h exposure to pancratistatin. Treatment
with pancratistatin also increased ROS production in wild-type p53 LNCaP cells, albeit to
a lesser extent than in DU145 cells, causing an approximate 5-fold increase over control
after 72 h (Figure 4A). This result suggests pancratistatin induced ROS production in
prostate cancer cells, which may be modulated by p53 function.
Loss of mitochondrial membrane potential results from exposure to pancratistatin
Pancratistatin has previously been shown to cause selective dissipation of
mitochondrial membrane potential in melanoma and colorectal adenocarcinoma cells
(Chatterjee et al, 2011; Griffin et al, 2011). To determine whether pancratistatin elicits a
similar response in metastatic prostate cancer cells, mitochondrial membrane potential
was monitored using TMRM dye following 72 h exposure to pancratistatin. Pancratistatin
treatment resulted in near complete loss of TMRM puncta, which indicates collapse of
the mitochondrial membrane potential, in both DU145 and LNCaP cells (Figure 4B).
When paired with the observed increase in ROS production, this result suggests that
pancratistatin induces mitochondrial-mediated apoptotic cell death.
Caspase activation following pancratistatin treatment
Regardless of whether the extrinsic or intrinsic pathway of apoptosis is induced,
apoptotic cell death typically culminates with cleavage and activation of caspases.
Mechanistically, caspase-9 is activated upstream of caspase-3, and downstream of
mitochondrial membrane permeabilization, thus indicates that the intrinsic pathway of
apoptosis is being induced. Caspase-8 becomes activated following death-receptor
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stimulation, which is characteristic of extrinsically-mediated apoptotic cell death. To
delineate the apoptosis pathway activated by pancratistatin, time-based caspase-activity
profiling was performed. Pancratistatin treatment resulted in caspase-9 activation in
prostate cancer cells; with 4-fold increase over control in LNCaP cells after only 24 h and
approximately 5-fold increase in DU145 cells after 72 h (Figure 4C). Caspase-9
activation correlated with increased caspase-3 activation in LNCaP cells, resulting in 5fold increased activity over control after 48 h treatment. Interestingly, activation of
caspase-3 in androgen-refractory, p53-mutant DU145 cells was much less pronounced
(less than 2-fold increase) after 72 h treatment with pancratistatin. Caspase-8 activity did
not significantly increase in either cell line in response to pancratistatin exposure (Figure
4C). Taken together these findings indicate that pancratistatin leads to activation of
caspases involved in the intrinsic pathway of apoptosis.
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Figure 4.
Pancratistatin selectively affects mitochondrial function of prostate
cancer cells. (A) Measurement of whole-cell ROS production in DU145 and LNCaP
cells after indicated length of exposure to control (Me2SO) or 1 µM pancratistatin.
Fluorescence generated by the oxidized product of H2DCFDA is expressed as folddifference of control per 10 000 cells in relative fluorescence units (RFU) and is
indicative of cellular ROS levels. Columns, mean (n=3); bars, SD; *, P < 0.05,
significantly different from control by paired t-test. (B) Representative fluorescence
micrographs of DU145, LNCaP and NHF cells stained with Hoechst and TMRM dye after
72 h with 1 µM pancratistatin (PST) or control (Me2SO). Scale bars represent 15 µm.
Pancratistatin induced MMP collapse in DU145 and LNCaP cells. (C) Caspase-3, -8 and
-9 activity was assayed in DU145 and LNCaP cells following treatment with control
(Me2SO) or 1 µM pancratistatin for the indicated time points. Cleavage of caspasespecific fluorogenic substrates (caspase-3, DEVD-afc; caspase-8, LEHD-afc; caspase-9,
IETD-afc) indicates the level of caspase activity in the sample. Caspase activity was
calculated relative to control and expressed as activity (RFU) per microgram protein.
Columns, mean (n=3); bars, SD; *, P < 0.05, significantly different from control by paired
t-test.
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Pancratistatin induces autophagy in p53 mutant prostate cancer cells
Autophagy is a process of self-digestion induced in response to nutrient
deprivation, and is used by tumor cells to survive adverse conditions in the tumor
microenvironment. Sustained autophagy however, can be detrimental to a cell, resulting
in autophagic cell death. To determine whether pancratistatin elicits an autophagy
response in metastatic prostate cancer cells, DU145 and LNCaP cells were treated with
1 µM pancratistatin or 5 µM tamoxifen, a known inducer of autophagy. Compared to
control-treated cells, there was an increase in autophagic vacuoles visualized by MDC
staining in DU145 cells after 96 h with pancratistatin, but no observable change in
LNCaP cells (Figure 5A). As anticipated, tamoxifen induced non-lethal autophagy in both
cell lines, at both 24 and 96 h (Figure 5A). To further confirm pancratistatin-induced
autophagy in DU145 cells, we analyzed the expression level of microtubule-associated
protein1 light chain 3 (LC3), an important marker and effector of autophagy. Indeed, after
96 h exposure to pancratistatin or tamoxifen, there was increased expression of LC3
compared to control (Figure 5B). There was no observable increase in LC3 expression
after 24 h pancratistatin treatment compared to control. These data indicate, for the first
time, that pancratistatin induces an autophagic cell death response in androgenindependent prostate cancer cells.
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Figure 5.
Pancratistatin induces autophagy in androgen-refractory prostate
cancer cells. (A) Representative images of DU145 and LNCaP cells stained with MDC
after 24- and 96-h with control (Me2SO), 1 µM pancratistatin (PST) or 5 µM tamoxifen
(TAM). Scale bars represent 15 µm. (B) DU145 cells were treated with control (Me 2SO),
1 µM pancratistatin (PST) for 24 and 96 h, or 5 µM tamoxifen (TAM) for 96 h. Postnuclear lysate was separated by SDS-PAGE followed by immunoblotting using specific
antibodies against LC-3 or β-actin. Immunoblot images were digitized and optical
densities were quantified using NIH Image J software.
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Anti-tumor effect of pancratistatin on prostate tumor xenografts
To assess the efficacy of pancratistatin in vivo, we tested its anti-tumor potential
against human prostate tumor xenografts grown in immune-compromised mice.
Pancratistatin (3 mg/kg) or vehicle (5 µl Me2SO in PBS) was administered intra-tumor
(IT) four times over three weeks in animals bearing DU145 xenografts. After the final
treatment, the average tumor volume in pancratistatin-treated mice was approximately
50% smaller than that of vehicle-treated mice (Figure 6A, 6B). The average body weight
of the animals did not vary significantly between treatment groups throughout the study
(Figure 6C). Importantly, there were no observable signs of stress such as redness or
swelling at the injection site or change in activity / behaviour of animals receiving
pancratistatin compared to control. This finding suggests that pancratistatin has antitumor activity against human prostate cancer in vivo, and is well-tolerated by mice at the
dosage tested.
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Figure 6.
Pancratistatin reduces growth of human prostate tumor xenografts.
(A) Representative images of DU145 tumor xenografts in control (Me2SO) and 3 mg/kg
pancratistatin (PST)-treated (IT) Nu/Nu immune-compromised mice. (B) Fold-difference
of tumor volume between control and PST treated mice upon completion of the study.
Columns, mean (n=3); bars, SD; **, P < 0.005, significantly different from control by
paired t-test. (C) Average body weights of control (Me2SO) and pancratistatin (PST)treated (3 mg/kg, IT) mice. The body weights of control and PST-treated mice did not
vary significantly throughout the study. Data points, mean (n=3); bars, SD.
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DISCUSSION
Metastatic prostate cancer is typically androgen-refractory and treatment options
are limited for advanced stages of the disease. It is proposed that resistance to
chemotherapy, specifically endocrine therapy, is a result of cancer cell protection through
evasion of apoptosis and/or induction of autophagy. Avoidance of apoptosis is
considered one of the hallmarks of cancer, and stimulation of apoptosis is the primary
aim of many anti-cancer drugs (Hanahan and Weinberg, 2000). In tumor cells, the
process of autophagy is thought to promote survival in adverse conditions of the tumor
microenvironment, including chemotherapeutic insult. Autophagy is a process of selfdigestion used by cells in times of starvation, or in attempt to clear damaged
proteins/organelles from the cell (Levine, 2007). Thus, inhibition of autophagy has
become an attractive approach to modulate resistance of tumor cells to chemotherapy
agents (White et al, 2009; Dalby et al, 2010).
The interplay between autophagy and apoptosis has garnered significant interest
in the past few years, and it has come to light that proteins traditionally viewed as proapoptotic or anti-apoptotic are also important regulators of autophagy (Dalby et al, 2010;
Olovnikova et al, 2009; Fimia and Piacentini, 2010). The quintessential tumor suppressor
protein p53 may be viewed as a central player in both processes, as it is known to
induce apoptosis and inhibit autophagy (Galluzzi et al, 2010; Green and Kroemer, 2009).
In response to extensive DNA damage or other lethal stressors, pro-apoptotic proteins
such as Bax and PUMA (p53-upregulated modulator of apoptosis) become activated by
p53 and result in mitochondrial-mediated apoptosis (Green and Kroemer, 2009).
Functional p53 also acts to inhibit autophagy either directly, through activation of DRAM
(damage-regulated autophagy modulator), or indirectly through suppression of mTOR
(mammalian target of Rapamycin) – the primary regulator of survival autophagy
(Olovnikova et al, 2009).
It is suggested that over half of human cancers have functionally inactive p53
mutations (Green and Kroemer, 2009). Lack-of-function mutations of p53 allow tumor
cells to escape apoptosis, use autophagy to protect against stressors, and survive on
enhanced glycolysis. Mitochondria of cancer cells are purportedly more vulnerable to
attack than non-cancerous cell mitochondria, due to their aberrant metabolic
reprogramming (Fulda et al, 2010). Cancer cells, unlike normal cells, primarily use
glycolysis for production of ATP, and largely bypass oxidative phosphorylation (a
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phenomenon known as the Warburg effect). As a result, cancer cells over-produce
lactate compared to their normal cell counterparts, contributing to acidification of the
tumor microenvironment (Fulda et al, 2010). Another aspect worth consideration is that
the rapid proliferation rate of cancer cells may result in improper lipid remodelling of
mitochondrial membranes (as well as other organelles), making cancer cell mitochondria
more susceptible to disruption (Alirol and Martinou, 2006). In this report, our findings
suggest that pancratistatin directly targets the mitochondria and leads to p53independent cell death.
Our results indicate that pancratistatin induces cell death with features
characteristic to apoptosis, and elicits an autophagy response in metastatic prostate
cancer cells. We suspect that pancratistatin is inducing autophagic cell death in prostate
cancer cells, rather than protective autophagy, due to the decreased cell viability,
collapsed mitochondrial membrane potential and increased ROS production that results
from prolonged exposure (96 h) to pancratistatin. Importantly, as proof-of-concept, we
report that intra-tumor administration of pancratistatin caused a significant reduction in
the growth of DU145 xenograft tumors in immune-compromised mice. The concentration
of pancratistatin used in vivo (3 mg/kg) is well under the previously determined maximum
tolerated dose (Gabrielsen et al, 1992). There was no morbidity due to treatment, nor
was there drastic variation in activity level or significant weight loss/gain between control
and treated animals, indicating low toxicity of pancratistatin in vivo. This current
observation correlated with previous histopathology analysis performed on vital organs
from pancratistatin-treated animals, which had no gross morphological differences from
vehicle-treated animals (Griffin et al, 2011). This proof-of-concept study indicated that
pancratistatin causes significant growth reduction of DU145 xenograft tumors without
deleterious side-effects.
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CONCLUSIONS
In this study, we report for the first time that pancratistatin induced apoptotic cell
death in metastatic prostate cancer cells independent of androgen sensitivity. In addition,
pancratistatin was found to have anti-tumor activity on human prostate tumors in vivo.
Pancratistatin treatment caused increased ROS production and is believed to selectively
target cancer cell mitochondria. For the first time, pancratistatin was shown to incite
autophagic cell death in p53-mutant metastatic prostate cancer cells. Taken together,
these results demonstrate that pancratistatin is a potent and selective natural anti-cancer
compound that may be an effective treatment option for metastatic prostate cancer,
independent of p53-status and hormone-sensitivity.
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CHAPTER 7

General Discussion
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The aim of this work was to evaluate the anti-cancer activity of the natural
alkaloid pancratistatin and to determine its mechanism of action. Pancratistatin,
extracted from H. littoralis, is considered one of the most important biologically active
metabolites of Amaryllidaceae plants, which have been used for the management of
cancer in folk medicine for centuries (Kornienko and Evidente, 2008).

The current standard of care for cancer has room for improvement to say the
least; the high fatality associated with metastatic disease has not changed dramatically
in the last decade, despite major advances in molecular medicine (Jemal et al, 2010).
Although based on observations made over half a century ago, the trend in cancer
research over the last few years has shifted away from oncogene-interference tactics
and towards exploiting the vulnerability of cancer cell mitochondria (Warburg, 1956;
Bouchier-Hayes et al, 2005; Fulda et al, 2010). This is evident by the popularity of the
new term “mitocan” in the literature, which is the moniker given to mitochondria-targeting
cancer drugs (Neuzil et al, 2006). Cancer cell mitochondria are typically hyperpolarized,
rely heavily on glycolysis, have deregulated mitochondrial respiration, an acidic
microenvironment, and high intracellular ROS (Galluzzi et al, 2010; Khandrika et al,
2009; Mathupala et al, 2010). Ultimately, the fundamental role of mitochondria in cell
death cannot be tamed; mitochondrial outer membrane permeabilization (MOMP)
causes even the most oncogene-addicted tumor cell to succumb to apoptotic death
(Green and Evan, 2002). Compounds that directly target the mitochondria to trigger
MOMP act independently of upstream anti-apoptotic signalling pathways (such as those
mediated by Bcl-2 proteins) that contribute to the chemo-resistance phenotype of many
tumors (Fulda, 2010; Biasutto et al, 2010).
Recently, many natural products have been discovered that directly target cancer
cell mitochondria, including alpha-tocopheryl succinate (α-TOS), methyl jasmonate,
resveratrol and green tea polyphenols (Biasutto et al, 2010; Ralph and Neuzil, 2009).
Alpha-tocopheryl succinate, a vitamin E analogue, is known to bind and inhibit complex II
of the MRC and has also been shown to disrupt interaction of pro-apoptotic Bak with Bcl2 and Bcl-XL, thus acting as a BH3-mimetic (Dong et al, 2009; Ralph and Neuzil, 2009).
Studies with mtDNA-deficient cells proved that α-TOS targets a component of the MRC,
which is similar to the findings presented in this work to delineate the target of
pancratistatin. Methyl jasmonate, a plant stress hormone, induces opening of the
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mitochondrial permeability transition pore (MPTP) by detaching hexokinase (HK) from
VDAC on the mitochondrial membrane (Goldin et al, 2008). HK is bound to VDAC
specifically in cancer cells to couple residual ATP to the rate-limiting step of glycolysis
(Biasutto et al, 2010). The possible modulation of mitochondrial-associated HK by
pancratistatin was studied in our laboratory, but there was no evidence of HK
dissociation from VDAC following treatment with pancratistatin in cancer cells
(unpublished data). The flavonoid polyphenols resveratrol and epigalocatechin gallate
(EGCG), also reportedly target the mitochondria, albeit in different ways. Resveratrol
acts at several different sites of the MRC, likely competing with coenzyme Q 10, and also
blocks the F1-ATPase (Ralph and Neuzil, 2009). EGCG, an anti-oxidant and
chemopreventative, acts as a BH3-mimetic to prevent inhibition of Bax and Bak by Bcl-2
anti-apoptotic proteins (Deorukhkar et al, 2010; Ralph and Neuzil, 2009).
In this work, it was determined that pancratistatin effectively and selectively
induces cell death in cancer cells in in vitro, ex vivo and in vivo models, by targeting the
mitochondria (Griffin et al, 2010; Griffin et al, 2011a,b). Pancratistatin was found to cause
increased ROS production, collapse of MMP, release of pro-apoptotic factors and
caspase activation, in a p53-independent manner. Moreover, mt-DNA deficient cancer
cells were insensitive to pancratistatin-induced cell death, suggesting that mt-DNA
encoded components of the MRC are crucial for the anti-cancer activity of pancratistatin.

Pancratistatin has high potential for clinical development as a potent anti-cancer
agent based on the „therapeutic window‟ of selective activity observed in vitro, ex vivo
and the significant anti-tumor affect in vivo (Griffin et al, 2010; Griffin et al, 2011a,b).
Clinical use of pancratistatin as a single agent could prove efficient against multiple types
of cancer. Natural compounds have the propensity to act on multiple sites, which may
mirror effects achieved by combination of two (or more) targeted drugs, but with the
toxicity of only one (Deorukhkar et al, 2010). Even so, combination therapy is the
standard practice of current cancer treatment (Blagosklonny, 2005). Thus, pancratistatin,
predicted to have low toxicity to non-cancerous tissues, in combination with standard or
targeted therapies, will likely enhance the overall response to treatment. Combination of
pancratistatin with other (low-toxicity) natural products may provide the best synergistic
effect. Combination of pancratistatin with curcumin, a component of turmeric spice that
has anti-inflammatory, anti-oxidant and anti-tumor activity, was shown to be more
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effective than either agent alone against melanoma cells in vitro (Chatterjee et al, 2011).
Effective treatment of cancer will likely be found in combination therapy with agents that
have non-overlapping targets and/or with natural products that have broad-range
activities.

Speculation of the target(s) of pancratistatin in attempt to explain its broad-range
of activity against different types of human cancer is up for debate until definitively
determined. It has been reported that some Amaryllidaceae alkaloids have antiglycosidic (and hence anti-viral) activity due to the similarity of their oxygenation pattern
to that of natural sugars (Gabrielsen et al, 1992; Hudlicky et al, 2002). Cancer cells rely
heavily on glucose metabolism for their energy needs, and have been shown to
upregulate the expression of glucose transporters (GLUT1 and/or GLUT3) on the plasma
membrane (Macheda et al, 2009). It may be possible that cancer cells are actively
importing metabolites other than glucose, such as pancratistatin, by GLUT1. GLUT1 is
also reported to regulate the influx of vitamin C in tumor cells, indicating its capacity for
transport of substrates other than glucose (KC et al, 2005). Another possible target of
pancratistatin may be anti-apoptotic proteins of the Bcl-2 family. Pancratistatin has
structural resemblance to the designer BH3 mimetic Gossypol, which has recently been
shown to modulate the interaction between Bcl-2/Bcl-XL and Beclin-1 to stimulate
autophagy in prostate cancer cells (Zhang et al, 2010). Other natural plant-based
compounds, i.e., resveratrol and EGCG, and some Amaryllidaceae alkaloids have been
shown to bind and inhibit anti-apoptotic Bcl-2 family proteins leading to activation of
Bax/Bak, MOMP and apoptotic cell death (Ralph and Neuzil, 2009). It is therefore
possible that pancratistatin may be modulating the anti-apoptotic effect of Bcl-2 proteins
to contribute to cell death. Lastly, due to the common confusion of its name,
pancratistatin is assumed to have cholesterol-lowering properties of common statins
(e.g., Lipitor); however, its name is actually derived from the Latin for its natural source
(Pancratium littorale) and for its plant-growth inhibitory activity (Gabrielsen et al, 1992).
Interestingly enough it can be argued that pancratistatin has a skeletal structure that
resembles that of cholesterol steroid hormones like estrogen. With this in mind,
pancratistatin may act as a hormone antagonist, blocking physiological roles of estrogen
such as growth stimulation and regulation of MRC components (Chen et al, 2009).
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Based on current literature and the data presented in this work, the mechanism of
action of pancratistatin is decidedly mitochondria-targeted. In some cancer cell lines,
caspase activation was noted as the initiating event in pancratistatin-induced apoptosis.
However, this hypothesis was revised after finding that caspase inhibition did not affect
pancratistatin activity, and mt-DNA deficient cells were insensitive to pancratistatininduced apoptosis. A common event in response to pancratistatin treatment was
increased ROS generation. Recently, ROS generation was discounted as the primary
cause of cell death, given that anti-oxidants were unable to protect cells from
pancratistatin-induced apoptosis. At this time, our data indicate that pancratistatin targets
a component of the mitochondrial respiratory chain to induce excess ROS production,
which destabilizes the mitochondrial membrane potential to the extent that the outer
mitochondrial membrane becomes permeable and releases cytotoxic factors to the
cytosol. Compared to other natural compounds, pancratistatin may also contribute to cell
death by indirect activation of pro-apoptotic Bcl-2 proteins, and/or interfering with antioxidant response mechanisms (Dong et al, 2009; Ralph and Neuzil, 2009). These
possible alternate actions of pancratistatin may contribute to cell death even when cotreated with anti-oxidants. Additionally, ROS generation may trigger mitochondriaselective autophagy (mitophagy) (Kroemer et al, 2007). Although pancratistatin-induced
ROS generation may incite mitophagy in attempt to clear away damaged organelles, our
current

hypothesis

is

that

pancratistatin

ultimately

induces

mitochondrial

permeabilization, leading to cell death that cannot be reversed by autophagy.
The reported anti-cancer activity of other Amaryllidaceae alkaloids, including
lycorine and narciclasine, strengthen our hypothesis and the significance of results
presented in this work. Lycorine has been implicated in the down-regulation of antiapoptotic Bcl-2 family member Mcl-1 (Liu et al, 2009). Our observation that pancratistatin
induces an autophagic response in p53-mutant prostate cancer cells (detailed in Chapter
6) may be due in part to possible down-regulation of Bcl-2 proteins by pancratistatin.
Decreased function of Bcl-2, an inhibitor of autophagy, would potentiate the activation of
Beclin-1-mediated autophagy induction (Fimia and Piacentini, 2010). Pancratistatin did
not increase levels of autophagy in p53-wild type prostate cancer cells, but these cells
did undergo apoptotic cell death – indicating that pancratistatin targets a protein
downstream of p53-regulatory jurisdiction.
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Narciclasine, an Amaryllidaceae alkaloid with a structure that closely resembles
pancratistatin, has also been shown to have potent anti-cancer properties with selective
action against cancer cells (Dumont et al, 2007). More recently, Narciclasine was shown
to have a growth-inhibitory effect in cellular and orthotopic tumor models of metastatic
brain cancer at low (50 – 100 nM) concentrations (Van Goietsenoven et al, 2010). The
authors report that narciclasine targets elongation factor 1A (eEF1A), a core component
of protein synthesis machinery (Van Goietsenoven et al, 2010). In a related study by
Ingrassia and colleagues, the stability of narciclasine was determined to be unaffected
after 7 days in media at 37°C, and oral administration of narciclasine to rats (3 mg/kg,
5X/week for 3 weeks) did not significantly affect body weight or cause fatality (Ingrassia
et al, 2009).
Recently, narciclasine was discovered to be a potent inhibitor of human
cytochrome P450 3A4 (CYP3A4) activity, which is one of the most important enzymes in
the oxidation and detoxification of xenobiotics (McNulty et al, 2010). The CYP3A
subfamily comprises approximately one third of the cytochrome P450 enzyme pool in the
liver, and the CYP3A4 isoenzyme accounts for ~60% of drugs metabolized (Nelson et al,
2004; Weinberg, 2007). Interestingly, the derivative dihydronarciclasine and native
pancratistatin did not inhibit this enzyme, which indicates a critical function of the double
bond at C-1 in narciclasine that is not present in the other two compounds (McNulty et al,
2009; McNulty et al 2010). Inhibition of CYP3A4 by narciclasine may lead to drug
accumulation and hepatic toxicity, and insufficient detoxification of potential carcinogens
by CYP3A4, which raises serious concerns for the clinical development of narciclasine
(McNulty et al, 2010).
Another recent study revealed pancratistatin as a novel substrate of ATP-binding
cassette transporter (ABCG2) protein (Deeken et al, 2009). ABCG2 is a membraneassociated protein believed to regulate oral availability and serve a protective role in
hematopoietic stem cells (HSCs), the blood-brain barrier and the maternal-fetal barrier
(Deeken et al, 2009). Interestingly, a thiosemicarbazone (NSC73306) was also
discovered as a substrate of ABCG2, and is reportedly active against cancer cells that
over-express functional P-glycoprotein, re-sensitizing these cells to chemotherapeutic
agents (Wu et al, 2007). ABCG2 is widely expressed in hematopoietic stem cells as
protection from potentially damaging xenobiotics, and it is possible that cancer stem
cells, proposed to have the self-renewal capabilities of HSCs, may harbour intrinsic
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chemotherapy resistance due to high expression of ABCG2 (Deeken et al, 2009). These
novel findings suggest that pancratistatin interacts with ABCG2 in such a way as to
facilitate activity against multi-drug resistant cancer cells, and does not inhibit the
important drug metabolizing enzyme CPY3A4, perhaps enabling its detoxification and
excretion.
Pancratistatin and plant alkaloids in general have low solubility in water (less than
0.4 mg/ml), which is an issue for pharmacokinetic analysis and clinical application
(Beijnen et al, 1995; Gabrielsen et al, 1992). Multiple efforts to synthesize more soluble
analogues that retain the anti-cancer activity of native pancratistatin, have lead to the
development of water-soluble sodium pancratistatin 3,4-O-cyclic phosphate (Shnyder et
al, 2008). Sodium pancratistatin 3,4-O-cyclic phosphate was shown to disrupt
mitochondrial function in colon cancer cells and significantly reduce growth of human
colon xenografts; however, these effects were achieved using the high concentration of
250 µM in vitro, and the (maximum tolerated) dose of 100 mg/kg in vivo (Shnyder et al,
2008). Compared to the native compound, the anti-cancer activity of this analogue is
significantly lower, but it is vastly more soluble in water than pancratistatin.
The challenging issues of solubility and bioavailability of pancratistatin mirror the
struggles that hindered clinical development of paclitaxel (Taxol), a natural product
extracted from the bark of the Pacific Yew tree. Taxol, first discovered in 1964, was
difficult to synthesize, could only be obtained from the natural source and was virtually
insoluble in aqueous media (Chabner et al, 2005). Synthetic analogues with increased
solubility and potent activity were developed, and in 1992 (nearly 30 years after its initial
discovery) Taxol was FDA approved for use against ovarian cancer (Chabner et al,
2005). Recent advances in the development of synthetic derivatives of pancratistatin
include an analogue with increased solubility but decreased potency, i.e., sodium
pancratistatin 3,4-O-cyclic phosphate; and an analogue with comparable potency but
similar insolubility, i.e., C-1 acetoxymethyl pancratistatin (see Chapter 1, figure 5).

It has been 24 years since the discovery of pancratistatin by Pettit and
colleagues, and research efforts since then have elucidated the minimum active
pharmacophore and provided clues as to its target and mechanism of action,
demonstrating the high potential of pancratistatin for advancement to clinical trials (Pettit
et al, 1986; McNulty et al, 2008; Griffin et al, 2011).
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FUTURE DIRECTION
Due to the low bioavailability of the native compound from its natural source, preclinical development of pancratistatin should continue with focus on active synthetic
derivatives, specifically C-1 acetoxymethyl pancratistatin. Future work on this project
should involve detailed characterization of the protein target(s) and determination of the
sub-cellular localization of pancratistatin and/or active synthetic derivatives. This may be
achieved by synthesis of a radioactive C14-labelled analogue and/or cross-linking of an
analogue to agarose beads for analysis by affinity chromatography. Synthesis of a radiolabelled analogue of pancratistatin will allow study of the uptake, localization and efflux of
the analogue, using both in vitro and in vivo models. Study of potential interacting
partners of (synthetic derivatives of) pancratistatin will elucidate possible target proteins
and give an indication of alternate effects. An active analogue may be cross-linked to
agarose beads using a 4-6 carbon long linker chain, preferably attached at a variable
region of the alkaloid (see Chapter 1, figure 5), which can then be analyzed by affinity
chromatography, followed by identification of binding partners using MALDI–TOF mass
spectrometry.
An alternate method to potentially identify the target(s) of pancratistatin is to
compare the differential expression of proteins between responsive and non-responsive
cancer cell lines by 2D-gel electrophoresis. This work has established that pancratistatin
targets the mitochondria, and possibly specific components of the mitochondrial
respiratory chain to induce cell death selectively in cancer cells. Previous studies in our
laboratory revealed that pancratistatin was unable to induce cell death in non-small cell
lung cancer cells (unpublished data). To better understand the mechanism of action of
pancratistatin, it would be advantageous to compare the differential protein expression
between this cancer cell line and a pancratistatin-sensitive cancer cell line.
Another important direction for the project is analysis of the in vivo effects of
active synthetic derivatives of pancratistatin. Already, a preliminary study has tested
intra-tumor (IT) administration of C-1 acetoxymethyl pancratistatin against human colon
tumor xenografts, with promising results; however, IT administration does not accurately
reflect clinical application. In the next animal study, intra-venous administration should be
employed, as the ideal mode of oral feeding is not feasible due to low solubility of the
alkaloid. Moreover, the route of administration will greatly affect the ADMET (absorption,
distribution, metabolism, excretion, toxicity) properties, which are largely unknown at this
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time. Pharmacokinetic and pharmacodynamic analysis is a critical step in the pre-clinical
development of anti-cancer agents.

This work is has significantly contributed to understanding the mechanism of
action of

the natural anti-cancer alkaloid pancratistatin, and structure-activity

relationship-based screening has lead to the synthesis of potent anti-cancer derivatives
of pancratistatin. Importantly, these studies are the first to report the mitochondriatargeting activity of pancratistatin, to detail its effect on autophagy levels and to
demonstrate the efficacy of pancratistatin in reducing growth of human colon and
prostate tumors in animal models. Collectively, this work highlights the potential for
advancement of (synthetic derivatives of) pancratistatin as an effective anti-cancer agent
for clinical use in the fight against cancer.
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APPENDIX B
UNPUBLISHED DATA
BACKGROUND
The results presented in this section of the thesis relate to the studies in chapters
2, 5 and 6 of this thesis, as indicated. These findings represent important experimental
data obtained after publication.
METHODS
Chemicals
Media, gentamycin, Hoechst 33342 dye, Annexin-V AlexaFluor 488, and JC-1
dye were purchased from Invitrogen. Cell proliferation reagent WST-1 was purchased
from Roche. A water-soluble formulation of Coenzyme Q10 (ws-CoQ10) was developed
and provided by Dr. M. Sikorska at NRC Ottawa (US patents #6,045,826,6,191,172 B1
and 6,632,443). Caspase-3 and -8 fluormetric substrates were purchased from MP
Biomedicals. The PM-MTOX1 plate, redox dyes and serum-free media were purchased
from BiOLOG, Inc. (Hayward, CA). Pancratistatin (PST) was isolated from H. littoralis
and provided by Dr. J. McNulty. All other chemicals were purchased from Sigma-Aldrich.
Cell culture
Human colorectal adenocarcinoma (HT-29, HCT116) and human metastatic
prostate carcinoma (DU145) cell lines were purchased from ATCC. HT-29 and HCT116
cells were grown in McCoy‟s 5A media and DU145 cells were grown in DMEM; all cell
lines were supplemented as recommended by ATCC. Human acute T-cell leukemia
(Jurkat, Clone E6-1) and a dominant-negative fas-associated death domain (dnFADD)
mutant of wild-type Jurkat cells (Jurkat, Clone I 2.1) were purchased from ATCC. These
cells were cultured in RPMI-1640 medium supplemented with 10% FBS and 40 µg/ml
gentamicin (GIBCO). Cultures were maintained at 5% CO 2 and 37°C.
Assessment of apoptosis
Apoptosis was detected by microscopy with cell-permeable Hoechst 33342 dye
and/or Annexin-V AlexaFluor-488. To monitor phosphatidyl serine exposure, Annexin-V
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binding assay was performed. Cells were treated as indicated, trypsinized and washed
2X in room temperature PBS, then resuspended in Annexin-V calcium-binding buffer (10
mM HEPES/NaOH pH 7.5, 140 mM NaCl, 2.5 mM CaCl 2), and incubated with Annexin-V
AlexaFluor 488 conjugate (1:50) for 15 min at 25ºC. For microscopy, 5 min incubation
with 10 μM Hoechst 33342 dye was included with the Annexin-V binding incubation.
Brightly stained, condensed nuclei were visible with Hoechst dye, characteristic of
apoptotic cells, as is phosphatidylserine externalization detected by Annexin-V binding.
Images of DU145 cells were captured on an inverted fluorescence microscope (Leica
DM IRB, Germany). The percent of condensed nuclei (indicative of apoptosis) was
calculated as: [(number of cells with condensed, brightly stained nuclei / total number of
cells)*100] with a minimum of 5 fields counted with 100 cells / field.
Cytotoxicity assays
Cytotoxicity was measured using the WST-1 colorimetric assay. HCT116 cells
were seeded at 2500 cells/well in 96-well tissue culture plates. After treatment with PST
as indicated, cells were incubated with WST-1 for 4 h at 37 °C. Absorbance was
measured at 450 nm on a VICTOR3 microplate reader. Absorbance is directly
proportional to the number of living cells in culture. Each assay was performed in
triplicate and the mean of three assays was calculated from the average absorbance of
control-treated cells.

Mitochondrial functionality assays
Mitochondrial membrane potential (MMP) was observed using cell permeable JC1 dye (1 µM final concentration). HT-29 and HCT116 cells were grown on cover-slips
and following treatment JC-1 was added directly to the media and incubated for 30 min
at 37°C in darkness; cell permeable Hoechst dye was added for the last 5 min of
incubation, to observe nuclear morphology.
ROS Detection in Isolated Mitochondria
Isolated mitochondria from untreated DU145 cells were subjected to direct
incubation with PST. Mitochondrial ROS generation was measured using Amplex Red
dye and HRP. In an opaque 96‑well plate, 100 µg mitochondrial suspension was
incubated in (200 µl) reaction buffer (2.5 mM malate and 10 mM succinate, in PBS) with
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50 µM Amplex Red reagent and 6 U HRP, and with control (Me 2SO), PST (1 µM),
Tamoxifen (5 µM), or co-treatment of PST and Tamoxifen (PST+TAM). Fluorescence
was measured in 1 min intervals over 2 h at excitation 560 nm and emission 590 nm
using a SpectraMax GeminiXPS spectrofluorometer.
Assessment of caspase activity
To monitor caspase activity, cellular lysate was collected from dnFADD Jurkat
cells and incubated with the desired fluorogenic substrate (caspase-3, DEVD-AFC;
caspase-8, IETD-AFC) in assay buffer (0.1 M HEPES, pH 7.4, 2 mM DTT, 0.1% CHAPS,
1% sucrose) and allowed to incubate at 37ºC for 45 min. Fluorescence was measured at
excitation 400 nm and emission 505 nm using a SpectraMax Gemini XPS
spectrofluorometer. Caspase activity was calculated per microgram of protein, and
expressed as a percentage of control activity.
Mitochondrial Toxicology Assay
A phenotype microarray plate was used to assess the effect of PST on
mitochondrial function in DU145 cells, as per manufacturer‟s protocol. The PM-MTOX1
96-well microarray plates are pre-coated with 8 different energy substrates, designed to
determine the metabolic pathways targeted by an unknown drug. Briefly, cells were
seeded at 4 000 / well in 40 µl of serum-free, glucose-free RPMI media and allowed to
attach overnight. Cells were treated with pancratistatin at increasing concentrations, or
with rotenone, Antimycin A or tamoxifen for 18 h. Cells were then incubated with 10 µl
BiOLOG redox dye “A” supplemented with 5 mM final concentration glucose / well for 4 h
at 37°C. Absorbance was measured at 590 nm on a VICTOR 3 microplate reader. Higher
absorbance (darker purple colour) is directly proportional to the number of living cells in
culture, and thus the degree of mitochondrial function with the specific metabolite. The
image presented depicts one assay of several that were run during the standardization of
this protocol.
In vivo xenograft models
Six-week old male homozygous CD-1 nude mice (25 – 30 g) were obtained from
Charles River Laboratories, St. Constant, QC. Animals were housed in constant
laboratory conditions of a 12 h light/dark cycle at 21°C in accordance with institutional
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animal protocols (University of Windsor Research Ethics Board - AUPP05). Prior to
injection, HT-29 and HCT116 cells were washed with PBS and centrifuged at 500 x g for
5 min; cell pellets were suspended in aliquots of 200 µl PBS (2 x 10 6 cells per mouse).
The HT-29 (p53mt) cell suspension was injected s.c. into the left hind flank of each
mouse; The HCT116 (p53wt) cell suspension was injected s.c. into the right hind flank of
each mouse. Tumors were allowed to grow for 10 days and thereafter animals were
randomized into treatment groups of 3 mice each. Animals were treated intra-tumor (I.T.)
with vehicle (5 µl Me2SO in PBS) or pancratistatin (3 mg/kg) twice a week for 5 weeks.
Tumors were assessed at each treatment using standard calipers measuring length and
width; tumor volume was calculated using the formula [π/6 x length x width 2]. All animals
were weighed at each treatment during the study.
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RESULTS
Chapter 2
Pancratistatin induces cell death and caspase-3 activation in dnFADD Jurkat cells
In this study, it was reported that Pancratistatin induces apoptosis in Jurkat cells
by activating caspase-3, with minimal effect on non-cancerous peripheral blood cells. To
extend this finding, the effect of 24 h treatment with 1 µM pancratistatin on Jurkat cells
that express a dominant-negative Fas-associated death domain (dnFADD) was tested.
FADD is a critical component of the death-inducing signalling complex (DISC) triggered
upon death-receptor stimulation, leading to caspase-8 activation and subsequent
activation of caspase-3. It was observed that dnFADD Jurkat cells were as sensitive to
pancratistatin-induced apoptosis as wild-type Jurkat cells (Appendix Figure 1A; also refer
to Chapter 2). Moreover, these cells had increased caspase-3 activity after only 3 h
treatment with pancratistatin; caspase-8 activity did not increase, as expected (Appendix
Figure 1B). This finding indictated that caspase-3 may reside upstream of caspase-8 in
dnFADD Jurkat cells (Aouad et al, 2004), leading to rapid induction of apoptosis
following pancratistatin treatment (also refer to Griffin et al 2007). Furthermore, this
finding indicated that pancratistatin does not trigger the death-receptor mediated
extrinsic pathway of apoptosis.
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Appendix Figure 1. Effect of pancratistatin treatment on dominant-negative FADD
Jurkat cells. (A) Hoechst staining was performed to observe nuclear morphology of
dominant-negative FADD (dnFADD) Jurkat cells after 24 h control or 1 µM pancratistatin
(PST) treatment. Condensed, brightly-stained nuclear morphology is a characteristic
feature of apoptotic cells. (B) Caspase activity was measured in dnFADD Jurkat cells
after the indicated treatment incubation with 1 µM pancratistatin. Results were calculated
per microgram of protein and the standard error was calculated using the data from three
separate sets of experiments. Columns, mean (n=3); bars, SD.
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Chapter 5
Effect of pancratistatin on colon cancer cell mitochondria function
In a study similar to that reported in Chapter 5 (Supp. Figure 2), HCT116 cells
were co-treated with and without pancratistatin and with and without anti-oxidants Nacetylcysteine (nac) or water-soluble coenzyme Q10 (q10), mitochondrial respiratory
chain complex inhibitors rotenone (rot) or antimycin A (aa), or mitochondrial permeability
transition pore inhibitor cyclosporin A (ca). In contrast to the results obtained with HT29
cells in Chapter 5, co-treatment of pancratistatin with any of these agents was not able to
protect cells from pancratistatin-induced toxicity after 72 h exposure (Appendix Figure 2).
The effect of co-treatment with pancratistatin and cyclosporin A (CA) on
mitochondrial membrane potential (MMP) in HT29 cells was also monitored. HT29 cells
co-treated with pancratistatin and cyclosporin A retained JC-1 dye, which indicated that
cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (MPTP),
offered protection against PST-induced MMP collapse (Appendix Figure 3, top).
Furthermore, this co-treatment lead to a decrease in the number of apoptotic cells
compared to treatment with pancratistatin alone (Appendix Figure 3, bottom). This
finding strengthens our hypothesis that pancratistatin-induced cell death ultimately
results from mitochondrial membrane permeabilization.
Additionally, the effect of co-treatment with pancratistatin and water-soluble
coenzyme Q10 (Q10) on MMP in HT29 and HCT116 cells was observed. Use of a watersoluble formation of Q10 enables study of the anti-oxidant capability of Q10 in vitro. Cotreatment with pancratistatin and Q10 was unable to protect colon cancer cells from
pancratistatin-induced apoptosis, as compared to pancratistatin treatment alone
(Appendix Figure 4). This finding correlates with Chapter 5 data, where the anti-oxidant
N-acetylcysteine was also unable to proctect cells from pancratistatin-induced cell death.
Complimentary to our in vivo findings presented in Chapter 5, the effect of
pancratistatin in vivo against tumors with differential p53 expression was studied.
Subcutaneous xenografts were established in immune-compromised mice with HT29
(mutant p53) and HCT116 (wt p53) cells. Pancratistatin effectively halted the growth of
both HT29 (left hind flank) and HCT116 (right hind flank) compared to control-treated
animlas (Appendix Figure 5). Moreover, pancratistatin did not have a significant effect on
the body weight of immune-compromised mice when administered intra-tumor (3 mg/kg),
compared to control-treated animals (Appendix Figure 5, top).
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Appendix Figure 2. HCT116 colon cancer cells were treated with 1 µM
pancratistatin (pst, p) with and without various antagonists. The effect of treatment
on cell viability was determined by WST-1 assay after 72 h. Antagonists studied: 10 µM
Rotenone (rot), 5 µM Antimycin A (aa), 5 µM cyclosporin A (ca), 5 mM N-acetylcysteine
(nac), 50 µg/ml water-soluble Coenzyme Q10 (q10). Columns, mean (n=6); bars, SD. Cotreatment with anti-oxidants (nac, q10), mitochondrial respiratory chain complex
inhibitors (rot, aa) or the mitochondrial permeability transition pore inhibitor (ca) was able
to protect cells from decreased viability due to pancratistatin.
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Appendix Figure 3. Effect of co-treatment with pancratistatin and cyclosporin A on
mitochondrial membrane potential. Representative fluorescence micrographs of HT29
cells stained with Hoechst and JC-1 dye after 72 h with control (Me2SO), 1 µM
pancratistatin (PST), 5 µM cyclosporin A (CA) or co-treatment of PST and CA.
Cyclosporin A binds to cyclophilin D, a component of the mitochondrial permeability
transition pore (MPTP), inhibiting its opening and the subsequent collapse of
mitochondrial membrane potential (MMP). Mitochondria of cells treated with PST and CA
retained JC-1 dye, indicating that CA offered protection against the effects of PSTinduced MMP collapse (top panel). Furthermore, there was a decrease in the percentage
of cells with brightly stained condensed nuclei, indicative of apoptosis, in PST and CA
co-treated cell compared to treatment with PST alone (bottom panel).
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Appendix Figure 4. Effect of pancratistatin (PST) and water-soluble Coenzyme Q10
(ws-CoQ10) co-treatment on colon cancer cells. Representative fluorescence
micrographs of HT-29 and HCT116 cells stained with Hoechst dye after 48 h with control
(Me2SO), 1 µM pancratistatin (PST), 50 µg/ml ws-CoQ10 (Q10) or co-treatment of PST
and Q10 (top panel). This water-soluble formulation enables study of the anti-oxidant
capability of Q10 to protect cells against ROS generated in the mitochondria. Coenzyme
Q10 (also referred to as ubiquinone) accepts electrons from complexes I (NADHubiquinone oxidoreductase) and II (succinate-ubiquinone oxidoreductase) and transports
them to complex III (ubiquinone-cytochrome c oxidoreductase) of the mitochondrial
respiratory chain. Co-treatment with ws-CoQ10 was unable to protect colon cancer cells
from pancratistatin-induced apoptosis.
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Appendix Figure 5. Evaluation of the effect of pancratistatin (PST) on colon cancer
xenografts established from cells expressing wild-type or mutant p53. Average
body weight of saline (5 µl Me2SO in 200 µl PBS) and 3 mg/kg pancratistatin (PST)
treated mice (top panel). The body weights of the saline and PST-treated mice did not
vary significantly throughout the study. Data points, mean (n=3); bars, SD. Tumor growth
curve of saline or pancratistatin (PST) (3 mg/kg) I.T. administration of HT-29 (mutant
p53) tumors (left panel). Tumor growth curve of saline or PST (3 mg/kg) I.T.
administration of HCT116 (wild-type p53) tumors (right panel). Data points, mean (n=3);
bars, SD. Representative tumor size of HCT116 (wild-type p53) and HT-29 (mutant p53)
xenografts in CD-1 nude mice at time of sacrifice (bottom panel).
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Chapter 6
Pancratistatin induces apoptosis in human prostate cancer cells
Complimentary to the data presented in Chapter 6 (Figure 2), human prostate
cancer cells (DU145) treated with pancratistatin for 24 and 48 h were positive for
Annexin-V binding, which indicates exposure of phosphatidylserine, a characteristic
feature of apoptosis (Appendix Figure 6).
In Chapter 6, our data suggested that pancratistatin induced reactive oxygen
species (ROS) production in DU145 cells (Figure 4A) and that tamoxifen (TAM) induced
non-lethal autophagy in DU145 cells (Figure 5A), which may be attributed to increased
ROS generation (Chen et al, 2009). To extend these findings, we monitored the effect of
pancratistatin and tamoxifen on DU145 isolated mitochondria. Our results suggested that
pancratistatin and co-treatment with pancratistatin and tamoxifen induced increased
ROS production after 2 h incubation (Appendix Figure 7).
Additionally, a preliminary metabolism-based experiment was performed with
DU145 cells using a phenotype microarray – mitochondrial toxicity (PM-MTOX) 96-well
plate. This PM-MTOX plate is pre-coated with various metabolites that allow study of the
metabolic pathway affected by pancratistatin treatment at increasing concentrations.
Preliminary findings suggested that the metabolic pathways that consume αketoglutarate and pyruvate for energy are not affected by pancratistatin treatment
(Appendix Figure 8). This is an interesting finding that requires additional testing to be
conclusive.
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Appendix Figure 6. Monitoring the apoptosis-inducing effect of pancratistatin
(PST) on human prostate cancer cells. Cells (DU145) were treated with PST for 24 or
48 h and stained with Hoechst to observe nuclear morphology; phosphatidylserine
flipping from the inner to the outer leaflet of the plasma membrane was monitored with
the Annexin-V binding assay. Pictures taken at 400x magnification.
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Appendix Figure 7. Effect of Pancratistatin and/or Tamoxifen treatment on the
production of ROS from isolated mitochondria. ROS generation from isolated DU145
mitochondria treated with 1 µM pancratistatin (PST), 5 µM tamoxifen (TAM) or both.
Measurements were recorded over 2 h in 1 min intervals and calculated as relative
fluoresence units (RFU) per 10 000 cells using Trypan Blue exclusion dye.
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Appendix Figure 8. Assessment of mitochondrial toxicity in prostate cancer cells
using a phenotype microarray plate. DU145 cells (4 X 103) were added to each well of
a PM-MTOX-1 96-well microarray plate and allowed to grow in serum-free, glucose-free
media and the indicated metabolite for 24 h prior to treatment. Cells were treated with
pancratistatin at increasing concentrations, rotenone (complex I inhibitor), Antimycin A
(complex III inhibitor), or tamoxifen (cited as a fatty acid β-oxidation uncoupler by the
manufacturer) for 18 h. Representative image taken after 4 h incubation with the
appropriate redox dye.
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DISCUSSION
The unpublished findings presented here correlate with published data in
Chapters 2, 5 and 6 of this thesis. Where appropriate, these results are indicated in the
main body of the thesis. Collectively, this additional experimental data supports the
overall hypothesis that pancratistatin treatment leads to increased ROS generation and
mitochondrial membrane collapse/permeabilization, resulting in caspase activation and
apoptotic cell death in cancer cells.
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APPENDIX C
CHEMICAL REAGENTS

REAGENT NAME
2',7'-dichlorodihydrofluorescein
diacetate (H2DCFDA)
3-[4,5-dimethylthiazol-2-yl]-2,5diphenyl tetrazolium bromide (MTT)
40% Acrylamide/Bis Solution (37.5:1)
5,5’,6,6’-tetrachloro-1,1’,3,3’ tetraethylbenzimidazolylcarbocyanine
iodide (JC-1)
Amplex Red
Annexin-V AlexaFluor 488
Anti-AIF (Rb pAb)
Anti-Bax (Ms mAb)
Anti-Bcl-2 (Ms mAb )
Anti-Cytochrome c (Ms mAb)
Anti-Endo G (Rb pAb)
Anti-H2AX (Ms mAb)
Anti-LC3 (pAb Rb)
Anti-Mouse FITC (whole molecule)
Anti-Mouse HRP (rabbit pAb)
Antimycin A
Anti-Rabbit FITC (whole molecule)
Anti-Rabbit HRP (goat pAb)
Anti-SDHA (Ms mAb)
Anti-β-Actin (Ms mAb)
Bradford Reagent
Cyclosporin A
DEVD-AFC (caspase-3 substrate)
Eosin
Etoposide (Vp-16)
Hematoxylin
Hoechst 33342
Horse Radish Peroxidase (HRP)
HTS-Tubulin Polymerization Assay Kit
IETD-AFC (caspase-8 substrate)
LEHD-AFC (caspase-9 substrate)
Leupeptin
MitoCasp Assay Kit

COMPANY NAME
Sigma
Sigma

CATALOGUE No.
D6883
M5655

BioRad
Invitrogen

161-0148
T3168

Sigma
Invitrogen
AbCam
Santa Cruz Biotech
Santa Cruz Biotech
AbCam
AbCam
Upstate (Millipore)
AbCam
Sigma
Abcam
Sigma
Sigma
Abcam
SantaCruz Biotech
SantaCruz Biotech
BioRad
Sigma
MP Biomedicals
Sigma
Sigma
Sigma
Invitrogen
Sigma
CytoSkeleton Inc.
MP Biomedicals
MP Biomedicals
Sigma
Cell Technology Inc.

90101
A13201
ab1998
sc7480
sc7382
ab13575
ab9647
05-636
ab58610
F2266
ab6728
A8674
F7512
ab6721
sc59687
sc81178
500-0006
C1832
03AFC138
E4382
E1383
H3136
H1399
P6782
BK004
03AFC140
03AFC154
L2023
000021
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Mitotracker
Mono-dansyl cadaverine (MDC)
N-acetylcysteine
Paclitaxel (Taxol)
Pepstatin A
Phenylmethanesulfonyl fluoride
(PMSF)
PM-MTOX-1 Assay
Rotenone
Tamoxifen (TAM)
Terminal deoxynucleotidyl
transferase dUTP nick-end labelling
(TUNEL) Assay Kit
Tetramethyl rhodamine methyl ester
(TMRM)
Trypan blue exclusion dye
WST-1
z-VAD-fmk (pan-caspase inhibitor)

Invitrogen
Sigma
Sigma
Sigma
Sigma
Sigma
BIOLOG Inc.
Sigma
Sigma
Invitrogen

Invitrogen
Invitrogen
Roche
EMD BioSciences Inc.

M7513
30432
A9165
T7402
77170
P7626
PM-MTOX1
R8875
T9262
A23210

T668
15250061
11 644 807 001
627610
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